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   Bromodeoxyuridine	  
BMPRII	   Bone	  Morphogenetic	  Protein	  2	  
BSA	   	   Bovine	  Serum	  Albumin	  
Ca2+	   	   Calcium	  
CADASIL	   Cerebral	  Autosomal	  Dominant	  Arteriopathy	  with	  Subcortical	  Infarcts	  and	  
Leukoencephalopathy	  
cDNA	   	   single	  stranded	  DNA	  
cGMP	   	   cyclic	  guanosine	  monophosphate	  
CCL2	   	   Chemokine	  receptor	  2	  
CH	   	   Chronic	  Hypoxia	  
CML	   	   Chronic	  MyelogenousLeukemia	  
CSL	   	   CBF1,	  Su(H)	  and	  Lag1	  
CTEPH	  	   Chronic	  Thromboembolic	  Pulmonary	  Hypertension	  
CX3CR1	   Chemokine	  receptor	  1	  	  	  
DBZ	   	   Dibenzapine	  (gamma-­‐secretase	  inhibitor)	  	  
DDAH2	   Dimethylarginine	  dimethyl	  aminohydrolase	  2	  
DLL	   	   Delta	  like	  Ligand	  
DPBS	   	   Dulbecco's	  Phosphate	  Buffer	  Saline	  
DNA	   	   Deoxyribo	  Nucleic	  Acid	  
DSL	   	   Delta	  Serrate	  Lag-­‐2	  
EC	   	   Endothelial	  cell	  
ECM	   	   Extracellular	  Matrix	  
EDTA	   	   Ethylenediaminetetraacetic	  acid	  
EGF	   	   Epidermal	  Growth	  Factor	  
eNOS	   	   endothelial	  Nitric	  Oxide	  Synthase	  
ER	   	   Endoplasmic	  Reticulum	  
ET-­‐1	   	   Endothelin	  1	  
ETRA	   	   Endothelin	  Receptor	  A	  
ETRB	   	   Endothelin	  Receptor	  B	  
FCS	   	   Fetal	  Calf	  Serum	  
FGF2	   	   Fibroblast	  Growth	  Factor	  2	  
GAPDH	   Glycelraldehyde	  3-­‐phosphate	  dehydrogenase	  
GSI	   	   gamma-­‐secretase	  inhibitor	  
HES	   	   Hairy/enhancer	  of	  split	  




LIST	  OF	  ABBREVIATIONS	  
	  
	   	  
HIF-­‐1α	  	   Hypoxia	  Inducible	  Factor	  1α	  
Hox	   	   Hypoxia	  
hPAEC	  	   human	  Pulmonary	  Artery	  Endothelial	  Cell	  
hPASMC	   human	  Pulmonary	  Artery	  Smooth	  Muscle	  Cell	  
HPV	   	   Hypoxic	  Pulmonary	  Vasoconstriction	  
HRP	   	   Horseradish	  Peroxidase	  
IAP	   	   Inhibitor	  of	  Apoptosis	  
ICD	   	   Intracellular	  domain	  
IGF	   	   Insulin-­‐like	  Growth	  Factor	   	  
IgG	   	   Immunoglobin	  
IL-­‐6	   	   Interlukin-­‐6	  
IPAH	   	   Idiopathic	  Pulmonary	  Arterial	  Hypertension	  
KO	   	   Knock	  Out	  
Kv	  channel	   Potassium	  channel	  
LNRs	   	   Lin-­‐12	  notch	  repeats	  
MCT	   	   Monocrotaline	  
MgCl2	   	   Magnesium	  Chloride	  
mRNA	   	   messenger	  Ribonucleic	  Acid	  
N1ICD	   	   Notch1	  Intracellular	  Domain	  
NEXT	   	   Notch	  Extracellular	  Truncation	  fragment	  
NO	   	   Nitric	  Oxide	  
NOS	   	   Nitric	  Oxide	  Synthase	  
PA	   	   Pulmonary	  Artery	  
PAH	   	   Pulmonary	  Arterial	  Hypertension	  
PAP	   	   Pulmonary	  Arterial	  Pressure	  
PAEC	   	   Pulmonary	  Artery	  Endothelial	  Cell	  
PAFBs	   	   Pulmonary	  Artery	  Adventitial	  Fibroblasts	  
PASMC	   Pulmonary	  Artery	  Smooth	  Muscle	  Cell	  
PBGD	   	   Phorphobilinogen	  Deaminase	  
PDE-­‐5	   	   Phosphodiesterae-­‐5	  
PDGF	   	   Platelet	  Derived	  Growth	  Factor	  
PDGFRβ	   Platelet	  Derived	  Growth	  Factor	  β	  
PGI2	   	   Prostacyclin	  
PPH	  	  	   	   Primary	  Pulmonary	  Hypertension	  
PVR	   	   Pulmonary	  Vascular	  Resistance	  
RBJκ	   	   Recombination	  signal	  sequence-­‐Binding	  Protein	  Jκ	  
RIPA	   	   Radioimmunoprecipitation	  Assay	  
RNA	   	   Ribonucleic	  Acid	  
RT	   	   Reverse	  Transcriptase	  
RVSP	   	   Right	  Ventricular	  Systolic	  Pressure	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SU5416	   SUGEN	  (Vascular	  Endothelial	  Growth	  Factor	  receptor-­‐2	  inhibitor)	  
SYBR	  Green	  	   asymmetrical	  cyanine	  dye	  used	  as	  a	  nucleic	  acid	  stain	  in	  molecular	  biology	  	  
TAE	  	  	   	   Tris	  base,	  acetic	  acid	  and	  EDTA	  buffer	  	  
TBS	  	   	   Tris	  Buffered	  Saline	  	  
TBST	  	   	   Tris	  Buffered	  Saline	  +	  Tween	  20	  
TGFβ	   	   Transforming	  Growth	  Factor	  β	  
TNF	   	   Tumor	  Necrosis	  Factor	  
TUNEL	  	   Terminal	  deoxynucleotidyltransferasedUTP	  nick	  end	  labeling	  
VEGF	   	   Vascular	  Endothelial	  Growth	  Factor	  
VEGFR2	   Vascular	  Endothelial	  Growth	  Factor	  receptor	  2	  
VIP	   	   Vasoactive	  Intestinal	  Peptide	  

















	   	  
1.	  INTRODUCTION	  
1.1	  Pulmonary	  Hypertension	  (PH)	  
Pulmonary	   Hypertension	   (PH)	   is	   a	   progressive	   disease	   characterized	   by	   increased	  
pulmonary	   vascular	   resistance	   (PVR)	   leading	   to	   right	   heart	   hypertrophy	   and	  ultimately	   death	  of	  
the	  patient	  due	  to	   right	  heart	   failure	   [1].	  Generally,	  pulmonary	  circulation	   is	  a	   low	  pressure	  and	  
high	   flow	   system,	   maintaining	   pressure	   of	   about	   15mm	   Hg;	   however,	   in	   PH	   due	   to	   increased	  
pulmonary	  vascular	  resistance,	  the	  pressures	  reach	  up	  to	  25mm	  Hg	  at	  rest	  and	  30mm	  Hg	  during	  
exercise	  [2].	  In	  all	  its	  different	  forms,	  PH	  is	  estimated	  to	  effect	  100	  million	  people	  worldwide,	  with	  
the	  median	  survival	  rate	  of	  2.8	  years	  after	  diagnosis	  [3].	  	  
1.1.1	  Classification	  of	  Pulmonary	  Hypertension	  
Dresdale	  and	  colleagues	  first	  reported	  a	  hemodynamic	  account	  of	  IPAH	  in	  1951[4].	  The	  first	  
classification	  of	  PH	  was	  carried	  out	  in	  1973	  at	  an	  international	  conference	  on	  primary	  PH,	  dividing	  
the	   patients	   into	   two	   categories,	   primary	   PH	   and	   secondary	   PH,	   depending	   on	   absence	   or	  
presence	  of	  recognizable	  causes	  [5].	  A	  new	  classification	  of	  PH	  was	  introduced	  in	  1998,	  at	  the	  2nd	  
World	   Symposium	   on	   Pulmonary	   Arterial	   Hypertension	   held	   in	   Evian,	   France.	   The	   “Evian	  
classiﬁcation”	  attempted	  to	  create	  categories	  of	  PH	  on	  the	  basis	  of	  shared	  pathologic	  and	  clinical	  
features	   as	   well	   as	   similar	   therapeutic	   options.	   This	   was	   a	   much	   broader,	   more	   precise	  
classification,	  with	   5	  major	   categories,	   allowing	   investigators	   to	   conduct	   clinical	   trials	   in	   a	  well-­‐
defined	  group	  of	  patients	  with	  a	  shared	  underlying	  pathogenesis	  [1].	  Since	  then,	  the	  classification	  
has	  undergone	  some	  revisions,	  owing	  to	  newfound	  knowledge	  about	  the	  disease.	  A	  major	  change	  
was	  proposed	  in	  the	  classification	  at	  3rd	  World	  Conference	  on	  PH	  in	  2003.	  In	  this	  classification,	  PPH	  
was	  replaced	  with	  idiopathic	  PAH	  (IPAH)	  or,	  when	  supported	  by	  genetic	  basis,	  familial	  PAH	  (FPAH)	  
[6].	   Current	   classification,	   agreed	   upon	   in	   4th	  World	   Symposium	   on	   Pulmonary	   Hypertension	   in	  












	   	  
1.	  Pulmonary	  arterial	  hypertension	  (PAH)	  
	  	  	  1.1	  Idiopathic	  PAH	  
	  	  	  1.2	  Heritable	  
	  	  	  	  	  	  	  	  	  	  	  1.2.1	  BMPR2	  
	  	  	  	  	  	  	  	  	  	  	  1.2.2	  ALK1,	  endoglin	  (with	  or	  without	  hereditary	  hemorrhagic	  telangiectasia)	  
	  	  	  	  	  	  	  	  	  	  	  1.2.3	  Unknown	  
	  	  	  1.3	  Drug-­‐	  and	  toxin-­‐induced	  
	  	  	  1.4	  Associated	  with	  
	  	  	  	  	  	  	  1.4.1	  Connective	  tissue	  diseases	  
	  	  	  	  	  	  	  1.4.2	  HIV	  infection	  
	  	  	  	  	  	  	  1.4.3	  Portal	  hypertension	  
	  	  	  	  	  	  	  1.4.4	  Congenital	  heart	  diseases	  
	  	  	  	  	  	  	  1.4.5	  Schistosomiasis	  
	  	  	  	  	  	  	  1.4.6	  Chronic	  hemolytic	  anemia	  
	  	  	  1.5	  Persistent	  pulmonary	  hypertension	  of	  the	  newborn	  
1'	  Pulmonary	  veno-­‐occlusive	  disease	  (PVOD)	  and/or	  pulmonary	  capillary	  hemangiomatosis	  (PCH)	  
2.	  Pulmonary	  hypertension	  owing	  to	  left	  heart	  disease	  
	  	  	  2.1	  Systolic	  dysfunction	  
	  	  	  2.2	  Diastolic	  dysfunction	  
	  	  	  2.3	  Valvular	  disease	  
3.	  Pulmonary	  hypertension	  owing	  to	  lung	  diseases	  and/or	  hypoxia	  
	  	  	  3.1	  Chronic	  obstructive	  pulmonary	  disease	  
	  	  	  3.2	  Interstitial	  lung	  disease	  
	  	  	  3.3	  Other	  pulmonary	  diseases	  with	  mixed	  restrictive	  and	  obstructive	  pattern	  
	  	  	  3.4	  Sleep-­‐disordered	  breathing	  
	  	  	  3.5	  Alveolar	  hypoventilation	  disorders	  
	  	  	  3.6	  Chronic	  exposure	  to	  high	  altitude	  
	  	  	  3.7	  Developmental	  abnormalities	  
4.	  Chronic	  thromboembolic	  pulmonary	  hypertension	  (CTEPH)	  
5.	  Pulmonary	  hypertension	  with	  unclear	  multifactorial	  mechanisms	  
	  	  	  5.1	  Hematologic	  disorders:	  myeloproliferative	  disorders,	  splenectomy	  
	  	  	  5.2	  Systemic	  disorders:	  sarcoidosis,	  pulmonary	  Langerhans	  cell	  histiocytosislymphangioleiomyomatosis,	  	  
	  	  	  	  	  	  	  	  	  	  neurofibromatosis,	  vasculitis	  
	  	  	  5.3	  Metabolic	  disorders:	  glycogen	  storage	  disease,	  Gaucher	  disease,	  thyroid	  disorders	  
	  	  	  5.4	  Others:	  tumoral	  obstruction,	  fibrosingmediastinitis,	  chronic	  renal	  failure	  on	  dialysis	  
	  
Table	   1.	   Updated	   Classification	   of	   PH	   (Dana	   Point,	   2008)	   [6]	   ALK1,	   activin	   receptor-­‐like	   kinase	   type	   1;	  
BMPR2,	  bone	  morphogenetic	  protein	  receptor	  type	  2;	  HIV,	  human	  immunodeficiency	  virus	  
1.1.2	  Patho-­‐physiology	  of	  Pulmonary	  Arterial	  Hypertension	  (PAH)	  
	   PAH	   has	   a	   multifactorial	   pathobiology.	   However,	   regardless	   of	   the	   initial	   trigger,	   the	  
increased	  pulmonary	  artery	  pressure	  and	  vascular	  resistance	  observed	  in	  patients	  suffering	  from	  






	   	  
arteries	  and	  arterioles,	  as	  well	  as	  sustained	  vasoconstriction	  [7].	  
1.1.2.1	  Pulmonary	  vasoconstriction	  	  
	   Vasoconstriction	  defined	  as	  narrowing	  of	  lumen	  of	  the	  blood	  vessel	  is	  a	  major	  contributor	  
to	   PVR,	   and,	   hence,	   elevated	   pulmonary	   artery	   pressure	   (PAP)	   [8].	   Under	   normal	   conditions,	  
pulmonary	  vascular	  tone	  is	  maintained	  by	  balancing	  actions	  of	  endothelium	  derived	  vasodilators,	  
mainly	   prostacyclin	   (PGI2),	   nitric	   oxide	   (NO)	   and	   vasoconstrictors,	   namely	   thromboxane	  A2	   and	  
endothelin-­‐1(ET-­‐1)	   [9].	   Endothelial	   dysfunction	   caused	  due	   to	   shear	   stress	   or	   inflammation,	   can	  
disturb	   this	   balance	   contributing	   to	   persistent	   vasoconstriction.	   Patients	   with	   PAH	   have	   been	  
shown	   to	   have	   reduced	   circulating	   levels	   of	   vasodilator,	   prostacyclin	   as	   compared	   to	   levels	   of	  
vasoconstrictor,	   thromboxane	   [10].	   Hypoxia	   mediated	   pulmonary	   vasoconstriction,	   an	   adaptive	  
mechanism	  unique	  to	  lungs,	  is	  also	  believed	  to	  be	  a	  major	  factor	  behind	  high	  altitude-­‐PH	  [8].	  	  
1.1.2.2	  In-­‐situ	  thrombosis	  
One	   of	   the	   major	   histological	   representations	   of	   PH	   is	   in	   situ	   thrombosis	   of	   pulmonary	  
arterioles	   [11].	  Endothelial	  dysfunction,	  abnormalities	   in	  clotting	  cascade	  and	  platelet	  activation,	  
creating	   a	   pro-­‐coagulant	   environment	   within	   the	   pulmonary	   vascular	   bed	   are	   believed	   to	   be	  
responsible	   for	   this	   pathological	   finding	   [7,	   8].	   Increased	   plasma	   levels	   of	   fibrinopeptide1,	   a	  
marker	   for	   fibrin	   generation	   and	   plasminogen	   activator	   inhibitor1,	   inhibitor	   of	   fibrinolysis	   have	  
been	   reported	   in	   IPAH	   patients	   [12].	   Von	  Willebrand	   factor	   (vWF),	   essential	   for	   interaction	   of	  
endothelial	   cells	  with	  platelets	  has	  been	   shown	   to	  have	   increased	  activity	   in	  patients	  with	   IPAH	  
[12].	   Imbalance	   in	   vasoactive	   mediators:	   increase	   in	   proaggregatory	   thromboxane	   A2	   and	  
decrease	  in	  aggregation	  inhibiting	  prostaglandins	  and	  NO	  observed	  in	  PAH	  patients,	  further	  results	  
in	   heightened	   platelet	   aggregation	   and	   enhanced	   thrombosis	   in	   pulmonary	   vasculature	   [13].	  
Though	   thrombotic	   lesions	   in	   pulmonary	   vasculature	   are	   found	   in	   all	   severe	   forms	  of	   PH,	   these	  
lesions	  have	  never	  been	  associated	  with	  the	  severity	  of	  disease	  [14].	  
1.1.2.3	  Vascular	  remodeling	  	  
	   Vascular	  remodeling	  refers	  to	  structural	  changes	  that	  result	  in	  hypertrophy	  and/or	  luminal	  
occlusions.	  A	  fine	  balance	  between	  proliferation	  and	  apoptosis	  of	  fibroblasts,	  pulmonary	  artery	  -­‐
smooth	   muscle	   cells	   (PASMCs)	   and	   -­‐endothelial	   cells	   (PAECs)	   are	   maintained	   under	   normal	  
conditions.	   Disturbing	   this	   balance	   in	   favour	   of	   proliferation	   as	   observed	   in	   PH,	   results	   in	  






	   	  
increased	   PVR	   [8].	   In	   PAH,	   the	   common	   vascular	   histological	   findings	   involve	   remodeling	   of	   all	  
three	   layers	   characterized	  by	   intimal	  hyperplasia	  and	  plexiform	   lesions,	  medial	  hypertrophy	  and	  
adventitial	  proliferation	  [2]	  (Figure	  1.1).	  	  
	  
Figure	   1.1	   Histology	   of	   PAH.	   Top:	   Plexiform	   lesions.	   Upper	   Left:	   Evidence	   of	   cell	   proliferation	   (red	   is	  
proliferating	   cell	   nuclear	   antigen	   [PCNA],	   green	   is	   smooth	  muscle	   [SM]	   actin,	   and	  blue	   is	  DAPI).	   Bottom:	  
Medial	  hypertrophy,	  intimal	  fibrosis,	  and	  adventitial	  proliferation.	  (Archer	  et.al,	  Circulation,	  2010)	  [15]	  
	  
Intimal	  lesions	  
Intimal	  lesions	  account	  for	  major	  reduction	  in	  luminal	  area	  of	  small	  pulmonary	  arteries	  and	  
hence,	   largely	   influence	  the	  overall	  PVR.	  These	   lesions	  consist	  of	  eccentric	   intima	  thickening	  and	  
concentric	  and	  fibrotic	  plexiform	  lesions	  [16].	  
Intima	  thickening	  can	  be	  concentric	  laminar,	  eccentric,	  or	  concentric	  nonlaminar.	  Cells	  present	  in	  
the	  thickening	  exhibit	  properties	  of	  fibroblasts,	  myofibroblasts	  and	  smooth	  muscle	  cells	  [16,	  17].	  In	  
severe	   cases,	   lesions	   are	   characterized	   by	   “fibrotic”	   pattern,	  with	   abundant	   extracellular	  matrix	  
(ECM)	  deposition.	  
Plexiform	   lesions,	  generally	  observed	  at	  branch	  points,	  are	  complex	  and	  disorganized	  pulmonary	  
arterial	  proliferative	  lesion	  consisting	  of	  a	  network	  or	  plexus	  of	  channels	  lined	  by	  endothelial	  cells	  






	   	  
Medial	  hypertrophy	  
A	   prominent	   feature	   of	   vascular	   remodeling	   is	   medial	   smooth	   muscle	   cell	   hypertrophy	  
involving	  muscularized	  arteries	  (70-­‐800μm	  in	  diameter)	  and	  pre-­‐capillary	  vessels	  (below	  70μm	  in	  
diameter)	  [16].	  In	  previously	  muscularized	  vessels,	  medial	  thickening	  is	  caused	  by	  hypertrophy	  and	  
hyperplasia	  of	  the	  existing	  smooth	  muscle	  cells	  (SMCs)	  [19].	  Increased	  proliferation	  of	  the	  cells	  is	  
accompanied	   with	   a	   decreased	   rate	   of	   apoptosis.	   Additionally,	   SMCs	   and	   fibroblasts	   produce	  
extracellular	  matrix	   proteins	  which	   further	   contribute	   to	   remodeling	   [16].	   In	   pre-­‐capillary	   (non-­‐
muscularized)	   vessels,	  de	   novo	   formation	   of	  muscular	  media	   is	   observed.	   Smooth	  muscle	   cells,	  
which	   form	   the	   new	   media,	   are	   suggested	   to	   be	   derived	   from	   either	   differentiation	   of	  
intermediate	   cells	   present	   in	   the	   vessels	   or	   from	   migration	   and	   differentiation	   of	   adventitial	  
fibroblasts	  [19,	  20].	  
Adventitial	  proliferation	  
Adventitial	   layer,	   mostly	   composed	   of	   fibroblasts,	   initially	   considered	   a	   mere	   structural	  
support	  for	  vessels	  has	  come	  up	  in	  recent	  research	  as	  an	  important	  player	  in	  pulmonary	  vascular	  
remodeling.	   In	  animal	  models	  of	  hypoxia,	   the	  earliest	  and	  most	  dramatic	   structural	   changes	  are	  
observed	  in	  the	  adventitial	  layer	  of	  the	  vessel	  wall,	  which	  further	  initiate	  remodeling	  of	  the	  medial	  
and	   intimal	   compartments	   [21].	   It	   has	   been	   established	   that	   the	   heterogenous	   population	   of	  
pulmonary	  artery	  adventitial	   fibroblasts	   (PAFBs),	  can	  proliferate	  and	  secrete	  various	  chemokines	  
facilitating	  recruitment	  of	  inflammatory	  cells	  and	  differentiate	  into	  myofibroblasts	  in	  response	  to	  
environmental	   stress	   [20].	   Myofibroblasts	   are	   the	   major	   producers	   of	   collagen	   and	   other	   ECM	  
proteins	   and	   can	   further,	   migrate	   to	   medial	   or	   intimal	   layer	   effecting	   neointima	   formation.	  
Accumulation	  of	  myofibroblasts	  in	  intima	  of	  patients	  with	  PAH	  is	  well	  documented	  [18].	  	  
1.2.3	  Molecular	  mediators	  of	  PAH	  
With	  the	  growing	  amount	  of	  research,	  perturbations	  in	  a	  number	  of	  molecular	  mechanisms	  
have	  been	  described	  as	  the	  players	  in	  pathogenesis	  of	  PAH.	  Various	  changes	  in	  signaling	  pathways	  
involving	   vasoconstriction,	   growth	   factors	   and	   inflammation	   have	   shown	   to	   drive	   the	   disease	  
progression.	  	  
1.2.3.1	  Vascular	  tone	  modulators	  and	  enhancers	  
Prostacyclin	  
	   Prostacyclin	  (PGI2),	  a	  product	  of	  arachidonate	  metabolism	  by	  cyclooxygenase,	  is	  a	  strong	  






	   	  
smooth	   muscle	   cells	   and	   anti-­‐aggregation	   effect	   on	   platelets[22].	   Prostacyclin	   production	   is	  
decreased	  in	  endothelial	  cells	  from	  PAH	  patients	  [10],	  attributable	  to	  suppression	  of	  prostacyclin	  
synthase	  expression	  in	  small	  and	  medium	  sized	  pulmonary	  arteries	  [23].	  PGI2	  -­‐receptor	  knockout	  
mice	   develop	   highly	   severe	   hypoxia-­‐induced	   PH	   [24]	   while	   PGI2	   receptor	   overexpressing	   mice	  
demonstrate	  a	  protection	  against	  hypoxia	  induced	  PH	  [23].	  	  
Nitric	  oxide	  (NO)	  
	   NO	   is	   synthesized	   from	   L-­‐arginine	   in	   endothelium	  by	   endothelial	  NO	   synthase	   (eNOS).	   It	  
stimulates	  soluble	  guanylate	  cyclase	  (sGC)	  to	  produce	  cyclic	  guanosine	  monophosphate	  (cGMP)	  in	  
PASMCs,	  exerting	  vasodilatory	  and	  anti-­‐proliferative	  effects	  [25].	  All	  forms	  of	  PH	  are	  believed	  to	  be	  
associated	  with	  a	  state	  of	  reduced	  NO	  bioavailability,	  as	  an	  outcome	  of	  reduced	  NOS	  expression	  
[26],	   oxidative	   stress	   [27]	   and/or	   inhibition	   of	   NO	   synthesis	   [28].	   Oxidative	   stress	   leads	   to	  
production	  of	   free	   radicals,	   like	   superoxide	  which	   react	  with	  NO	   to	   form	  peroxynitrite,	   reducing	  
NO	   levels	   [27].	   Asymmetric	   dimethyl	   arginine	   (ADMA),	   an	   endogenous	   competitor	   of	   NOS	   is	  
increased	  in	  IPAH	  patients	  while	  enzyme	  responsible	  for	  its	  hydrolysis,	  dimethyl	  arginine	  dimethyl	  
aminohydrolase	  (DDAH2)	  is	  decreased	  in	  IPAH	  patients	  [28].	  
Vasoactive	  intestinal	  peptide	  (VIP)	  
	   VIP,	   primarily	   functioning	   as	   a	   neurotransmitter,	   also	   acts	   as	   a	   potent	   pulmonary	  
vasodilator	   and	   anti-­‐proliferative	   agent	   [29].	   Low	   serum	   concentrations	   and	   decreased	   VIP	  
immuno-­‐reactivity	  were	  shown	  in	  pulmonary	  arteries	  from	  IPAH	  patients	  [30].	  
Endothelin-­‐1	  (ET-­‐1)	  
	   ET-­‐1	  is	  a	  potent	  vasoconstrictor	  and	  mitogenic	  factor	  for	  PASMCs	  and	  has	  been	  found	  to	  be	  
upregulated	  in	  lungs	  and	  plasmaof	  patients	  with	  PH	  of	  various	  etiologies	  [31]	  [32].	  ET-­‐1	  mediates	  
its	  proliferative	  functions	  in	  PASMCs	  via	  binding	  to	  ET-­‐A	  and	  ET-­‐B	  receptors	  (ETRA,	  ETRB)	  [33].	  As	  
ETRB	  on	  endothelial	  cells	   is	   involved	  in	  release	  of	  vasodilators	  [34],	  hence,	  selective	  inhibition	  of	  
ETRA	  has	  moved	  into	  focus	  in	  therapeutic	  targeting	  	  of	  ET-­‐1	  pathway	  in	  PH	  [33].	  	  
Serotonin	  	  
Serotonin	   (5-­‐Hydroxytryptamine,	   5-­‐HT),	   produced	   in	   pulmonary	   artery	   endothelial	   cells	   (PAECs),	  
causes	   vasoconstriction	   and	   remodeling	   in	   PASMCs	   and	   PAFBs	   in	   a	   paracrine	   manner,	   via	  
serotonin	   transporter	   (5-­‐HTT)	   and	   receptors	   [35].	   Increased	   circulating	   5-­‐HT	   levels,	   along	   with	  
increased	  5-­‐HTT	  expression	  on	  PASMCs	  are	  observed	   in	  PAH	  patients	   [36,	   37].	   	   5-­‐HTT	   knockout	  
mice	  are	  protected	  to	  an	  extent	  against	  hypoxia-­‐induced	  PH	  [38],	  while	  5-­‐HTT	  overexpressing	  mice	  






	   	  
K+/	  Ca2+	  channels	  
The	  classical	  function	  of	  these	  ion	  channels	  is	  to	  regulate	  membrane	  potential	  and	  vascular	  
tone.	  Microarray	   studies	   have	   shown	   downregulation	   of	   voltage	   gated	   potassium	   channels	   (Kv	  
channel)	  genes	  in	  PAH	  lungs	  [40].A	  selective	  loss	  of	  pulmonary	  artery	  smooth	  muscle	  Kv	  channels	  
has	   been	   described	   in	   lung	   tissue	   from	   humans	   with	   PAH	   (notably	   Kv1.5)	   and	   from	   rats	   with	  
hypoxia	   induced	   PH	   (Kv1.5	   and	   Kv1.2),	   leading	   to	   membrane	   depolarization,	   increase	   in	  
intracellular	  calcium	  and	  	  induction	  of	  vasoconstriction	  and	  proliferation	  [29].	  Elevated	  expression	  
of	   transient	   receptor	  potential	   channels	   (TRPC),	   TRPC3	  and	  TRPC6,	   in	  PASMCs	  of	   IPAH	  patients,	  
indicate	  important	  role	  of	  Ca2+	  signaling	  through	  TRP	  channels	  in	  IPAH	  [41].	  
1.2.3.2	  Pro-­‐proliferative	  mediators	  
Transforming	  growth	  factor	  β	  (TGF	  β)	  	  
	   The	  TGF	  β	  superfamily	  comprises	  of	  a	   large	  number	  of	  growth	   factors	   that	  control	  many	  
cellular	   functions	   including	   proliferation,	   migration,	   differentiation	   and	   extracellular	   matrix	  
secretion	   and	   deposition.	   Alterations	   in	   two	   TGF	   β	   family	   members	   have	   been	   linked	   to	  
pathogenesis	  of	  PAH.	  Germline	  mutations	  in	  gene	  coding	  for	  BMPR2	  have	  been	  identified	  in	  more	  
than	  60%	  cases	  of	  familial	  PAH	  and	  10	  to	  30%	  cases	  of	  IPAH	  [42,	  43].	  Furthermore,	  mutations	  in	  
genes	   for	   type	   I	   TGF	   β	   receptors	   ALK-­‐1	   and	   endoglin	   have	   been	   linked	   with	   severe	   PAH	  
development	  in	  families	  with	  hereditary	  hemorrhagic	  telangiectasia	  [44].	  	  	  
Platelet	  derived	  growth	  factor	  (PDGF)	  
	   PDGFacts	  as	  potent	  mitogen	  and	  chemoattractant	  for	  SMCs	  [45].	  An	  increased	  expression	  
of	  PDGF	  and	  PDGF	  receptors	  has	  been	  demonstrated	  in	  pulmonary	  arteries	  of	  IPAH	  patients	  [46].	  
Additionally,	  upregulation	  of	  PDGF	  receptor	  β	  (PDGFR	  β)	  has	  been	  observed	  in	  animal	  models	  of	  
PAH,	   contributing	   primarily	   to	   the	   proliferative	   and	   migratory	   phenotype	   of	   PASMCs	   [47].	  
Administration	   of	   Imatinib	   (PDGFR	   antagonist)	   after	   establishment	   of	   disease	   in	  monocrotaline	  
and	   hypoxia	   models,	   dose	   dependently	   reversed	   the	   vascular	   remodeling	   and	   improved	  
hemodynamics	  [48].	  
Other	  growth	  factors	  
	   Similar	  to	  PDGF,	  several	  other	  growth	  factors	  have	  been	  implicated	  in	  pathogenesis	  of	  PAH.	  
Activation	  of	  tyrosine	  kinase	  receptors	  by	  these	  growth	  factors	   leads	  to	   initiation	  of	   intracellular	  
signaling	  cascades	  leading	  to	  cellular	  proliferation,	  migration	  and	  apoptotic	  resistance.	  






	   	  
(VEGFR2)	  has	  been	  reported	  in	  plexiform	  lesions	  found	  in	  lungs	  of	  IPAH	  and	  secondary	  PH	  patients	  
[49].	  	  
	   Epidermal	   growth	   factor	   (EGF)	   was	   found	   to	   be	   co	   localized	   with	   Tenascin	   C,	   an	   ECM	  
component,	  in	  the	  vascular	  lesions	  in	  PAH	  patients	  [50].	  EGFR	  signaling	  was	  further	  demonstrated	  
to	  be	  deregulated	   in	  MCT	   induced	  PAH	   rats	   and	   treatment	  with	  EGF	   receptor	   inhibitor,	   PKI166,	  
induced	  PASMC	  apoptosis	  and	  increased	  survival	  of	  the	  rats	  [51].	  	  	  
	   Increased	  levels	  of	  basic	  fibroblast	  growth	  factor	  (bFGF/FGF-­‐2)	  have	  been	  found	  in	  plasma	  
and	   urine	   samples	   from	   PAH	   patients	   [52].	   Recent	   findings	   demonstrate	   that	   PAECs	   from	   PAH	  
patients	   produce	   increased	   levels	   of	   FGF-­‐2,	   which	   contributes	   to	   increased	   proliferation	   of	  
PASMCs	  and	  additionally,	  inhibition	  of	  FGF2	  signaling	  using	  SU5402	  reversed	  established	  PH	  in	  the	  
same	  model	  [53].	  	  
Survivin	  
	   Survivin	  is	  the	  smallest	  member	  of	  family	  of	  “inhibitor	  of	  apoptosis”	  (IAP)	  proteins,	  known	  
to	   be	   essentially	   expressed	   in	   all	   cancers	   but	   not	   in	   normal	   adult	   tissues	   [54].	   It	   was	   found	   be	  
exclusively	   expressed	   in	   remodelled	   pulmonary	   arteries	   in	   PAH	   patients	   and	  MCT	   induced	   PAH	  
rats.	   Administration	   of	  mutant	   survivin	   with	   dominant	   negative	   features	   via	   inhaled	   adenoviral	  
gene	  therapy	  reversed	  MCT	  induced	  PAH,	  while	  administration	  of	  wild	  type	  survivin	  to	  normal	  rats	  
induced	  PH	  [55].	  
1.2.3.4	  Inflammation	  
Presence	   of	   inflammatory	   cells	   including	   monocytes,	   macrophages,	   T	   lymphocytes	   and	  
dendritic	   cells	   in	   plexiform	   and	   other	   vascular	   lesions	   in	   PAH	   patients	   and	   occurrence	   of	   PAH	  
secondary	   to	  classical	   inflammatory	   syndromes	   (HIV	   infection,	   schistosomiasis)	   clearly	   indicate	  a	  
strong	   role	   of	   inflammation	   in	   pathogenesis	   of	   PAH	   [56].	   In	   response	   to	   infection	   and	  
inflammatory	   events,	   lung	   vascular	   cells	   produce	   inflammatory	   mediators	   (chemokines	   and	  
cytokines),	  thereby	  recruiting	  the	  inflammatory	  cells.	  	  
Cytokines	  
	   Heightened	   levels	  of	   circulating	  cytokines,	  Tumor	  necrosis	   factor	   (TNF),	   Interlukin-­‐1β	  and	  
Interlukin-­‐6	  (IL-­‐6)	  has	  been	  shown	  in	  IPAH	  patients	  [13].	  These	  findings	  are	  further	  supported	  by	  
animal	  models	  as	  MCT	  induced	  PH	  rats	  exhibit	  an	   increased	  expression	  of	   IL-­‐6	   in	  their	   lungs	  and	  
rats	  injected	  with	  IL-­‐6	  develop	  PH.	  IL-­‐6	  knockout	  mice	  are	  protected	  to	  an	  extent	  against	  hypoxia-­‐






	   	  
PH	  [58].	  Further	  data	  suggested	  interaction	  between	  IL-­‐6	  and	  BMPRII	  where	  loss	  of	  BMPRII	  in	  mice	  
lead	   to	   upregulation	   of	   IL-­‐6	   production	   [59]	   and	   increased	   IL-­‐6	   levels	   were	   found	   to	   suppress	  
expression	  of	  BMPRII	  [60].	   	  
Chemokines	  
	   Chemokines	   play	   a	   role	   in	   leukocyte	   recruitment	   and	   trafficking	   in	   PH,	   such	   as	   rolling,	  
activation,	  adhesion	  and	  extravasation	  into	  the	  inflamed	  tissue	  along	  a	  chemoattractant	  gradient	  
[56].	  Fractalkine	   (CX3CL1)	  a	  soluble	  chemotactic	  protein	  which	   is	  also	   found	  as	  a	  membrane	  cell	  
adhesion	   molecule	   on	   ECs,	   promotes	   chemokine	   receptor	   1	   (CX3CR1)	   expressing	   leukocyte	  
recruitment	   [13].	   CXCL3	   expression	   is	   found	   to	   be	   upregulated	   in	   circulating	   CD4+	   and	   CD8+	   T-­‐
lymphocytes	   and	   inflammatory	   cells	   surrounding	   PA	   lesions	   in	   IPAH	   patients	   [61].	   Other	  
chemokines	   upregulated	   in	   PAH	   patients	   are	   RANTES	   (CCL5)	   and	   chemokine	   ligand	   2	   (CCL2).	  
Elevated	   levels	   of	   CCL2	   are	   produced	   from	   PAECs	   of	   IPAH	   patients	   and	   interestingly,	   PASMCs	  
isolated	  from	  the	  patients	  also	  exhibit	  a	  stronger	  migratory	  and	  proliferative	  response	  to	  CCL2	  as	  
compared	  with	  control	  subjects	  [62].	  	   	   	   	  
1.2.4	  Treatment	  approaches	  for	  PAH	  
	   Pulmonary	  Hypertension	   is	  characterized	  by	  poor	  prognosis	  and	  until	  now,	  no	  cure	  exists	  
for	   the	   disease.	   However,	   improved	   understanding	   of	   the	   patho-­‐biological	   mechanisms	   of	   the	  
disease	   has	   resulted	   in	   the	   development	   of	   effective	   therapies	   targeting	   specific	   aberrant	  
pathways.	  At	  present,	  there	  are	  three	  classes	  of	  vasodilatory	  medications	  available	  :	  prostanoids,	  
endothelin	   receptor	   antagonists	   and	   phosphodiesterase-­‐5	   (PDE-­‐5)	   inhibitors,	  which	   have	   shown	  
efficacy	   in	   treatment	   of	   PAH	   by	   targeting	   different	   pathways	   involved	   in	   proliferation	   and	  
contraction	   of	   PASMCs	   (Figure	   1.3,	   green	   lines).	   Several	   other	   potential	   pathways	   targeting	  
pulmonary	   vascular	   remodeling	   have	   been	   identified	   and	   are	   under	   investigation	   for	   drug	  






	   	  
	  
Figure	  1.2	  Current	  and	  emerging	  targets	  and	  therapies	  for	  Pulmonary	  Arterial	  Hypertension.	  Pulmonary	  
artery	  smooth	  muscle	  cell	  therapeutic	  targets	  and	  corresponding	  licensed	  (green	  boxes)	  and	  investigational	  
(red	   boxes)	   treatment	   approaches	   for	   pulmonary	   arterial	   hypertension.	   Arrows	   represent	   receptor	  
stimulation,	  whereas	   terminated	   lines	  show	  receptor	  blockade.	  AC,	  adenylate	  cyclase;	  cAMP,	  cyclic	  AMP;	  
cGMP,	  cyclic	  GMP;	  ECE-­‐1,	  endothelin	  converting	  enzyme	  1;	  eNOS,	  endothelial	  nitric	  oxide	  synthase	  ;	  ETA,	  
endothelin	   receptor	   type	   A;	   ETB,	   endothelin	   receptor	   type	   B;	   ERA,	   endothelin	   receptor	   antagonists;	   IP,	  
prostaglandin	  I2;	  PDE-­‐5,	  phosphodiesterase	  type	  5;	  PDGF,	  platelet	  derived	  growth	  factor;	  PDGF-­‐R	  TKI,	  PDGF	  
receptor	   tyrosine	   kinase	   inhibitors;	   PGIS,	   prostaglandin	   I	   synthase;	   sGC,	   soluble	   guanylate	   cyclase;	  VPAC,	  
vasointestinal	  peptide	  receptor.	  (O’Callaghan	  et.	  al.,	  Nat.	  Rev.	  Cardiol.,	  2011)	  [63]	  
1.2.4.1	  Currently	  available	  therapies	  
Prostanoids	  
	   Endothelium	   derived	   prostacyclin	   is	   a	   potent	   pulmonary	   vasodilator,	   also	   exerting	   anti-­‐
proliferative	   and	   anti-­‐thrombotic	   effects	   [22].	   Intravenous	   Epoprostenol	   was	   the	   first	   approved	  
therapeutic	  approach	   to	  show	   improved	  conditions	  and	  survival	   in	  PAH	  patient	   [64].	  Due	   to	   the	  
disadvantage	  of	  short	  half-­‐life	  and	  systemic	  side	  effects,	  new	  prostacyclin	  analogs	  with	  longer	  half-­‐
life	  and	  alternative	  routes	  of	  administration	  were	  developed.	  They	  include:	  Treprostenol	  with	  half-­‐
life	  of	  4.5	  hours	  [65],	  Iloprost	  [66]	  and	  Beraprost	  [67],	  administered	  intravenous,	  subcutaneous	  or	  
by	  inhalation	  in	  PAH	  patients.	  	  
Endothelin	  receptor	  antagonists	  (ERAs)	  
	   ET-­‐1,	   produced	   by	   endothelial	   cells,	   is	   a	   potent	   vasoconstrictor	   and	   PASMCs	   mitogen	  
playing	  an	  important	  role	  in	  pathogenesis	  of	  PAH	  [31].	  Bosentan,	  an	  oral	  non	  selective	  antagonist	  
(binding	  to	  both	  receptor	  A	  and	  B),	  has	  proved	  its	  efficacy	  for	  treatment	  of	  PAH	  in	  two	  randomized	  






	   	  
patients	   taking	   the	  drug.	  As	  binding	  of	   endothelin	   to	   receptor	  A	  has	  been	  described	   in	   vascular	  
remodeling,	   ERA	   specific	   antagonists,	   Sitaxentan	   [69]	   and	   Ambrisentan	   [70]	   were	   developed.	  
Though	   Sitaxentan	   was	   withdrawn	   from	   the	   market	   in	   2010	   as	   an	   outcome	   of	   a	   number	   of	  
patients	  death	  due	  to	  acute	  liver	  failure	  [63],	  Ambrisentan	  is	  an	  approved	  drug	  for	  PAH.	  A	  novel,	  
highly	   potent,	   tissue-­‐targeting	   ERA,	   Macitentan	   characterized	   by	   high	   lipophilicity	   is	   under	  
investigation	  [71].	  
Phosphodiesterase-­‐5	  (PDE-­‐5)	  inhibitors	  	  
	   PDE-­‐5,	   enzyme	   abundantly	   found	   in	   pulmonary	   vasculature,	   inactivates	   cGMP,	   the	  
secondary	  messenger	  responsible	  for	  mediating	  the	  vasodilatory	  activity	  of	  NO	  [25].	  Hence,	  PDE-­‐5	  
inhibitor,	   Sildenafil,	   initially	   used	   for	   erectile	   dysfunction,	   has	   emerged	   as	   an	   important	   drug	  
therapy	   for	   PAH	   [72,	   73].	   Beneficial	   effects	   including	   improved	   symptoms,	   hemodynamics,	  
exercise	  capacity	  and	  survival	  have	  been	  shown	  by	  a	  one-­‐year	  extension	  study	  after	  a	  daily	  oral	  
treatment	   with	   sildenafil	   for	   12	   weeks	   [73].	   Another	   PDE-­‐5inhibitor,	   Tadalafil,	   having	   the	  
advantage	  of	  once-­‐daily	  dosing,	  has	  been	  granted	  regulatory	  approval	  for	  use	  in	  patients	  with	  PAH	  
in	  2009	  [74].	  
1.2.4.2	  Emerging	  treatment	  approaches	  
VIP	  
	   As	   described	   above	   (section	   1.2.3.1),	   VIP	   has	   been	   documented	   to	   contribute	   to	   the	  
pathogenesis	   of	   PAH,	   suggesting	   that	   targeting	   VIP	   might	   be	   a	   useful	   approach.	   Aviptadil,	   VIP	  
analog,	   administered	   by	   inhalation,	   has	   demonstrated	  modest	   increase	   in	   cardiac	   output	   along	  
with	   transient	   vasodilation	   and	   increased	   stroke	   volume	   in	   PAH	  patients	  with	   various	   etiologies	  
[75].	  	  
sGC	  stimulators	  and	  activators	  
	   As	   the	   therapeutic	   effect	   of	   PDE-­‐5	   inhibitors	   is	   dependent	   on	   baseline	   NO	   expression,	  
typically	  reduced	  in	  PAH	  [76],	  therefore,	  treatments	  that	  act	  directly	  on	  soluble	  Guanalyte	  cyclase	  
(sGC)	  could	  potentially	  have	  a	  greater	  efficacy	  than	  them.	  Interestingly,	  one	  such	  NO	  independent	  
sGC	   stimulator,	   Riociguat	   has	   proven	   to	   be	   effective	   in	   hypoxia	   induced	   PH	   in	   mice	   and	   MCT	  
induced	   PAH	   in	   rats	   [77].	   Improvements	   in	   symptoms,	  NYHA	   functional	   class,	   exercise	   capacity,	  
NT-­‐proBNP	   level,	   and	   pulmonary	   hemodynamics	   was	   observed	   in	   PAH	   and	   CTEPH	   patients	   in	  
Phase	   II	   trials	   with	   oral	   Riocioguat	   for	   12	   weeks	   [78].	   Preliminary	   results	   of	   Phase	   III	   trials	   are	  






	   	  
Prostacyclin	  receptor	  agonists	  
	   Effectiveness	  demonstrated	  by	  prostanoids	  in	  therapy	  of	  PAH	  has	  led	  to	  development	  of	  a	  
new	  class	  of	  non-­‐prostanid	  agonists	  specific	  for	  prostacyclin	  IP	  receptors.	  Selexipag	  is	  first-­‐in-­‐class	  
orally	  active	  prodrug	  which	  is	  metabolized	  to	  highly	  selective	  IP	  receptor	  agonist	  MRE-­‐269,	  having	  
half-­‐life	  of	  over	  6hrs	   [79].	   Treatment	  of	  43	  patients	  with	   this	  drug	   in	  Phase	   IIa	   trials	  has	   shown	  
significant	  improvements	  in	  PVR	  values	  and	  6	  min	  walk	  distance,	  leading	  to	  phase	  III	  randomized	  
trials.	  
Tyrosine	  kinase	  inhibitors	  
	   The	   current	   therapeutic	   approaches	   as	   well	   as	   above	   mentioned	   emerging	   strategies	  
mainly	   provide	   symptomatic	   relief	   and	   some	   improvement	   in	   prognosis.	   Thus,	   a	   need	   of	  
compounds	   that	   reverse	   the	   remodeling	   observed	   in	   the	   disease	   has	   led	   to	   use	   of	   receptor	  
tyrosine	  kinase	  inhibitors	  (RTKs)	  in	  PAH.	  Most	  promising	  drug	  from	  this	  class	  is	  Imatinib	  (ST1571),	  
an	  orally	  active	  selective	  inhibitor	  of	  RTK	  BCR-­‐ABL	  and	  PDGFRβ,	  currently	  licensed	  for	  treatment	  of	  
chronic	  myleogenous	   leukemia	   (CML)	   and	   gastrointestinal	   tumors.	   RTKs	   including	   PDGFRβ	   have	  
been	   implicated	   in	   pathogenesis	   of	   PAH	   in	   humans	   and	   in	   rodent	   PH	   models	   (as	   discussed	   in	  
section	  1.2.3).	  Imatinib	  was	  shown	  to	  reverse	  experimental	  pulmonary	  hypertension	  via	  inhibition	  
of	  PDGFRβ	  signaling	  [48].	  	  
	   The	  drug	  was	  first	  used	  in	  patients	  with	  advance	  disease	  receiving	  other	  PAH	  specific	  drugs	  
[80]	   and	   in	   PAH	   patients	   with	   CML	   [81]	   in	   2005.	   Results	   showed	   favourable	   clinical	   and	  
hemodynamic	   responses.	   Enrolment	   for	   the	   phase	   III	   randomized	   clinical	   trials	   has	   been	  
completed	  and	  preliminary	  results	  are	  expected	  soon	  [63].	  
The	  muitikinase	  inhibitor,	  Sorafenib	  and	  the	  EGFR	  inhibitor,	  Iressa,	  have	  already	  shown	  to	  
attenuate	   vascular	   remodeling	   in	   the	   animal	   models	   of	   PH	   [51,	   82]	   and	   appear	   promising	   for	  
future	  therapy	  of	  PAH.	  	   	  
1.2	  Notch	  Signaling	  Pathway	  
	   Notch	  gene	  was	  discovered	  more	  than	  90	  years	  ago	  and	  was	  named	  after	  the	  notched	  wing	  
phenotype	  observed	  in	  mutant	  Drosophila	  [83].	  It	  is	  an	  evolutionarily	  conserved	  signaling	  pathway	  
essential	  for	  cell-­‐fate	  determination	  during	  embryonic	  development	  in	  organisms	  ranging	  from	  sea	  
urchins	   to	  humans	   [84].	   There	  are	  many	  unique	   features	  of	   this	   cascade	   that	   sets	   it	   apart	   from	  
other	   signaling	   pathways.	   Firstly,	   both	   the	   receptors	   and	   ligands	   are	   transmembrane	   proteins.	  






	   	  
an	  active	   fragment	  which	  translocates	   to	   the	  nucleus	  and	  activates	   transcription	  of	  downstream	  
target	  genes	  [85].	  
1.2.1	  Components	  of	  Canonical	  Notch	  Signaling	  Pathway	  
Notch	  receptors	  
	   Notch	   receptors	   are	   large	   single	   pass	   type	   I	   transmembrane	   proteins	   first	   identified	   in	  
Drosophila	   [86-­‐88]	   and	   later	   in	   mammals,	   Notch1	   [89],	   2	   [90],	   3	   [91]	   and	   4	   [92].	   Drosophila	  
melanogaster	   possesses	   only	   one	   Notch	   receptor,	   C.	   Elegans	   possesses	   two	   redundant	   notch	  
receptors	   while	   mammals	   have	   4	   notch	   receptors	   (Notch1-­‐4),	   displaying	   both	   redundant	   and	  
unique	   functions	   [85].	   Notch	   is	   synthesized	   as	   a	   single	   polypeptide	   in	   ER	   where	   it	   is	   further	  
fucosylated	  by	  O-­‐fucosyl-­‐	  transferase	  (OFUT1)	  and	  glycosylated	  by	  O-­‐glucosyl-­‐transferase	  (Rumi).	  
It	   is	   then	   translocated	   to	  Golgi	  where	   it	   is	   cleaved	  by	   Furin	  protease	  at	   the	  S1	   site	   and	   further,	  
modified	  by	  N-­‐acetylglucosaminyltransferase,	  Fringe	  [93].	  	  
	   Notch	   receptor	   is	  displayed	  on	  cell	   surface	  as	  a	  heterodimer,	   consisting	  of	  an	  N-­‐terminal	  
extracellular	  domain	   joined	  non-­‐covalently	   to	  C-­‐terminal	   fragment	   consisting	  of	   transmembrane	  
domain	   and	   intracellular	   domain.	   The	  N	   terminal	   part	   of	   notch	   extracellular	   domain	   consists	   of	  
EGF	   (Epidermal	   growth	   factor)-­‐like	   repeats	   and	   LNRs	   (lin-­‐12	   Notch	   repeats).	   In	   mammals,	   EGF	  
repeats	   11	   and	   12	   interact	   with	   the	   ligands.	   NICD	   (Notch	   Intra-­‐cellular	   Domain)	   consists	   of	   N	  
terminal	  RAM	  (recombination	  binding	  protein-­‐Jκ	  associated	  molecule)	  domain,	  an	  ankyrin	  domain,	  
and	  less	  conserved	  regions,	  a	  variable	  trans	  activation	  domain	  and	  a	  C-­‐terminal	  PEST	  (Pro-­‐Glu-­‐Ser-­‐
Thr)	  degradation	  sequence	  (Figure	  1.4)	  [94].	  In	  addition,	  Notch	  receptors	  1-­‐3	  contain	  two	  nuclear	  
localization	  signals	  (NLS)	  compared	  to	  one	  NLS	  in	  Notch4.	  
	  
	  
Figure	   1.3	   Schematic	   representation	   of	   general	   domain	   organization	   of	   Notch	   pathway	   receptors	   in	  
mammals.	  NLS,	  nulclear	   localization	  signal;	  TAD,	  transcriptional	  activation	  domain	   	  PEST,	  Pro-­‐Glu-­‐Ser-­‐Thr;	  






	   	  
DSL	  Ligands	  
	   The	  canonical	  DSL	  (Delta,	  Serrate,	  Lag2)	  ligands	  are	  responsible	  for	  most	  of	  Notch	  signaling	  
mediated	  effects.	  Mammals	  have	  5	  DSL	  family	  ligands.	  On	  the	  basis	  of	  structural	  homology	  to	  the	  
Drosophila	  ligands,	  the	  mammalian	  ligands	  are	  either	  termed	  as	  Delta	  Like	  (DLL1,	  DLL3	  and	  DLL4)	  
or	   Serrate	   like	   (Jagged1	   and	   Jagged2).	   Like	   the	   Notch	   receptors,	   DSL	   ligands	   are	   also	  
transmembrane	   proteins	   having	   extracellular	   domain	   consisting	   of	   tandem	   EGF	   repeats	   and	   a	  
cysteine	   rich	   N-­‐terminal	   DSL	   domain	   [95].	   DSL	   domain	   mediates	   binding	   of	   the	   ligands	   to	   the	  
Notch	   receptors	   [96].	   The	   intracellular	   regions	   lack	   sequence	   homology	   except	   some,	   contain	  
multiple	   lysine	   residues	  and	  a	  C-­‐terminal	  PDZ	   (PSD-­‐95/Dlg/ZO-­‐1)	   ligand	  motif,	  needed	   for	   ligand	  
signaling	  activity	  and	  interactions	  with	  the	  cytoskeleton	  respectively	  (Figure	  1.5)	  [97].	  
	  
Figure	  1.4	  Schematic	   representation	  of	  domain	  organization	  of	  DSL	   ligands	   in	  mammals.	  DLL,	  Delta	   like	  
ligand;	  DSL,	   Delta	   Serrate	   Lag2;	  EGF,	   epidermal	   growth	   factor;	  PM,	   plasma	  membrane;	   CR,	   cysteine	   rich	  
domain.	  	  
γ	  -­‐Secretase	  complex	  
	   Initial	   clues	   for	   identification	   of	   the	   γ	   -­‐Secretase	   complex	   came	   from	   genetic	   studies	   of	  
autosomal	  dominant	  forms	  of	  familial	  Alzheimer's	  disease	  (AD)	  in	  mid	  1990s.	  Missense	  mutations	  
in	   two	  unknown	  genes,	  Presenilin	  1	  and	  2	   (Psen-­‐1	  and	  2)	  were	  sufficient	   to	  cause	  an	  aggressive	  
and	  inherited	  form	  of	  AD,	  though	  their	  proteolytic	  functions	  were	  identified	  much	  later	  [98,	  99].	  
Psen-­‐1	  knockout	  not	  only	  revealed	  a	  notch	  phenotype	  but	  also,	  substantiated	  its	  requirement	  for	  
γ-­‐secretase	   proteolytic	   activity	   [100].	   Since	   then,	   γ-­‐secretase	   complex	   has	   been	   shown	   to	   have	  
three	   additional	   proteins,	   Nicastrin,	   Aph	   and	   Pen-­‐2	   [98].	   Psen1	   forms	   the	   catalytic	   core	   of	   the	  
complex,	   though	   the	  other	   three	  proteins	  are	  also	  needed	   for	  proper	   γ-­‐secretase	  activity	   [101].	  
Two	   conserved	   aspartyl	   residues,	   located	   within	   transmembrane	   domain	   6	   and	   7	   harbor	   the	  






	   	  
CSL	  transcription	  factor	  
	   Key	   effector	   molecule	   of	   the	   Notch	   signaling	   pathway	   is	   a	   DNA	   binding	   protein,	   CSL	  
((CBF1/Suppressor	   of	  Hairless/LAG-­‐1),	  which	   is	   similar	   to	   the	   Rel	   family	   of	   transcription	   factors.	  
Like	   the	   Rel	   family,	   CSL	   has	   the	   two	   Rel-­‐homology	   domains	   (RHR-­‐N,	   RHR-­‐D),	   required	   for	   DNA	  
binding	   and	   dimerisation,	   along	   with	   an	   extra	   β-­‐trefoil	   domain	   (BTD)	   between	   the	   two	   Rel	  
domains.	   This	   BTD	   domain	   is	   believed	   to	   mediate	   interaction	   with	   NICD	   [94].	   The	   target	   DNA	  
sequence	   for	   CSL	   is	   CGTGGGA	   [103].	   Interaction	   between	   Notch	   intra-­‐cellular	   domain	   and	   CSL	  
transcription	   factor	   became	   clear	   when	   a	   nuclear	   complex	   bound	   to	   a	   promoter	   regulated	   by	  
Notch	  was	  shown	  to	  contain	  CSL	  and	  Notch	  [104].	  
Notch	  target	  genes	  
	   Although	   signals	   mediated	   through	   the	   Notch	   receptors	   have	   diverse	   outcomes,	   only	   a	  
limited	  number	  of	  Notch	  target	  genes	  have	  been	  identified.	  These	  genes	  belong	  to	  the	  family	  of	  
bHLH	  (basic	  helix	  loop	  helix)	  transcription	  factors,	  namely,	  HES	  (hairy/enhancer	  of	  split)	  and	  HERP	  
(Hes	   related-­‐repressor	   protein,	   also	   called	   HEY)	   family	   [83].	   Both	   families	   share	   structure	  
similarities	  like	  bHLH	  domain,	  responsible	  for	  DNA	  binding	  and	  hetero-­‐	  or	  homo-­‐dimerization	  and	  
orange	   domain.	   The	  most	   striking	   difference	   between	   Hes	   and	   Hey	   proteins	   is	   replacement	   of	  
WRPW	   tetrapeptide	   in	   former	   to	   YRPW	   peptide	   in	   latter	   (Figure	   1.6).	   In	   mammals,	   seven	   Hes	  
(Hes1-­‐7)	   and	   three	  Hey	   (Hey1,	   2	   and	   L)	   genes	   have	   been	   identified,	  which	   are	   highly	   similar	   in	  
structure	   to	   their	  Drosophila	  ancestors,	  Hairy,	  E	   (spl)	  and	  Hey	   [105].	  Out	  of	   these,	  all	   three	  Hey	  
genes	  and	  Hes1,	  5	  and	  7	  are	  known	  to	  be	  induced	  by	  Notch,	  as	  activation	  of	  their	  promoters	  by	  




Figure	  1.5	  Domain	  organization	  of	  Hes	  and	  Hey	  proteins.	  HLH,	  helix-­‐loop-­‐helix;	  YRPW,	  tyrosine-­‐arginine-­‐
prolie-­‐tryptophan;	  WRPW,	  tryptophan-­‐arginine-­‐proline-­‐tryptophan.	  	  
Though	  Hes	  and	  Hey	  genes	  are	  the	  major	  targets	  of	  notch	  pathway,	  other	  targets	  have	  also	  






	   	  
identified	  are	   c-­‐myc	   [107],	   cyclin	  D1	   [108]	  and	  p21/Waf1	   [109].	  Most	   importantly,	   regulation	  of	  
these	  genes	  is	  tissue-­‐specific	  and	  context-­‐dependent.	  
1.2.2	  Notch	  signaling	  cascade	  
	   Notch	  signaling	  is	  triggered	  on	  direct	  cell-­‐cell	  contact.	  Interaction	  between	  Notch	  receptors	  
and	   ligands	   (Jagged	   or	   DLL),	   expressed	   on	   adjacent	   cell	   membranes	   results	   in	   activation	   of	  
signaling.	  Binding	  of	  the	  ligand,	  triggers	  two	  proteolytic	  cleavages	  in	  Notch	  receptor.	  A	  Disintegrin	  
And	   Metalloproteinase	   (ADAM)-­‐family	   of	   proteases	   catalyses	   first	   cleavage	   called	   S2	   cleavage	  
generating	   membrane	   -­‐anchored	   Notch	   extracellular	   truncation	   (NEXT)	   fragment.	   The	   NEXT	  
fragment	  acts	  as	  a	  substrate	   for	  gamma-­‐secretase	  enzyme	  complex.	  γ-­‐secretase	  mediated	  S3/S4	  
cleavage	  releases	  Notch	  intra-­‐cellular	  domain,	  which	  then	  translocates	  to	  the	  nucleus.	  In	  nucleus,	  
NICD	   binds	   to	   the	   DNA	   binding	   protein	   CSL,	   also	   called	   RBJκ	   (recombination	   signal	   sequence-­‐
binding	  protein	  Jκ).	  In	  absence	  of	  NICD,	  CSL	  is	  associated	  with	  ubiquitous	  corepressor	  proteins	  or	  
histone	   deacetylases	   (HDACs)	   to	   prevent	   transcription	   of	   target	   genes.	   Upon	   NICD	   binding,	  
allosteric	   changes	   occur	   in	   CSL,	   facilitating	   displacement	   of	   repressors.	   Coactivators,	   including	  
MAML	  (Mastermind-­‐like),	  CBP	  and	  others	  are	  subsequently	  recruited,	   leading	  to	  transcription	  of	  
Notch	  target	  genes	  (Figure	  1.7)	  [83,	  110,	  111].	  
	   MAML	  further	  recruits	  CyclinC/	  Cdk8	  pair	  which	  strongly	  enhances	  NICD	  phosphorylation.	  
This	  facilitates	  unbiquitinylation	  of	  NICD	  by	  the	  Fbw7/	  Sel10	  ubiquitin	  ligase	  resulting	  in	  rapid	  NICD	  
degradation	  and	  formation	  of	  RBP-­‐Jκ	  corepressor	  complexes	  [112].	  
	  






	   	  
R,corepressors;	   ER,	   endoplasmic	   reticulum;	   NEXT,	   notch	   extracellular	   truncation	   fragment;	   RBK-­‐Jκ,	  
recombination	  signal	  sequence	  binding	  protein	  Jκ;	  TACE,	  tumor	  necrosis	  factor-­‐α	  converting	  enzyme.	  	  
1.2.3	  Functions	  of	  Notch	  signaling	  pathway	  
Notch	  Signaling	  controls	  numerous	  cellular	  processes	  like	  stem	  cell	  maintenance,	  cell	  fate	  
specification,	  differentiation,	  proliferation	  and	  apoptosis.	  The	  three	  main	  ways	  of	  its	  function	  are:	  
Stem	  cell	  maintenance	  
Signal	   from	   the	   ligand	   expressing	   differentiated	   progeny	   cells	   prevent	   the	   notch	   expressing	  
precursor	  cells	  to	  differentiate	  and	  thus,	  maintain	  stem	  cell	  characters	  (Figure	  1.8a)	  as	  observed	  in	  
vertebrate	   nervous	   system	   where	   Notch	   signaling	   is	   believed	   to	   maintain	   balance	   between	  
precursor	  and	  differentiated	  cell	  pools	  [113,	  114].	  
Binary	  cell	  fate	  decision	  
This	   term	   refers	   to	   a	   condition	   where	   precursor	   cell	   has	   to	   choose	   between	   two	   different	   cell	  
fates.	  Notch	  signaling	  influences	  binary	  cell	  fate	  decisions	  by:	  
Lateral	  signaling:	  Initially	  two	  equipotent	  cells	  express	  equal	  amounts	  of	  the	  ligand	  (L)	  and	  notch	  
(N)	  but	  gradually	   the	  concentrations	   start	  differing.	  The	  mechanism	  behind	   this	   change	   remains	  
unknown.	   The	   ligand	   expressing	   cells	   send	   activating	   signals	   to	   notch	   expressing	   cells	   adopting	  
different	  cell	  fates	  (Figure	  1.8b)	  [115].	  
Inductive	  signaling:	  It	  involves	  signaling	  between	  two	  different	  cell	  types	  where	  a	  precursor	  cell	  is	  
instructed	   to	  differentiate	   into	  a	  particular	   cell	   fate	   after	   interacting	  with	  a	  distinct	  neighboring	  
cell	  expressing	  ligands.	  In	  absence	  of	  the	  signal	  from	  ligands,	  precursor	  would	  adopt	  another	  fate	  
(Figure	  1.8c)	  [116].	  	  
Induction	  of	  terminal	  differentiation	  
Notch	  signaling	  between	  two	  developmentally	  related	  cells	  could	  initiate	  terminal	  differentiation	  
and	  induce	  the	  cells	  to	  exit	  from	  cell	  cycle	  (Figure	  1.7d).	  For	  example,	  DLL1	  induced	  notch	  signaling	  







	   	  
	  
Figure	   1.7	   Pleiotropic	   effects	   of	   Notch	   signaling.	   Three	  main	   effects	   are	   represented	   schematically.	   (a)	  
Notch	   signaling	   can	  maintain	   stem	   cells	   or	   precursor	   populations	   in	   an	   undifferentiated	   state.	   (b)	   Notch	  
signaling	  influences	  binary	  cell-­‐fate	  decisions	  via	  lateral	  or	  inductive	  signaling.	  (c)	  A	  third	  property	  of	  Notch	  
is	  its	  ability	  to	  influence	  differentiation	  and	  cell-­‐cycle	  progression.	  (Radtke	  and	  Raj,	  Nat.	  Rev.	  Cancer,	  2003)	  
[114]	  
1.2.4	  Notch	  signaling	  in	  vasculature	  
1.2.4.1	  Notch	  and	  vascular	  development	  
Transgenic	  studies	  in	  mice,	  involving	  loss	  and	  gain	  of	  function,	  have	  shown	  that	  Notch	  signaling	  is	  
essential	   for	   vascular	   development.	   Altering	   notch	   signaling	   leads	   to	   abnormal	   vascular	  
development	  at	  different	  stages	  and	  to	  various	  degrees.	  Notch1	  homozygous	  knockout	  results	  in	  
embryonic	   lethality	  due	   to	  defects	   in	   somitogenesis	   and	   cardiovascular	   abnormalities	   [118].	  Cre	  
mediated	   deletion	   of	   endothelial	   Notch1	   during	   embryonic	   development	   is	   also	   lethal,	   proving	  
that	  arrested	  growth	  is	  associated	  with	  loss	  of	  gene	  in	  vessels/endocardium	  [119].	  Double	  knock	  
out	  of	  Notch4	  and	  Notch1,	  have	  a	  more	  severe	  vascular	  phenotype	  than	  embryonic	  Notch1	  knock	  
out	   [118],	   indicating	   that	   though	   Notch4	   is	   not	   essential	   for	   embryonic	   vascular	   development,	  
Notch1	  and	  Notch4	  have	  partially	  over	   lapping	   functions.	  Moreover,	   endothelial	   specific	   gain	  of	  
function	  of	  Notch	  4	  also	  reveals	  vascular	  defects	  [120],	  indicating	  that	  precise	  levels	  of	  Notch	  are	  






	   	  
knock	   outs	   provide	   additional	   argument	   supporting	   importance	   of	   notch	   signaling	   in	   vascular	  
development	  [121].	  	  	  
	   Analysis	  of	  zebrafish	  embryos	  lacking	  Notch	  signaling	  gave	  initial	  clue	  that	  primary	  function	  
of	   Notch	   signaling	   in	   vascular	   development	   is	   specification	   of	   arterial	   fate	   in	   endothelial	   cells.	  
These	  embryos	  exhibit	  decreased	  expression	  of	  arterial	  markers	   like	  ephrinB2	  with	  expansion	  of	  
venous	  markers	   [122].	   Notch	  was	   found	   to	   act	   downstream	  of	   VEGF	   and	   sonic	   hedgehog	   (shh)	  
pathway	   via	   activation	   of	   gridlock	   (zebrafishortholog	   of	   mammalian	   Hey)	   to	   regulate	   arterial	  
identity	   [123].	   Furthermore,	  Notch3	  null	  mice	  exhibit	  marked	  arterial	  defects	   including	  enlarged	  
arteries	  with	  abnormal	  distribution	  of	  elastic	   laminae,	   revealing	  Notch3	  as	  a	  gene	  necessary	   for	  
differentiation	  and	  acquisition	  of	  arterial	  identity	  of	  vascular	  smooth	  muscle	  cells	  [124,	  125].	  
	   In	   addition	   to	   these	   findings,	   the	   role	   of	   notch	   signaling	   in	   vascular	   development	   is	  
highlighted	  by	  the	  fact	  that	  mutations	   in	  notch	  signaling	  components	   leads	  to	   inherited	  vascular	  
disorders.	   Mutations	   in	   Notch3	   gene	   causes	   cerebral	   autosomal	   dominant	   arteriopathy	   with	  
subcortical	  infarcts	  and	  leukoencephalopathy	  (CADASIL)	  characterized	  by	  adult	  onset	  conditions	  of	  
stroke	   and	  dementia	   [126].	   The	  disease	   is	   associated	  with	   progressive	   degeneration	  of	   vascular	  
smooth	  muscle	  cells	  (vSMCs)	  and	  accumulation	  of	  granular	  osmiophilic	  material	  (GOM)	  in	  smooth	  
muscle	  cell	  vascular	  membrane	  [127].	  	  
1.2.4.2	  Notch	  signaling	  in	  adult	  vasculature	  
	   All	   four	   notch	   receptors	   are	   expressed	   in	   adult	   vasculature.	  Notch1,	  Notch2	   and	  Notch4	  
have	  been	  reported	  to	  be	  expressed	  in	  endothelial	  cells	  in	  vivo,	  while	  Notch3	  expression	  appears	  
to	  be	  restricted	  to	  the	  smooth	  muscle	  cells.	  Among	   ligands,	  only	  Jagged1,	   Jagged2	  and	  DLL4	  are	  
found	   to	   be	   involved	   in	   activating	   Notch	   signaling	   in	   vasculature	   [128].	   Notch4	   activation	   was	  
shown	  to	  promote	  survival	  in	  endothelial	  cells	  by	  up	  regulating	  anti-­‐apoptotic	  protein	  Bcl-­‐2	  [129].	  
On	  the	  other	  hand,	  constitutive	  activation	  of	  Notch	  ICD	  or	  activation	  of	  Notch	  pathway	  by	  Jagged1	  
inhibited	   proliferation	   of	   endothelial	   cells	   by	   upregulating	   p21Cip1	   [130,	   131].	   Expression	   of	  
Notch3	   is	   shown	   to	   repress	   expression	   of	   genes	   encoding	   contractile	   proteins	   and	   to	   promote	  
proliferation	  in	  vSMCs	  [132,	  133].	  During	  hypoxia,	  hypoxia	  inducible	  factor	  1α	  (HIF-­‐1α),	  is	  shown	  to	  
interact	  with	  NICD	  to	  activate	  notch	  responsive	  genes,	  to	  maintain	  cells	   in	  undifferentiated	  state	  
[134].	  Notch3	  is	  also	  shown	  to	  regulate	  expression	  of	  platelet-­‐derived	  growth	  factor	  receptor	  β	  in	  
vSMCs	  [135].	  






	   	  
vascular	  injury	  [132,	  136-­‐138].	  The	  expression	  of	  several	  Notch	  pathway	  components,	  comprising	  
of	  Notch1,	  Notch3,	   Jag1,	   Jag2	  and	  downstream	   target	   genes,	  Hey1	  and	  Hey2	  are	   regulated	   in	  a	  
temporal	  manner	  after	  experimentally	  induced	  vascular	  injury.	  Decreased	  neointima	  formation	  in	  
heterozygous	   Notch1+/-­‐	   mice	   [139]	   and	   Hey2-­‐/-­‐	   [140]	   mice	   after	   carotid	   artery	   ligation,	   provide	  
strong	  evidence	  for	  modulation	  of	  notch	  signaling	  components	  during	  response	  to	  vascular	  injury.	  	  	  
1.2.5	  Targeting	  the	  Notch	  signaling	  pathway	  
Accumulating	  evidence	  support	  the	  role	  of	  Notch	  signaling	  in	  several	  diseases,	  in	  particular	  
cancer	   [141],	   has	   led	   to	   an	   increased	   interest	   in	   therapeutic	  modulation	   of	   the	   pathway.	  Many	  
genetic	  and	  pharmacologic	  approaches	  are	  either	  available	  or	   theoretically	  possible	   to	  block	  the	  
signaling	   at	   different	   levels	   (Figure	   1.8).	   Targeting	   could	   be	   achieved	   by	   selective	   strategies	  
including	   monoclonal	   antibodies	   and	   RNA	   interference;	   non-­‐selective	   strategies	   comprising	   of	  
soluble	  ligands	  and	  receptor	  decoys;	  or	  inhibition	  of	  enzymes	  involved	  in	  glycosylation	  or	  cleavage	  
of	  receptors,	  like	  γ-­‐secretase	  inhibitors	  (GSIs)	  and	  ADAM	  inhibitors	  [142,	  143].	  	  	  	  	  	  	  	  
	  
Figure	  1.8	  Schematic	   representation	  of	  putative	   therapeutic	   targets	   in	  Notch	  Signaling.	   (Red)	   Flat	   tiped	  
arrows	  indicate	  inhibition.	  GSIs,	  γ	  secretase	  inhibitors;	  mAb,	  monoclonal	  antibody;	  MAML,	  mastermind	  like;	  
miRNA,	  micro	  RNA.	  	  
	  
GSIs,	  a	  class	  of	  small	  molecule	  inhibitors	  of	  γ-­‐secretase	  enzyme,	  form	  the	  pioneering	  group	  
of	  notch	   inhibitors,	  both	   in	   lab	  and	  clinic.	  They	  were	   found	   to	  be	  active	   in	   several	  experimental	  
models	   of	   tumors	   and	   some	   of	   them,	  MK-­‐0752	   (Merck)	   and	   RO4929097	   (Roche)	   have	   already	  






	   	  
administration,	   oral	   bioavailability	   and	   low	   cost.	   Furthermore,	   a	   single	   molecule	   can	   block	   the	  
cleavage	  of	  all	  four	  Notch	  homologs	  which	  may	  be	  favorable	  in	  conditions	  where	  more	  than	  one	  
Notch	   receptors	  needs	   to	  be	   targeted.	  However,	  main	  challenges	  with	  use	  of	  GSIs	  are	   their	  off-­‐
target	  effects	  as	  γ-­‐secretase	  has	  numerous	  targets	  other	  than	  notch	  and	  gastrointestinal	  toxicity	  
observed	   in	   pre-­‐clinical	   models	   [144]	   and	   early	   clinical	   studies.	   Though,	   intermittent	  
administration	  of	  GSIs	  was	  shown	  to	  greatly	  ameliorate	  the	  intestinal	  toxicity	  [142].	  	  
A	   more	   specific	   alternative	   to	   GSI	   based	   therapy	   is	   to	   use	   antibodies	   directed	   against	  
receptors,	   ligands	   or	   other	   components	   of	   the	   pathway.	   In	   vitro	   studies	   on	   human	   tumor	   lines	  
indicated	   that	   antibodies	   targeting	   Notch1	   and	   Notch3	   were	   able	   to	   inhibit	   oncogenic	   Notch	  
signaling,	  though	  not	  as	  potently	  as	  cell-­‐penetrating,	  small	  molecule	  GSI	  compounds	  [145].	  Several	  
Notch-­‐targeting	   antibodies	   are	   now	   being	   evaluated	   in	   preclinical	   studies,	   and	   the	   anti-­‐Notch	  
monoclonal	  antibody	  OMP-­‐59R5	  is	  in	  phase	  I	  clinical	  trials	  [146].	  
1.2.6	  Notch	  signaling	  in	  Pulmonary	  Arterial	  Hypertension	  
	   Notch3	  and	  its	  downstream	  target	  gene,	  Hes5	  were	  found	  to	  be	  elevated	  in	  lung	  biopsies	  
as	   well	   as	   in	   PASMCs	   of	   non-­‐familial	   PH	   patients.	   In	   vitro,	   Notch3	   induced	   a	   proliferative	  
phenotype	   in	   PASMCs	  which	  was	   obliterated	   by	  Hes5	   knock	   down.	   Interestingly,	  Notch3-­‐/-­‐	  mice	  
were	   resistant	   to	   development	   of	   hypoxia	   induced	   PH.	   Furthermore,	   treatment	  with	   DAPT,	   a	   γ	  
secretase	   inhibitor,	  effectively	  attenuated	  hypoxia	   induced	  PH	  in	  mice	  [147].	  This	  work	  elegantly	  
addresses	  the	  role	  of	  Notch3	  in	  phenotypic	  alterations	  of	  PAH-­‐PASMCs.	  However,	  the	  expression	  
and	  regulation	  of	  different	  Notch	  receptors	  and	  ligands	  in	  human	  PAH	  as	  well	  as	  in	  experimental	  
models	   of	   PH	   need	   to	   be	   addressed	   in	   detail.	  Most	   importantly,	   the	   role	   of	   Notch	   signaling	   in	  
initiation/	  progression	  of	  complex	  vascular	  lesions	  in	  PH	  remains	  unexplored.	  
1.3	  Animal	  models	  of	  Pulmonary	  Hypertension	  
	   Recent	   advances	   in	   our	   understanding	   of	   the	   pathophysiological	  mechanisms	   underlying	  
the	  pathogenesis	  of	  PH	  can	  be	  attributed	  to	  the	  use	  of	  experimental	  animal	  models.	  These	  animal	  
models	   have	   not	   only	   been	   the	   source	   of	   scientific	   information	   such	   as	   role	   of	   molecular	  
mechanisms	  and	  genetic	   contributions	   in	  PH	  but	   also,	  played	  an	   indispensable	   role	   in	  discovery	  
and	  testing	  of	  possible	  therapeutic	  approaches.	  	  
1.3.1	  Monocrotaline	  (MCT)	  induced	  PAH	  model	  






	   	  
toxic	   pyrrolizidine	   alkaloid	   obtained	   from	   plant	   Crotalaria	   Spectabilis,	   is	   injected	   once	   either	  
intraperitoneally	   or	   subcutaneously	   to	   induce	   PAH.	   Injected	   MCT	   is	   metabolized	   in	   liver	   by	  
cytotchrome	  P450	  3A	  to	  MCT	  pyrole,	  the	  active	  form.	  Severe	  pulmonary	  vascular	  disease	  occurs	  
within	   a	   few	   days,	   followed	   by	   pulmonary	   vascular	   remodeling	   (Figure	   1.3)	   and	   elevated	   PAP	  
[148].	   Basic	   underlying	  mechanism	   of	  MCT	   induced	   PAH	   is	   unknown,	   though	   direct	   endothelial	  
damage	   triggering	   development	   and	   progression	   of	   severe	   PH	   [149]	   and	   infiltration	   of	  
mononuclear	   inflammatory	   cells	   into	   adventitia	   leading	   to	  medial	   hypertrophy	   [150]	   have	   been	  
suggested.	   Response	   to	   MCT	   varies	   among	   strains	   and	   species	   of	   animals.	   While	   rats	   are	   the	  
preferred	   choices,	   exhibiting	   consistent	   and	  predictable	   response,	   and	  mice	  are	   resistant	   to	   the	  
effects	   of	   MCT.	   Despite	   being	   used	   extensively,	   this	   model	   is	   not	   perfect	   for	   human	   PAH	   as	  
neointima	  lesions	  observed	  in	  PAH	  patients	  are	  not	  formed	  in	  MCT	  rats.	  Moreover,	  it	  is	  relatively	  
easy	  to	  cure	  as	  so	  far	  30	  agents	  have	  been	  reported	  to	  prevent	  or	  cure	  the	  remodeling,	  very	  unlike	  
the	  human	  with	  PAH	  [151].	  	  
1.3.2	  Chronic	  Hypoxia	  (CH)	  model	  of	  PH	  	  
	   Normo-­‐	  and	  hypo-­‐baric	  hypoxia	  are	  commonly	  used	  to	  induce	  PH	  in	  wide	  variety	  of	  animal	  
species.	   Chronic	   hypoxia	   in	   rats	   exhibit	   pulmonary	   vasoconstriction,	   medial	   hypertrophy,	   and	  
increased	  muscularization	   of	   the	   small	   arteries	   with	   elevated	   smooth	  muscle	   actin	   (Figure	   1.3)	  
[148],	   mimicking	   human	   disease	   pathogenesis.	   Though	   CH	   rats	   develop	   more	   severe	   vascular	  
remodeling	  as	  compared	  to	  mice,	  but	  availability	  of	  genetically	  modified	  strains	  of	  mice	  has	  led	  to	  
more	   frequent	  use	  of	  CH	  model	   in	  mice.	  Exposure	  of	  mice	  to	  chronic	  hypoxia	   is	  associated	  with	  
minimal	  vascular	  remodeling	  causing	  an	  elevation	  in	  PAP	  and	  RV	  hypertrophy.	  The	  most	  common	  
pathological	   findings	   are	  muscularization	   of	   previously	   non-­‐muscularized	   walls	   and	   a	  moderate	  
medial	   thickening	   of	   muscular	   resistance	   walls	   [151].	   CH	   mouse	   model	   has	   been	   used	   to	  
investigate	  the	  role	  of	  NO	  pathway,	  reactive	  oxygen	  species	  (ROS)	  and	  cytoskeletal	  architecture	  in	  
development	  of	  PH	  [77,	  152,	  153].	  
	   The	  main	  limitation	  of	  this	  model	  is	  that	  CH	  induced	  PH	  in	  mice	  and	  rats	  is	  reversed	  once	  






	   	  
	  
Figure	  1.9	  Pulmonary	  artery	  remodeling	  in	  animal	  models	  compared	  to	  IPAH.	  Staining,	  elastic	  van	  Gieson.	  
Elastic	   fibers,	   blue/black/brown;	   nuclei,	   black/brown;	   collagen	   fibers,	   red;	   media,	   epithelia,	   nerves,	  
erythrocytes,	   yellow;	   IPAH,	   idiopathic	   pulmonary	   arterial	   hypertension;	   HOX,	   3	  weeks	   hypoxic	   exposure;	  
NOX,	  normoxic	  control;	  MCT,	  monocrotaline	   injection;	  EE,	  elastic	  externa;	  EI,	  elastic	   interna;	  L,	   lumen;	  N,	  
neointima,	  M,	  media;	  A	  adventitia;	  PL,	  plexiform	  lesion.	  (Pak	  et.al.,	  Drug	  Discovery	  Today,	  2010)	  [154]	  
1.3.3	  Chronic	  Hypoxia	  with	  Su5416	  rat	  model	  
In	   contrast	   to	   the	   human	   disease,	   both	   above	   mentioned	   classical	   models,	   MCT	   and	  
Chronic	   hypoxia	   model,	   lack	   formation	   of	   plexiform	   lesions,	   clustered	   proliferative	   endothelial	  
cells	   in	   lumen	  of	  pulmonary	  arteries.	  A	  modification	  of	  the	  CH	  model	   involving	  administration	  of	  
SU5416,	  vascular	  endothelial	  growth	  factor	  receptor	  2	  (VEGFR2)	  antagonist,	   to	  CH	  rats	  has	  been	  
developed,	   which	   emulates	   the	   hyperproliferative	   endothelial	   cell	   etiology	   and	   irreversible	   PH	  
(Figure	   1.3)	   [155].	   It	   was	   postulated	   that	   VEGFR2	   blockade	   with	   SU5416	   initiates	   an	   initial	  
endothelial	  cell	  apoptosis	  and	  this	  endothelial	  cell	  death	  together	  with	  chronic	  hypoxia	  results	  in	  
selection	   of	   apoptosis	   resistant	   hyper-­‐proliferative	   endothelial	   cell	   phenotype.	   Because	   of	   the	  
severity	  of	  PH,	  the	  formation	  of	  neointimal	  lesions	  and	  the	  progressive	  nature	  of	  the	  model,	  this	  
model	  has	  been	  used	  to	  evaluate	  new	  treatments	  for	  PAH	  such	  as	  bradykinin	  antagonist,	  B-­‐9430	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2.	  AIM	  OF	  THE	  STUDY	  
	   Despite	  the	  plethora	  of	  scientific	  work	  carried	  out	  in	  the	  field	  of	  pulmonary	  hypertension,	  
clinical	  interventions	  can	  only	  alleviate	  the	  symptoms	  but	  cannot	  cure	  the	  disease.	  	  
	   In	   the	   cardiovascular	   system,	   Notch	   signaling	   modulates	   multiple	   aspects	   of	   vascular	  
development	   including	   vasculogenesis,	   angiogenesis	   and	   differentiation	   of	   vascular	   smooth	  
muscle	   cells.	  Notch	   signaling	  molecules	   are	   not	   only	   instrumental	   in	   vascular	   development,	   but	  
also	  key	  mediators	   in	  pathological	   conditions,	   including	  vascular	   injury.	  Hence,	  we	  hypothesized	  
that	  Notch	  signaling	  pathway	  may	  be	  involved	  in	  pathogenesis	  of	  PH.	  
	   The	  overall	   focus	  of	   the	  work	  presented	   in	   this	   thesis	   is	  on	  elucidating	   the	   role	  of	  Notch	  
Signaling	  in	  PH.	  Specifically,	  we	  aimed	  to:	  
 Study	  the	  expression	  profile	  of	  Notch	  receptors	  and	  ligands	   in	  different	  animal	  models	  of	  
PH.	  
 Study	  the	  expression	  profile	  of	  Notch	  receptors	  and	  ligands	  in	  lungs	  and	  pulmonary	  arteries	  
from	  patients	  with	  IPAH	  and	  donors.	  
 Investigate	   the	   localization	   of	   candidate	   Notch	   in	   lungs	   from	   patients	   with	   IPAH	   and	  
Hox+Su5416	  rats.	  
 Investigate	   the	   effect	   of	   candidate	   Notch	   receptor	   knockdown	   and	   overexpression	   on	  
proliferation	  of	  hPAECs	  and	  hPASMCs.	  
 Investigate	  the	  effect	  of	  candidate	  Notch	  receptor	  knockdown	  and	  constitutive	  activation	  
on	  survival	  of	  hPAECs.	  
 Investigate	   the	   effect	   of	   pan	   Notch	   inhibitor	   (γ	   secretase	   inhibitor)	   on	   proliferation	   of	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3.	  MATERIALS	  AND	  METHODS	  
3.1	  Materials	  
3.1.1	  Reagents	  and	  Chemicals	  
Reagent	   Company	  
Acetic	  acid,	  glacial	  99%	   Sigma,	  USA	  
Acrylamide	  solution	  (30)	   Sigma,	  USA	  
Agarose	   Carl	  Roth,	  Germany	  
Ammonium	  Persulfate	   Sigma,	  USA	  
Ampicilin	   Sigma,	  USA	  
β	  mercaptoethanol	   Sigma,	  USA	  
Bromophenol	  Blue	   Roche,	  Germany	  
Bovine	  serum	  albumin	   Carl	  Roth,	  Germany	  
BSA	  solution	  (2mg/ml)	   BioRad,	  USA	  
Chloroform	   Carl	  Roth,	  Germany	  
DAPI	   Invitrogen,	  USA	  
Dimethyl	  sulfoxide	   Sigma,	  USA	  
Digest	  All	  2	  (Trypsin)	   Invitrogen;	  USA	  
DNA	  ladder	  (100bp,1Kb)	   Fermentas,	  USA	  
Ethanol	  absolute	   Carl	  Roth,	  Germany	  
Ethidium	  Bromide	   Carl	  Roth,	  Germany	  
Ethylenediamine-­‐	  Tetraceticacid	  (EDTA)	   Carl	  Roth,	  Germany	  
Fluorescence	  mounting	  medium	   Dako,	  USA	  
Formaldehyde	   Carl	  Roth,	  Germany	  
Glycerol	   Sigma,	  USA	  
Glycine	   Sigma,	  USA	  
Hydrochloric	  acid	   Carl	  Roth,	  Germany	  
IQ	  SYBR®	  Green	  Supermix	   BioRad,	  USA	  
Isopropanol	   Carl	  Roth,	  Germany	  
JM109	  competent	  cells	   Promega,	  USA	  
Luria	  Broth	  agar	   Sigma,	  USA	  
Luria	  Broth	   Sigma,	  USA	  
Lipofectamine	  2000	   Invitrogen,	  USA	  
Methanol	   Carl	  Roth,	  Germany	  
Milk	  powder	   Carl	  Roth,	  Germany	  
N,N,N´,N´-­‐Tetramethyl-­‐1,2-­‐diaminomethane	  (TEMED)	   Sigma,	  USA	  
Ponceau	  S	  Solution	   Sigma,	  USA	  
Potassium	  dihydrogenphosphate	   Carl	  Roth,	  Germany	  
Potassium	  phosphatemonobasic	   Carl	  Roth,	  Germany	  
Rainbow	  protein	  molecular	  weight	  marker	   AmershamBiosciences,	  USA	  
RIPA	  lysis	  Buffer	   Thermo	  Scientific,	  USA	  
RNase	  Away	   Invitrogen,	  USA	  
SOC	  medium	   Carl	  Roth,	  Germany	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Sodium	  citrate	  tribasictrihydrate	   Carl	  Roth,	  Germany	  
Sodium	  	  dodecylsulfate	  (20%	  w/v)	   Carl	  Roth,	  Germany	  
Sodium	  hydroxide	   Carl	  Roth,	  Germany	  
Stripping	  Buffer	   Thermo	  Scientific,	  USA	  
TOPRO-­‐3	   Invitrogen,	  USA	  
Trisbase	   Sigma,	  USA	  
Tris	  1.5M	  (pH	  8.9)	   Amresco,	  Germany	  
Tris	  0.5	  M	  (pH	  6.8)	   Amresco,	  Germany	  
Trizol	  reagent	   Invitrogen,	  USA	  
Tween	  20	   	   Sigma,	  USA	  
Xtreme	  gene	  siRNA	  transfection	  reagent	   Roche,	  Germany	  
Xylol	   Carl	  Roth,	  Germany	  
	  
3.1.2	  Kits	  
Names	  	   Company	  
BrdU	  Incoportation	  assay	  kit	   Roche,	  Germany	  
Dc	  Protein	  assay	  kit	   BioRad,	  USA	  
EndoFree	  plasmid	  maxiprep	  kit	   Qiagen,	  USA	  
InProm-­‐II	  Reverse	  Transcriptase	  kit	   Promega,	  USA	  
In	  situ	  apoptosis	   Roche,	  Germany	  
NovaRed	  Substrate	  kit	   Vector,	  USA	  
RNeasy	  mini	  kit	   Qiagen,	  USA	  
Supersignal	  west	  femto	  maximum	  sensitivity	  substrate	  
kit	  
Thermo	  Scientific,	  USA	  
NovaRED	  substrate	  kit	   Vector,	  USA	  
	  
3.1.3	  Cell	  culture	  medium	  and	  reagents	  
Names	  	   Company	  
Dulbecco's	  Phosphate	  Bufffer	  saline	  (DPBS)	   PAA,	  USA	  
DBZ	  (γ	  secretase	  inhibitor)	   AXON,	  Netherlands	  
Endothelial	  growth	  medium	  (EGM-­‐2)	   Lonza,	  USA	  
Fetal	  calf	  serum	   PAA,	  USA	  
OptiMEM-­‐I+	  GutaMax-­‐I	   Gibco,	  Germany	  
Pencillin/Streptomycin	   Lonza,	  USA	  
Smooth	  muscle	  cell	  medium	  (SmGM)	   Lonza,	  USA	  
Trypsin/EDTA	   Lonza,	  USA	  
	  
3.1.4	  Equipments	  
Names	  	   Company	  
Agarose	  electrophoresis	  chambers	   Biometra,	  USA	  
BioDoc	  Analyzer	   INTAS,	  Germany	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Centrifuge	   Thermoscientific	  
CFX96	  tm	  Real-­‐Time	  PCR	  detection	  system	   BioRad,	  USA	  
Fluorescence	  microscope	   Leica,	  USA	  
Fujifim	  LAS	  4000	   Fujifilm,	  Japan	  
Light	  microscope	   Hund,	  Germany	  
Precellys	  Homogenizer	   PeQLab,	  Germany	  
Microplate	  reader	  Infinite	  200	   TECAN,	  Germany	  	  
PCR	  thermocycler	   Eppendorf,	  USA	  
Power	  supply	   BioRad,	  USA	  
Water	  bath	  (cell	  culture)	   Heraus,	  Germany	  
Western	  blot	  chambers	   BioRad,	  USA	  
	  
3.1.5	  Other	  materials	  
Names	  	   Company	  
Cell	  scrapers	   BD	  Falcon,	  USA	  
Cell	  culture	  dishes	  (10cm,	  3cm,	  6well,	  48well,	  96well)	   Griener	  bio-­‐one,	  Germany	  
Cell	  culture	  flasks	  (75cm2,	  25cm2)	   Griener	  bio-­‐one,	  Germany	  
Centrifugal	  protein	  concentrators	   Millipore,	  USA	  
Filter	  tips	  (10,	  100,	  1000	  μl)	   Griener	  bio-­‐one,	  Germany	  
Gel	  blotting	  paper	   Whatman,	  USA	  
Microcentrifuge	  tubes	   Eppendorf,	  USA	  
Nitroceullulose	  membrane	   Pall	  Corporation,	  USA	  
Polypropylene	  tubes	  (15ml,	  50ml)	   Griener	  bio-­‐one,	  Germany	  
Precellys	  Tubes	  with	  beads	   PeQLab,	  Germany	  
Real	  time	  PCR	  plates	   BioRad,	  USA	  
Tips	  (10,	  100,	  1000	  μl)	   Eppendorf,	  USA	  













MATERIALS	  AND	  METHODS	  
	  
	   	  
3.2	  Methods	  
3.2.1	  Animal	  experiments	  
	   Animals	   (mice	   and	   rats)	   were	   purchased	   from	   Charles	   River	   Laboratories	   (Sulzfeld,	  
Germany).	  All	  the	  experiments	  were	  performed	  in	  accordance	  with	  the	  National	  Institute	  of	  Health	  
Guidelines	   on	   the	  Use	   of	   Laboratory	   Animals.	   Study	   protocols	   (Nr.	   B2/191,	   Nr.	   40/2009	   and	  GI	  
2010-­‐Nr.	   03/2009	   and	   Nr.	   80/2009)	   were	   approved	   by	   both,	   the	   University	   Animal	   Care	  
Committee	  and	  the	  Federal	  Authorities	   for	  Animal	  Research	  of	  the	  Regierungspräsidium	  Giessen	  
(Hessen,	  Germany).	  
3.2.1.2	  Monocrotaline	  (MCT)	  induced	  PH	  rat	  model	  
	   The	  alkaloid	  MCT	  was	   dissolved	   in	   1mol/L	  HCl	   and	   then	   adjusted	   to	   pH	   7.4	  with	   1mol/L	  
NaOH,	   resulting	   in	  a	  clear	   solution	  with	  a	   final	   concentration	  of	  20mg/ml.	  Adult	  male	   rats	   (250-­‐
300g	  in	  body	  weight)	  were	  randomized	  and	  injected	  with	  a	  single	  subcutaneous	  (s.c.)	  injection	  of	  
MCT	   (60mg/kg	   body	   weight)	   to	   induce	   pulmonary	   hypertension,	   or	   an	   injection	   of	   the	   same	  
volume	  of	   saline	   as	   a	   control.	  Drinking	  water	   supplemented	  with	   antibiotic	  Baytril	  was	   given	   to	  
MCT-­‐injected	  rats	  for	  2	  weeks	  at	  the	  second	  day	  of	  MCT	  injection	  [48].	  Hemodynamic	  studies	  and	  
freezing	  of	  tissues	  were	  carried	  out	  3	  weeks,	  4	  weeks	  and	  5	  weeks	  after	  MCT	  injection.	  
3.2.1.3	  Hypoxia	  (Hox)	  induced	  PH	  mouse	  model	  
	   C57BL/6	   mice	   (8-­‐week-­‐old)	   were	   exposed	   to	   chronic	   hypoxia	   (10%	   O2)	   in	   a	   ventilated	  
chamber	   or	   kept	   under	   normoxic	   conditions	   as	   control,	   as	   described	   previously	   [48].	  
Hemodynamic	   studies	   and	   freezing	   of	   tissues	   were	   carried	   out	   after	   3	   weeks	   and	   5	   weeks	   of	  
hypoxia	  exposure.	  	  
3.2.1.4	  Hypoxia+Su5416	  induced	  PH	  rat	  model	  
Su5416	   (Semaxanib)	   was	   dissolved	   in	   DMSO	   at	   a	   concentration	   of	   25mg/ml.	   Adult	   rats	  
(200-­‐250g	  in	  body	  weight)	  were	  randomized	  and	  injected	  with	  a	  single	  subcutaneous	  injection	  of	  
freshly	  prepared	  Su5416	   (20mg/kg	  body	  weight)	   in	   the	  area	  of	  neck.	  Animals	  were	  put	   into	   the	  
ventilated	   hypoxia	   chamber	   (10%	   O2)	   immediately	   after	   the	   injection.	   Saline	   injected	   control	  
animals	  were	   kept	   in	  normoxic	   conditions	   for	   the	   same	   time	  period.	  Hemodynamic	   studies	   and	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3.2.1.5	  Hemodynamics	  measurement	  
	   At	  the	  end	  of	  the	  treatment,	  the	  rats	  were	  anesthetized	  with	  an	   intraperitoneal	   injection	  
(i.p.)	  of	  ketamine	  (9mg/kg	  body	  mass)	  and	  medetomidine	  (100μg/kg	  body	  mass),	  followed	  by	  an	  
intramuscular	   (i.m.)	   injection	   of	   heparin	   (50IU/kg	   body	   mass)	   to	   measure	   the	   hemodynamic	  
parameters.	  The	  rats	  were	  then	  tracheotomized	  and	  ventilated	  at	  a	  frequency	  of	  60	  breaths/min,	  
with	   a	   positive	   end	   expiratory	   pressure	   at	   1cm	   H2O	   throughout.	   To	   measure	   right	   ventricular	  
pressure,	   a	   right	  heart	   catheter	   (PE	  50	   tube)	  was	   inserted	   through	   the	   right	   jugular	   vein	  and	   to	  
measure	  arterial	  pressure	  a	  polyethylene	  catheter	  was	  inserted	  into	  the	  left	  carotid	  artery.	  
3.2.2	  RNA	  isolation	  
3.2.2.1	  RNA	  isolation	  from	  tissues	  
Total	   RNA	  was	   isolated	   from	   lung	   homogenates	   using	   Qiagen	   RNeasy	  mini	   kit.	   30mg	   of	  
tissue	  was	  placed	  in	  600µl	  of	  RLT	  buffer.	  Tubes	  were	  put	  into	  tissue	  homogenizer	  for	  30sec	  spins	  in	  
three	  repeats.	  In	  between	  the	  spins,	  tubes	  were	  incubated	  on	  ice.	  After	  homogenization,	  samples	  
were	   centrifuged	   at	   full	   speed	   for	   3min.	   Supernatant	   was	   removed	   by	   pipetting	   into	   a	   new	  
microcentrifuge	   tube.	   Equal	   volume	   of	   70%	   ethanol	   was	   added	   to	   the	   lysate,	   mixed	   well	   and	  
transferred	   to	   RNeasy	   spin	   column.	   Column	   was	   centrifuged	   at	   10,000rpm	   for	   15sec	   and	   flow	  
through	  was	  discarded.	  700µl	  of	  buffer	  RW1	  was	  added	  to	  the	  column,	  followed	  by	  centrifugation	  
at	  10,000	  rpm	  for	  15sec	  and	  removal	  of	   flow	  through.	  To	  wash	  the	  column,	  500µl	  of	  Buffer	  RPE	  
was	  added	   to	   the	   column	  and	  centrifuged	  at	  10,000rpm	   for	  15sec.	   Flow	   through	  was	  discarded	  
and	  the	  wash	  was	  repeated.	  For	  elution,	  column	  was	  placed	   in	  a	  new	  1.5ml	  collection	  tube	  and	  
30µl	   of	   RNase	   free	   water	   was	   added	   directly	   to	   the	   spin	   column	   membrane,	   followed	   by	  
centrifugation	  at	  10,000rpm	  for	  1min.	  
3.2.2.2	  RNA	  isolation	  from	  cells	  
RNA	  isolation	  from	  primary	  hPAECs	  and	  hPASMCs	  was	  carried	  out	  using	  TRIzol™	  reagent.	  
Media	  was	  removed	  from	  the	  wells,	  followed	  by	  a	  PBS	  wash.	  250µl	  of	  TRIzol™	  was	  directly	  added	  
to	  each	  well	  of	  6	  well	  plates	  and	  after	  2min	  of	  incubation;	  lysates	  were	  scratched	  with	  cell	  scrapers	  
and	  transferred	  to	  microcetrifuge	  tubes.	  50μl	  of	  chloroform	  was	  added	  to	  each	  sample	  followed	  
by	  vortexing,	  incubation	  for	  10min	  at	  RT	  and	  centrifugation	  at	  4°C	  for	  30min	  at	  12,000g.The	  upper	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incubated	  at	  RT	  for	  10min	  and	  centrifuged	  for	  20min	  at	  4°C	  at	  12,000g.	  Supernatant	  was	  discarded	  
and	  the	  precipitated	  RNA	  was	  washed	  with	  freshly	  prepared	  75%	  ethanol	  and	  centrifuged	  for	  5min	  
at	  4°C	  at	  7,500g.	  RNA	  pellet	  was	  dried	  for	  10min	  and	  dissolved	  in	  12μl	  of	  RNase	  free	  water	  at	  60°C.	  
Nanoquant	   analyser	   was	   used	   to	   analyze	   the	   RNA	   concentration	   and	   purity.	   1.5μl	   of	  
sample	  was	  applied	  to	  the	  nanoquant	  plate	  and	  spectroscopical	  absorance	  analysis	  was	  set	  as	  the	  
ratio	   of	   260/280	   nm	   wavelengths.	   RNA	   samples	   with	   260/280	   ratio	   around	   1.8	   were	   used	   for	  
further	  experiments.	  
3.2.3	  Reverse	  transcription	  
Reverse	   transcription	   refers	   to	   the	   enzymatic	   method	   of	   synthesizing	   complementary	  
single	   stranded	   cDNA	   from	  mRNA	  with	   the	   help	   of	   a	   robust	   RNA	   dependent	   DNA	   polymerase,	  
Reverse	  Transcriptase.	  
cDNA	  was	  synthesized	  from	  RNA	  isolated	  from	  different	  samples	  by	  two	  step	  PCR	  reaction	  
using	   ImProm-­‐II™	   Reverse	   transcription	   system	   according	   to	   the	  manufacturer’s	   instructions.	   In	  
step	  I,	  template-­‐primer	  mix	  consisting	  of	  1μg	  of	  RNA	  and	  1μl	  of	  oligo	  dT	  primer	  was	  incubated	  at	  
70°C	  for	  5min	  to	  allow	  denaturation	  of	  RNA,	  followed	  by	  incubation	  at	  4°C	  for	  5min.	  For	  step	  II,	  a	  
reverse	  transcription	  mix	  was	  prepared	  on	  ice	  as	  follows:	  	  
Components	   Final	  	  Concentration	   Volume	  (in	  µl)	  
InProm-­‐II™	  5X	  reaction	  buffer	   1X	   4	  
MgCl2,	  25mM	   5mM	   	  
dNTP	  mix,	  10mM	   0.5mM	   1	  
RNasin®	  ribonuclease	  inhibitor	   0.5U	   0.5	  
InProm-­‐II™	  reverse	  transcriptase	   1U	   1	  
Nuclease	  free	  water	  (to	  a	  final	  volume	  of	  15μl)	   	   	  
	  
Reverse	   transcription	  mix	   was	   added	   to	   the	   template-­‐primer	  mix	   and	   was	   subjected	   to	  
25°C	  for	  5min	  to	  allow	  annealing,	  followed	  by	  an	  incubation	  at	  42°C	  for	  1hr.	  Finally,	  the	  mix	  was	  
subjected	   to	   70°C	   for	   15min	   to	   allow	   thermal	   inactivation	   of	   the	   reverse	   transcriptase.	   cDNA	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3.2.4	  Quantitative	  real	  time	  PCR	  (qRT	  PCR)	  
Real	  time	  PCR	  is	  a	  technique	  based	  on	  polymerase	  chain	  reaction	  that	  allows	  simultaneous	  
amplification	  and	  quantification	  of	   target	  cDNA	  sequences	  by	  employing	   target	   specific	  primers.	  
Quantity	  of	  the	  target	  sequence	  is	  expressed	  as	  a	  relative	  amount	  normalized	  to	  the	  housekeeping	  
gene.	  
Intron	  spanning	  primers	  were	  designed	  using	  Primer-­‐Blast	  program	  (NCBI)	  and	  are	  shown	  
in	  Appendix	  Table	  1.	  Product	  size	  was	  kept	  in	  between	  100-­‐250bp.	  Real	  time	  PCR	  was	  performed	  
from	  the	  cDNA	  samples	  in	  25µl	  reactions	  using	  iQ™	  SYBR®	  Green	  Supermix	  (BioRad).	  The	  reaction	  
was	  prepared	  as	  follows:	  	  
Component	   Volume	  added	  (in	  µl)	  
iQ™	  SYBR®	  Green	  Supermix,	  2X	   12.5	  
Forward	  primer,	  10µM	   0.5	  
Reverse	  primer,	  10µM	   0.5	  
cDNA	  template	   2	  
Nuclease	  free	  water	   9.5	  
	   The	  reaction	  mix	  were	  pipetted	  into	  96	  well	  plate	  and	  centrifuged	  for	  1min.	  qRT	  PCR	  was	  
carried	  out	  in	  CFX96™	  Real-­‐Time	  PCR	  detection	  system,	  using	  the	  following	  program:	  
qRT	  PCR	  steps	   Temperature	   Time	   Number	  of	  repeats	  
Initial	  denaturation	   95°C	   3	  minutes	   1	  
Denaturation	   95°C	   10sec	   	  
Annealing	   58°C/60°C*	   30sec	   40	  
Elongation	   72°C	   30sec	   	  
Denaturation	   95°C	   10sec	   1	  
Melting	  curve	   65°C	  to	  95°C	   Increment	  0,5°C	  for	  5sec	   1	  
*depending	  on	  the	  melting	  temperature	  of	  the	  primer	  set	  (Appendix	  Table	  1)	  
3.2.5	  Protein	  isolation	  
3.2.5.1	  Protein	  isolation	  from	  tissues	  
100mg	   of	   tissue	   was	   weighed	   and	   put	   into	   500μl	   of	   RIPA	   buffer	   (Thermo	   Scientific)	  
containing	  protease	  and	  phosphatase	   inhibitor	   cocktail.	   Tissues	  were	  homogenized	  as	  described	  
above	  (Section3.2.1.1),	  followed	  by	  centrifugation	  for	  30min	  at	  4°C	  (13,000xg).	  Supernatants	  were	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3.2.5.2	  Protein	  isolation	  from	  cells	  
Protein	   isolation	   from	   primary	   hPAECs	   and	   hPASMCs	   was	   carried	   out	   using	   RIPA	   buffer	  
(Thermo	   Scientific)	   containing	   protease	   and	   phosphatase	   inhibitor	   cocktail	   (Thermo	   Scientific).	  
Media	   was	   removed	   from	   the	  wells,	   followed	   by	   a	   PBS	  wash.	   75µl	   of	   RIPA	   buffer	   was	   directly	  
added	  to	  each	  well	  of	  6	  well	  plates	  and	  after	  10min	  of	   incubation	  at	  4°C;	  plates	  were	  scratched	  
with	   cell	   scrapers	   and	   supernatants	  were	   put	   into	   1.5ml	   tubes.	   The	   tubes	  were	   centrifuged	   for	  
30min	  at	  4°C	  (13,000xg).	  Supernatants	  were	  transferred	  to	  1.5ml	  tubes	  and	  directly	  quantified	  or	  
stored	  at	  -­‐80°C.	  
3.2.6	  Protein	  estimation	  
Protein	   quantification	   was	   carried	   out	   using	   Bio-­‐Rad	   DC	   Protein	   Assay	   kit.	   It	   is	   a	  
colorimetric	  assay	  based	  on	  Lowry’s	  method	  involving	  reaction	  of	  protein	  with	  an	  alkaline	  copper	  
tartrate	  solution	  and	  Folin	  reagent	  giving	  rise	  to	  a	  characteristic	  blue	  color	  showing	  absorbance	  at	  
750nm.	  Different	  concentrations	  of	  BSA	  in	  range	  of	  0.125-­‐2mg/ml	  were	  used	  as	  standard.	  Protein	  
samples	  were	  prediluted	   in	   range	  of	   the	   standard	  and	   the	  absorbance	  was	  measured	  at	  750nm	  
using	   a	   microplate	   reader	   (TECAN).	   Exact	   concentrations	   were	   calculated	   depending	   on	   the	  
standards.	  
3.2.7	  SDS	  polyacrylamide	  gel	  electrophoresis	  (SDS-­‐PAGE)	  
SDS	   PAGE	   is	   carried	   out	   to	   separate	   various	   proteins	   in	   a	   sample	   according	   to	   their	  
molecular	  weights	   for	   further	   immunoblot	  analysis.	  Protein	   samples	   from	  cells	  and	   tissues	  were	  
equalized	   to	   same	   concentrations	   and	   mixed	   with	   5X	   gel	   loading	   buffer	   at	   a	   ratio	   of	   4:1	   and	  
denatured	  at	  95°C	   for	  10min.	  Protein	  samples	  were	   loaded	  along	  with	  molecular	  weight	  marker	  
into	  the	  wells	  of	  7%	  or	  10%	  (depending	  on	  protein	  sizes	  to	  be	  separated)	  polyacrylamide	  gels.	  Gels	  
were	   run	   in	   vertical	   electrophoretic	   assembly	   using	   1X	   running	   buffer	   at	   100-­‐120V	   for	   2-­‐3	   hrs.	  
Buffers	  used	  are	  as	  follows:	  	  
5X	  gel	  loading	  buffer	  components	   Final	  concentration	  
Tris-­‐HCl	  (2M,	  pH-­‐6.8)	   375mM	  
SDS	   10%	  (w/v)	  
Glycerol	   50%(v/v)	  
β-­‐Mercaptoethanol	   12.5%(v/v)	  
Bromophenol	  Blue	   0.02%(w/v)	  




MATERIALS	  AND	  METHODS	  
	  
	   	  
1X	  SDS	  Running	  buffer	  components	   Final	  concentration	  
Tris	   25mM	  
Glycine	   250mM	  
SDS	  10%	  (w/v)	   0.1%(w/v)	  
	  
Stacking	  gel	  (5%)	  
Gel	  Component	  	   Final	  Concentration	  
Tris-­‐HCl	  (0.5M,	  pH-­‐6.8)	   125mM	  
Acrylamide/Bis-­‐acrylamide	   6%	  
SDS	  10%	  (w/v)	   0.10%	  
APS	  10%	  (w/v)	   0.05%	  
TEMED	   0.10%	  
Water	  upto	  the	  final	  volume	   	  
Resolving	  gel	  
Gel	  component	   Percentage	  of	  gel	  
	   7%	   10%	  
Tris-­‐HCl	  (1.5M,	  pH-­‐8.8)	   375mM	   375mM	  
Acrylamide/Bis-­‐acrylamide	   7%	   10%	  
SDS	  10%	  (w/v)	   0.10%	   0.10%	  
APS	  10%	  (w/v)	   0.05%	   0.05%	  
TEMED	   0.10%	   0.10%	  
Water	  upto	  the	  final	  volume	   	   	  
3.2.8	  Immunoblotting	  
Proteins	   separated	   on	   gel	   were	   transferred	   to	   a	   nitrocellulose	   membrane	   by	  
electrophoretic	  transfer.	  The	  transfer	  was	  carried	  out	  for	  1hr	  at	  100V	  in	  transfer	  buffer.	  
Blotting	  buffer	  components	   Final	  concentration	  
Tris	   25mM	  
Glycine	   192mM	  
Methanol	   20%(v/v)	  
	   After	   the	   transfer,	  membranes	  were	   removed	   and	   blocked	   in	   blocking	   buffer	   for	   1hr	   on	  
shaker	  at	  RT,	  followed	  by	  overnight	  incubation	  in	  primary	  antibodies	  diluted	  in	  blocking	  buffer	  (for	  
dilutions,	  Appendix	   Table	  2)	   at	   4°C.	   Following	  day,	  membranes	  were	  washed	  3	   times	   for	   10min	  
with	  1xTBST	  buffer	  and	  subsequently	  incubated	  in	  secondary	  HRP-­‐conjugated	  antibodies	  diluted	  in	  
blocking	  buffer	  for	  1hr	  at	  RT.	  After	  1hr	  of	  incubation,	  membranes	  were	  washed	  thrice	  for	  10min	  in	  
1x	   TBST	   and	   incubated	  with	   ECL	   substrate	   (Thermo	   Scientific)	   in	   the	   Image	   reader	   (Fujifilm)	   to	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Tris	  buffer	  saline	  (TBS)	  components	   Final	  Concentration	  
Tris	   20mM	  
Sodium	  chloride	   137mM	  
Tween	  20	   0.1%	  (v/v)	  
HCl	   to	  set	  the	  pH	  to	  7.4	  
Water	   Upto	  final	  volume	  
	   	  
Blocking	  buffer	  (5%	  non-­‐fat	  dry	  milk	  in	  1xTBST)	  
In	  order	  to	  re-­‐probe	  the	  membranes	  for	  housekeeping	  genes,	  membranes	  were	  stripped	  in	  
a	   stripping	  buffer	   (Thermo	  Scientific)	   for	  30min	  at	  37°C,	  washed	   in	  TBST	  and	  probed	  again	  with	  
primary	  antibody.	  
3.2.9	  Densitometric	  analysis	  of	  the	  immunoblots	  
Western	   blots	  were	   quantified	   using	   the	  multi	   gauge	   software	   (Fujifilm).	   Expression	  was	  
quantified	   using	   bands	   intensity	   values	   (in	   arbitrary	   units),	   which	   were	   normalized	   to	   the	  
housekeeping	  genes	  (GAPDH	  or	  β-­‐actin).	  
3.2.10	  Immunohistochemistry	  
4μm	  thick	  sections	  were	  cut	  from	  paraffin	  embedded	  lung	  tissues.	  Sections	  were	  incubated	  
at	   65°C	   for	   20min,	   followed	   by	   deparaffinization	   in	   xylene	   and	   rehydration	   in	   series	   of	   grade-­‐
decreasing	   ethanol	   solutions.	   Sections	   were	   washed	   with	   PBS	   and	   incubated	   in	   boiling	   10mM	  
citrate	   buffer	   for	   8min	   at	   630watt	   in	   microwave	   for	   antigen	   retrieval.	   When	   needed,	   antigen	  
retrieval	   was	   carried	   out	   by	   using	   0.25%	   trypsin	   for	   10min	   at	   37°C.	   After	   blocking	   endogenous	  
peroxidases	  activity	  by	   treatment	  with	  15%	  hydrogen	  peroxide	   for	  20min,	  NovaRED	  horseradish	  
peroxidase	   (HRP)-­‐substrate	   kit	   was	   used	   for	   immunohisotchemical	   staining	   according	   to	   the	  
manufacturer’s	   instructions.	  Sections	  were	  kept	  in	  serum	  blocking	  for	  1hr,	  followed	  by	  overnight	  
incubation	  with	  primary	   antibody	   at	   4°C.	  After	  washing	  with	  PBS,	   sections	  were	   incubated	  with	  
biotinylated	   secondary	   antibody	   for	   10min,	   followed	   by	   again	   a	   PBS	   wash	   and	   incubation	  with	  
streptavidin	  conjugated	  HRP	  for	  5min.	  Sections	  were	  washed	  and	  color	  development	  was	  carried	  
out	  using	  a	  substrate/chromogen	  mixture,	  followed	  by	  counterstaining	  with	  hematoxylin.	  Stained	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3.2.11	  BrdU	  incorporation	  assay	  
Cellular	   proliferation	   for	   hPASMCs	   and	   hPAECs	   was	   determined	   using	   colorimetric	   BrdU	  
incorporation	  assay	  kit	   (Roche)	  according	  to	  manufacturer’s	   instructions.	  The	  kit	   is	  based	  on	  the	  
principle	  of	  detecting	  Br-­‐deoxycitidine	  incorporated	  into	  DNA	  during	  DNA	  synthesis	  by	  using	  anti-­‐
BrdU	  antibody	  conjugated	  with	  peroxidase	  enzyme.	  Rate	  of	  DNA	  synthesis	  is	  taken	  as	  a	  marker	  for	  
cellular	  proliferation.	  
After	  defined	  period	  of	  culture,	  transiently	  transfected	  or	   inhibitor	  treated	  cells	   in	  48well	  
plate	  or	  96well	  plate	  respectively,	  were	  incubated	  with	  BrdU	  labeling	  solution	  for	  2hrs.	  After	  the	  
2hr	   incubation,	  wells	  were	  washed	  with	   PBS	   and	   subsequently	   fixed	  with	   FixDenat	   solution	   for	  
30min.	   Fixed	   cells	   were	   then	   incubated	  with	   anti-­‐BrdU-­‐POD	   antibody	   for	   90min,	   washed	   three	  
times	  with	  PBS	  and	  further	  incubated	  with	  substrate	  solution	  until	  color	  development.	  Absorbance	  
was	  measured	  at	  370nm	  with	  reference	  at	  492nm	  in	  ELISA	  plate	  reader	  (TECAN).	  Proliferation	  of	  
cells	  was	  plotted	  as	  a	  function	  of	  absorbance	  at	  370nm.	  
3.2.12	  Transformation	  and	  plasmid	  isolation	  
In	  order	  to	  amplify	  the	  plasmids,	  they	  were	  transformed	  into	  competent	  bacterial	  cells	  by	  
heat	  shock	  method	  and	  isolated	  using	  endofree	  Plasmid	  maxiprep	  kit	  (Qiagen).	  	  
100μl	  aliquots	  of	  chemically	  competent	  XL-­‐blue	  strain	  of	  E.coli	  cells	  were	  thawed	  on	  ice.	  To	  
each	  aliquot,	  20-­‐50ng	  of	  plasmid	  DNA	  was	  added,	  mixed	  by	  gentle	  flicking	  and	  incubated	  on	  ice	  for	  
5min,	   followed	   by	   a	   heat	   shock	   at	   42°C	   for	   90sec.	   Cells	  were	   placed	   on	   ice	   for	   2min	   and	   then	  
incubated	  at	  37°C	  for	  1hr	  with	  900μl	  of	  SOC	  medium.	  100μl	  of	  the	  transformation	  mix	  was	  spread	  
on	   LB	   agar	   plates	   containing	   ampicillin	   suitable	   for	   selecting	   transformed	   bacteria.	   Plates	   were	  
incubated	  for	  16hrs	  at	  37°C.	  
For	   plasmid	   isolation,	   single	   bacterial	   colony	   was	   picked	   from	   the	   LB	   agar	   plate	   with	   a	  
sterile	  pipette	  tip	  and	  inoculated	  in	  5ml	  of	  LB	  medium	  with	  ampicillin	  for	  8hrs	  at	  37°C.	  100μl	  of	  this	  
culture	  was	   further	   inoculated	   in	   250ml	   of	   ampicillin	   containing	   LB	  medium,	   grown	   at	   37°C	   for	  
16hrs	  with	  shaking.	  Bacterial	  cells	  were	  harvested	  by	  centrifuging	  at	  4500	  rpm	  for	  20min	  at	  4°C.	  
Plasmids	  were	  isolated	  using	  Endo-­‐free	  Plasmid	  Maxi	  kit,	  according	  to	  manufacturer’s	  protocol.	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3.2.13	  Cell	  culture	  
	   All	   the	   cell	   culture	   experiments	   were	   carried	   out	   in	   human	   pulmonary	   artery	   -­‐smooth	  
muscle	  cells	  (hPASMCs)	  and	  -­‐endothelial	  cells	  (hPAECs).	  Cells	  were	  maintained	  at	  37˚C	  and	  5%O2	  in	  
humidified	  chamber	  and	  cultured	  in	  the	  medium	  provided	  from	  the	  company	  (EGM-­‐2	  for	  hPAECs	  
and	   SmGM	   for	   hPASMCs).	   Cells	   were	   allowed	   to	   grow	   until	   90-­‐95%	   confluency	   and	   then	  
subcultured.	   For,	   subculturing,	   cells	   were	   washed	   twice	   with	   DPBS	   and	   incubated	   with	  
Trypsin/EDTA	  for	  4mins.	  Trypsin/EDTA	  was	  neutralized	  by	  addition	  of	  equal	  volume	  of	  FCS.	  Cells	  
were	  centrifuged,	  resuspended	  in	  normal	  growth	  medium,	  counted	  and	  seeded	  into	  new	  culture	  
dishes.	  	  
For	   freezing	   the	  cells,	  after	   trypsinization,	  cells	  were	   resuspended	   in	  FCS	  with	  5%	  DMSO.	  
Then	  the	  cells	  were	  aliquoted	  in	  1ml	  cryovials,	  which	  were	  subsequently	  frozen	  in	  an	  isopropanol	  
box	  in	  -­‐80˚C.	  Next	  day,	  the	  cryovials	  were	  transferred	  to	  liquid	  nitrogen.	  When	  needed,	  cryovials	  
containing	  the	  cells	  were	  thawed	  quickly	  at	  37˚C	  and	  seeded	  into	  a	  new	  culture	  dish.	  The	  following	  
day,	  medium	  was	  changed	  to	  remove	  traces	  of	  DMSO.	  	  
3.2.14	  Transfection	  with	  over	  expression	  plasmid	  
	   Transfection	  refers	  to	  the	  process	  of	  introducing	  foreign	  DNA	  or	  RNA	  into	  the	  mammalian	  
cells.	  In	  this	  study,	  lipofection	  was	  used	  as	  the	  method	  of	  transfection.	  Lipofection	  refers	  to	  use	  of	  
synthetic	  cationic	  lipid	  to	  facilitate	  the	  delivery	  of	  DNA	  into	  the	  cells.	  These	  cationic	  lipids	  tend	  to	  
form	   liposomes	   in	   aqueous	   solution.	   Liposomes,	   thus	   formed,	   interact	   with	   negatively	   charged	  
DNA	   to	   form	   lipid-­‐DNA	   complexes.	   The	   complex	   fuses	   with	   the	   plasma	   membrane	   of	   cells,	  
resulting	  in	  the	  uptake	  of	  DNA	  and	  further	  expression	  of	  the	  gene	  carried	  by	  the	  plasmid	  DNA.	  
	   hPAECs	   and	   hPASMCs	   were	   cultured	   to	   70-­‐80%	   confluence	   in	   6	   well	   plates	   (for	   protein	  
isolation)	   or	   48	   well	   plates	   (for	   proliferation	   assay).	   Plasmid	   and	   lipofectamine	   were	   diluted	   in	  
antibiotic	  free	  opti-­‐MEM	  medium	  and	  mixed	  within	  5	  min	  at	  ratio	  of	  1:2	  (DNA	  in	  μg	  to	  transfection	  
reagent	   in	   μl).	   The	   mixture	   was	   incubated	   at	   RT	   for	   30min	   and	   added	   to	   the	   cells	   that	   were	  
cultured	  in	  antibiotic	  free	  transfection	  medium	  (opti-­‐MEM	  medium	  +	  basal	  growth	  medium	  with	  
0.1%	  FCS).	  After	  5hrs,	  medium	  was	  changed	  to	  the	  normal	  growth	  medium	  upto	  48hrs,	  followed	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3.2.15	  RNA	  interference	  
Cells	  were	  transfected	  with	  siRNA	  using	  X-­‐tremeGENE	  siRNA	  transfection	  reagent	  (Roche)	  
according	  to	  manufacturer’s	  protocol.	  hPAECs	  and	  hPASMCs	  were	  cultured	  to	  50-­‐60%	  confluence.	  
siRNA	   and	   transfection	   reagent	   were	   diluted	   in	   antibiotic	   free	   opti-­‐MEM	   medium	   and	   mixed	  
within	  5	  min	  at	  ratio	  of	  1:5	  (siRNA	  in	  μg	  to	  transfection	  reagent	  in	  μl).	  The	  mixture	  was	  incubated	  
at	  RT	  for	  20min	  and	  added	  to	  the	  cells	  that	  were	  cultured	  in	  antibiotic	  free	  transfection	  medium	  
(opti-­‐MEM	  medium	  +	  basal	  growth	  medium	  with	  0.1%	  FCS).	  After	  5hrs,	  medium	  was	  changed	  to	  
the	   normal	   growth	   medium	   after	   48hrs,	   followed	   by	   protein	   isolation,	   proliferation	   assay	   or	  
apoptosis	  assay.	  	  
3.2.16	  In	  vitro	  apoptosis	  assay	  
hPAECs	  were	  assessed	  for	  apoptosis	  using	  In	  Situ	  cell	  death	  detection	  kit	  (Roche)	  according	  
to	   manufacturer’s	   instructions.	   The	   method	   is	   based	   on	   labeling	   double	   stranded	   DNA	   breaks	  
(hallmark	   of	   cellular	   apoptosis)	   in	   individual	   cells	   by	   using	   terminal	   transferase	   (TdT),	   which	  
incorporates	  fluorescein	  dUTP	  at	  3’	  OH	  ends	  of	  genomic	  DNA.	  	  
hPAECs	   were	   grown	   in	   8	   well	   chamber	   slides,	   transfected	   with	   siRNA	   and	   48hrs	   later,	  
washed	  and	   fixed	  with	  4%	  para	   formaldehyde	   for	  1hr.	  Fixed	  cells	  were	  permeabilized	  by	  adding	  
0.1%	  sodium	  citrate	  solution	  for	  2min	  on	  ice	  and	  incubated	  with	  labeling	  solution	  for	  1hr	  at	  37°C.	  
Slides	  were	  washed	  thrice	  with	  PBS,	  incubated	  with	  nuclear	  stain,	  Draq5	  for	  10min	  and	  mounted	  
with	  anti-­‐fade	  mounting	  medium.	  Slides	  were	  analyzed	  for	  fluorescence	  using	  Leica	  fluorescence	  
microscope.	  
3.2.17	  Bax/Bcl-­‐2	  ratio	  
	   The	  ratio	  of	  Bax	   (an	  apoptosis	  promoter)	   to	  Bcl-­‐2	   (an	  apoptosis	   inhibitor)	  protein	   is	  used	  
widely	  to	  determine	  the	  susceptibility	  of	  cells	   towards	  apoptosis,	  under	  given	  conditions.	  Higher	  
ratio	  is	  indicative	  of	  increased	  apoptosis	  while	  lower	  ratio	  is	  indicative	  of	  cell	  survival.	  In	  order,	  to	  
determine	   the	   ratio,	   western	   blots	   were	   carried	   out	   using	   antibodies	   against	   Bax	   and	   Bcl-­‐2	  
proteins.	  
	   Standardization	  of	  protein	  loading	  was	  achieved	  as	  follows:	  (i)	  protein	  measurements	  of	  all	  
samples	  were	  performed	  using	  the	  DcBioRad	  assay	  as	  described	  above	  (section	  3.2.1.1)	  and	  equal	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blots	   was	   checked	   by	   staining	   the	   membranes	   with	   0.5%	   Ponceau	   Red	   in	   1%	   acetic	   acid;	   (iii)	  
detection	   of	   Bax	   and	   Bcl-­‐2	   was	   performed	   separately	   on	   the	   same	   membrane.	   Thus,	   this	  
procedure	   is	  valid	   to	  determine	   the	  protein	   ratios	   in	   the	  same	  sample	   (on	   the	  same	   lane	  of	   the	  
gel).	   Quantitative	   analysis	   of	   the	   Bax	   and	   Bcl-­‐2	   protein	   expression	   was	   performed	   using	   multi	  
gauge	  software	  (Fujifilm)	  and	  band	  density	  values	  are	  expressed	  in	  arbitary	  units	  (A.U.).	  
3.2.18	  Statistical	  analysis	  
	   All	  data	  are	  expressed	  as	  Mean	  ±	  standard	  error	  of	  mean	  (SEM).	  Statistical	  comparisons	  of	  
samples	   were	   performed	   by	   Student's	   t	   test	   for	   comparing	   two	   groups	   or	   by	   one-­‐way	   ANOVA	  
followed	   by	   the	   Newman-­‐Keuls	   post-­‐hoc	   test	   for	  multiple	   comparisons.	   Difference	  with	   p<0.05	  





























	   	  
4.	  RESULTS	  
4.1	  Regulation	  of	  Notch	  receptors	  and	  ligands	  in	  monocrotaline	  (MCT)	  induced	  PH	  rats	  
4.1.1	  Hemodynamics	  and	  right	  heart	  hypertrophy	  in	  MCT	  rats	  
Increase	   in	   right	   ventricular	   systolic	   pressure	   (RVSP)	   and	   ratio	   of	   right	   ventricular	   to	   left	  
ventricular	  plus	  septal	  weight	  (RV/LV+S)	  are	  taken	  as	  index	  of	  severity	  of	  pulmonary	  hypertension.	  
Monocrotaline	   (MCT)	   treatment	   led	   to	   a	   marked	   increase	   in	   RVSP	   after	   3	   weeks	   (42.3±5.33	  
mmHg),	   4	  weeks	   (81.1±9.90	  mmHg)	   and	   5	  weeks	   (88.7±7.76	  mmHg),	  when	   compared	   to	   saline	  
injected	   control	   animals	   (28.3±2.16	   mmHg)	   (Figure	   4.1A)	   without	   a	   significant	   difference	   in	  
systemic	  arterial	  pressure	  (SAP)	  (Figure	  4.1B).	  The	  ratio	  of	  right	  ventricular	  to	  left	  ventricular	  plus	  
septal	  weight	   (RV/LV+S),	  was	   significantly	   increased	  after	  MCT	  administration	   from	  0.29±0.01	   in	  
control	  animals	  to	  0.63±0.04	  in	  5	  weeks	  MCT	  rats	  (Figure	  4.1C).	  
	  
Figure	  4.1	  Hemodynamic	  measurements	  and	  right	  heart	  hypertrophy	  in	  Monocrotaline	  induced	  PH	  rats.	  
Physiological	  measurements	  were	  taken	  3	  weeks	  (3w	  MCT),	  4	  weeks	  (4w	  MCT)	  and	  5	  weeks	  (5w	  MCT)	  after	  
MCT	   injection	   (A)	   Right	   ventricular	   systolic	   pressure	   (RVSP),	   (B)	   measurement	   of	   RV	   hypertrophy	  
[RV/(LV+S)]	  and	  (C)	  systemic	  arterial	  pressure	  (SAP).	  *p<	  0.05,	  **p<	  0.01,	  ***p<	  0.001	  Vs	  Healthy	  ,	  (n=6).	  
4.1.2	  mRNA	  expression	  of	  Notch	  receptors	  and	  ligands	  in	  lung	  homogenates	  
The	  mRNA	  expression	  profile	  of	  canonical	  Notch	  signaling	  pathway	  receptors	  (Notch1,	  2,	  3	  
and	  4)	  and	  ligands	  (Jagged1	  and	  2,	  DLL1,	  3	  and	  4)	  was	  analyzed	  in	  lungs	  from	  MCT	  induced	  PH	  rats	  
after	   3-­‐,	   4-­‐	   and	   5-­‐	   weeks	   of	  MCT	   injection	   as	   well	   as	   in	   healthy	   rats.	   Among	   Notch	   receptors,	  
Notch1	  and	  Notch4	   showed	  a	  marked	  decrease	   in	  mRNA	  expression	   in	   lungs	   from	  3-­‐,	   4-­‐	   and	  5-­‐	  
weeks	  MCT	  treated	  rats	  as	  compared	  to	  the	  control	   lungs	  while	  Notch3	  exhibited	  an	   increase	   in	  
MCT	   rats	   (Figure	   4.2A).	  Out	   of	   the	   five	   ligands,	   only	  DLL4	   exhibited	   a	   strong	   downregulation	   in	  
mRNA	  expression	  in	  MCT	  lungs	  (Figure	  4.2B).	  Other	  receptors	  and	  ligands	  did	  not	  show	  significant	  






	   	  
	  
Figure	  4.2	  mRNA	  expression	  of	  Notch	  receptors	  and	  ligands	  in	  lung	  homogenates	  of	  Monocrotaline	  (MCT)	  
induced	  PH	  rats.	  mRNA	  expression	  of	  Notch	  (A)	  receptors	  and	  (B)	  ligands	  in	  MCT	  induced	  PH	  rat	  lungs	  after	  
3	   weeks	   (3w	   MCT),	   4	   weeks	   (4w	   MCT)	   and	   5	   weeks	   (5w	   MCT)	   of	   MCT	   injection	   and	   healthy	   animals.	  
Regulation	  was	  analyzed	  by	  real-­‐time	  PCR	  with	  the	  Ct	  method	  (n=5).	  *p<	  0.05,	  **p<	  0.01,	  ***p<	  0.001	  Vs	  
Healthy.	  
4.1.3	  Protein	  expression	  of	  Notch	  receptors	  and	  ligands	  in	  lung	  homogenates	  
Protein	  expression	  profile	  was	   further	   investigated	   in	   the	   lungs	  of	  MCT	   rats	  3-­‐,	  4-­‐	  and	  5-­‐	  
weeks	  after	  MCT	  injection	  and	  compared	  with	  healthy	  rat	  lungs.	  Western	  blot	  analysis	  followed	  by	  
quantification	  (normalized	  to	  GAPDH)	  demonstrated	  a	  marked	  decrease	  in	  protein	  levels	  of	  Notch	  
receptors	  1,	  3	  and	  4	  (Figure	  4.3A	  and	  C)	  and	  ligands;	  DLL1,	  DLL4	  and	  Jagged1	  (Figure	  4.3B	  and	  D)	  in	  












	   	  
	  
Figure	   4.3	   Protein	   expression	   of	   Notch	   receptors	   and	   ligands	   in	   lung	   homogenates	   of	   Monocrotaline	  
(MCT)	  induced	  PH	  rats.	  Western	  blot	  analysis	  of	  Notch	  (A)	  receptors	  and	  (B)	  ligands	  in	  MCT	  induced	  PH	  rat	  
lungs	   after	   3	  weeks	   (3w	  MCT),	   4	  weeks	   (4w	  MCT)	   and	   5	  weeks	   (5w	  MCT)	   of	  MCT	   injection	   and	   healthy	  
animals,	  followed	  by	  the	  densitometry.	  Quantification	  of	  the	  immunoblots	  for	  (C)	  Notch	  receptors	  and	  (D)	  
Notch	  ligands.	  GAPDH	  was	  taken	  as	  the	  loading	  control.*p<	  0.05,	  **p<	  0.01,	  ***p<	  0.001	  Vs	  Healthy.	  
4.2	  Regulation	  of	  Notch	  receptors	  and	  ligands	  in	  hypoxia	  (Hox)	  induced	  PH	  mice	  
4.2.1	  Hemodynamics	  and	  right	  heart	  hypertrophy	  in	  Hox	  mice	  
	   Hypoxia	   exposure	   caused	   a	  marked	   increase	   in	   right	   ventricular	   systolic	   pressure	   after	   3	  
weeks	  (33±1.29	  mmHg)	  and	  5	  weeks	  (35±0.91	  mmHg),	  when	  compared	  to	  normoxic	  mice	  (26±0.40	  
mmHg)	  (Figure	  4.4A).	  The	  ratio	  of	  right	  ventricular	  to	  left	  ventricular	  plus	  septal	  weight	  (RV/LV+S),	  
was	   significantly	   increased	   after	   hypoxia	   exposure	   from	   0.23±0.13	   in	   control	   animals	   to	  
0.36±0.014	  in	  5weeks	  hypoxic	  mice	  (Figure	  4.4B).	  No	  significant	  changes	  were	  observed	  systemic	  







	   	  
	  
Figure	  4.4	  Hemodynamic	  measurements	  and	  right	  heart	  hypertrophy	  in	  Hypoxia	  (HOX)	  induced	  PH	  mice.	  
Physiological	  measurements	  were	  taken	  3	  weeks	  (3week	  Hox)	  and	  5	  weeks	  (5w	  Hox)	  of	  hypoxia	  exposure.	  
(A)	  Right	  ventricular	  systolic	  pressure	  (RVSP),	  (B)	  systemic	  arterial	  pressure	  (SAP)	  and	  (C).	  measurement	  of	  
RV	  hypertrophy	  [RV/(LV+S)]	  *p<	  0.05,	  **p<	  0.01,	  ***p<	  0.001	  Vs	  NOX,	  (n=6).	  
4.2.2	  mRNA	  expression	  of	  Notch	  receptors	  and	  ligands	  in	  lung	  homogenates	  
Expression	  of	  Notch	  receptors	  and	  ligands	  was	  investigated	  by	  qRT-­‐PCR	  in	  lungs	  from	  mice	  
exposed	  to	  hypoxia	  for	  3-­‐	  and	  5-­‐weeks	  and	  normoxic	  mice.	  Notch3	  expression	  was	  increased	  and	  
DLL4	  expression	  was	  decreased	  significantly	  in	  3-­‐	  and	  5-­‐weeks	  hypoxia	  exposed	  mice	  lungs	  (Figure	  
4.5A)	   in	   comparison	   with	   normoxic	   mice.	   Apart,	   no	   significant	   changes	   were	   observed	   in	   the	  








	   	  
	  
Figure	  4.5	  Expression	  of	  Notch	  receptors	  and	   ligands	   in	   lung	  homogenates	  of	  Hox	   induced	  PH	  mice.	   (A)	  
mRNA	  expression	  of	  Notch3	  and	  DLL4	  in	   lung	  homogenates	  of	  Hypoxia	  after	  3	  weeks	  (3	  week	  Hox)	  and	  5	  
weeks	  (5	  week	  Hox)	  of	  hypoxia	  exposure	  and	  healthy	  normoxic	  (NOX)	  mice.	  Regulation	  at	  mRNA	  level	  was	  
analyzed	  by	  real-­‐time	  PCR	  with	  the	  Ct	  method	  (n=4).	  (B)	  Protein	  levels	  of	  Noth3ICD	  and	  DLL4	  as	  analyzed	  by	  
western	   blotting,	   followed	   by	   (C)	   densitometric	   analysis	   of	   the	   blots.	   ßactin	   was	   taken	   as	   the	   loading	  
control.*p<	  0.05,	  **p<	  0.01,	  ***p<	  0.001	  Vs	  NOX.	  
4.2.4	  Protein	  expression	  of	  Notch	  receptors	  and	  ligands	  in	  lung	  homogenates	  
In	   agreement	  with	   the	  mRNA	  expression,	  Notch3ICD	  protein	   levels	  were	   increased	  while	  
DLL4	  levels	  were	  decreased	  in	  Hox	  mice	  in	  comparison	  with	  NOX	  mice	  (Figure	  4.5B	  and	  C).	  	  
4.3	   Regulation	   of	  Notch	   receptors	   and	   ligands	   in	  Hypoxia+Su5416	   (Hox+Su5416)	   induced	   PAH	  
rats	  
4.3.1	  Hemodynamics	  and	  right	  heart	  hypertrophy	  in	  Hox+Su5416	  rats	  
Compared	   with	   saline	   injected	   normoxia	   exposed	   rats	   (35.0±0.84	   mm	   Hg),	   Su5416	  
injection,	  followed	  by	  hypoxia	  exposure	  resulted	  in	  a	  marked	  increase	  in	  right	  ventricular	  systolic	  
pressure	   (65.0±2.32	   mm	   Hg)	   (Figure	   4.6A)	   without	   a	   significant	   difference	   in	   systemic	   arterial	  
pressure	   (Figure	   4.6B).	   The	   RV	   hypertrophy	   was	   significantly	   increased	   in	   Hox+Su5416	   rats	  







	   	  
Figure	  4.6	  Hemodynamic	  measurements	  and	  right	  heart	  hypertrophy	  in	  Hypoxia+Su5416	  induced	  PH	  rats.	  
Physiological	   measurements	   were	   taken	   after	   3	   weeks	   (3wHox+Su5416)	   of	   hypoxia	   exposure.	   (A)	   Right	  
ventricular	   systolic	   pressure	   (RVSP),	   (B)	   systemic	   arterial	   pressure	   (SAP)	   and	   (C)	   measurement	   of	   RV	  
hypertrophy	  [RV/(LV+S)]	  *p<	  0.05,	  **p<	  0.01,	  ***p<	  0.001	  Vs	  Healthy	  (n=6).	  
4.3.2	  mRNA	  expression	  of	  Notch	  receptors	  and	  ligands	  in	  lung	  homogenates	  
Expression	  of	  Notch	  receptors	  and	  ligands	  was	  investigated	  by	  qRT-­‐PCR	  in	  lungs	  from	  rats	  
exposed	  to	  hypoxia	  for	  3	  weeks	  after	  Su5416	  injection	  and	  healthy	  rats.	  Notch1,	  Notch3,	  Notch4,	  
Jagged1	   and	   Jagged2	  were	   strongly	   upregulated	  while	  DLL4	  was	   downregulated	   in	  Hox+Su5416	  
rats	  as	  compared	  to	  healthy	  rats	  (Figure	  4.7A).	  
4.3.3	  Protein	  expression	  of	  Notch	  receptors	  and	  ligands	  in	  lung	  homogenates	  
Western	   blot	   analysis	   of	   Notch	   receptors	   and	   ligands	   revealed	   a	   marked	   increase	   in	  
Notch1ICD	  and	  Notch3ICD	  protein	  levels	  in	  lungs	  from	  Hox+Su5416	  rats	  in	  comparison	  to	  healthy	  




Figure	  4.7	  Expression	  of	  Notch	  receptors	  and	  ligands	  in	  Hypoxia+Su5416	  rats	  lungs.	  (A)	  mRNA	  expression	  
of	   Notch	   receptors	   and	   ligands	   in	   lung	   homogenates	   of	   Hypoxia+Su5416	   rats	   after	   3	   weeks	  






	   	  
real-­‐time	   PCR	   with	   the	   Ct	   method	   (n=6)	   (B)	   Protein	   levels	   of	   Noth1ICD	   and	   Notch3ICD	   as	   analyzed	   by	  
western	   blotting,	   followed	   by	   (C)	   densitometric	   analysis	   of	   the	   blots.	   GAPDH	   was	   taken	   as	   the	   loading	  
control.*p<	  0.005,	  **p<	  0.01,	  ***p<	  0.001	  Vs	  Healthy.	  
4.4	  Regulation	  of	  Notch	  receptors	  and	  ligands	  in	  IPAH	  patients	  
4.4.1	  mRNA	  expression	  of	  Notch	  receptors	  and	  ligands	  in	  lung	  homogenates	  
In	   order	   to	   define	   the	   mRNA	   expression	   of	   Notch	   receptors	   and	   ligands	   in	   lung	  
homogenates	   from	  donors	   and	  patients	  with	   IPAH,	   qRT	  PCR	  was	   carried	  out.	  Among	   the	  Notch	  
receptors,	   Notch	   1,	   3	   and	   4	   were	   significantly	   upregulated	   in	   IPAH	   lungs.	   Among	   the	   ligands,	  
Jagged1	  and	  2	  were	  increased	  in	  IPAH	  lungs	  as	  compared	  to	  Donor	  lungs	  (Figure	  4.9A).	  
4.4.2	  Protein	  expression	  of	  Notch	  receptors	  and	  ligands	  in	  lung	  homogenates	  
Protein	   expression	   analysis	   of	   Notch	   receptors	   and	   ligands	   in	   lung	   homogenates	   from	  
patients	  with	   IPAH	  and	  donors	   revealed	  a	  significant	   increase	   in	  Notch1ICD	   levels	   in	   IPAH	   lungs,	  
compared	   to	   donors	   as	   observed	   by	  western	   blot	   analysis	   (Figure	   4.9B-­‐C).	   Other	   receptors	   and	  










	   	  
	  
Figure	   4.8	   Expression	   of	   Notch	   receptors	   and	   ligands	   in	   human	   donors	   and	   IPAH	   lungs.	   (A)	   mRNA	  
expression	  of	  Notch	  receptors	  and	  ligands	  in	  lung	  homogenates	  of	  donors	  and	  IPAH	  patients.	  Regulation	  at	  
mRNA	  level	  was	  analyzed	  by	  real-­‐time	  PCR	  using	  Ct	  method	  (n=7)	  (B)	  Western	  blot	  analysis	  of	  Notch1ICD,	  
followed	  by	   (C)	   its	   densitometric	   analysis.	  GAPDH	  was	   taken	   as	   the	   loading	   control.*p<	   0.05,	   **p<	   0.01,	  
***p<	  0.001	  Vs	  donors.	  
4.4.3	  mRNA	  and	  protein	  expression	  of	  Notch1	  in	  pulmonary	  arteries	  
To	  further	  investigate	  whether	  the	  upregulation	  of	  Notch1	  observed	  in	  lung	  homogenates	  
from	  IPAH	  patients	  is	  representative	  of	  pulmonary	  vasculature,	  Notch1	  expression	  was	  checked	  in	  
pulmonary	  arteries	  isolated	  from	  IPAH	  and	  Donor	  lungs	  by	  qRT	  PCR	  and	  western	  blot.	  There	  was	  
no	   significant	   change	  observed	   in	  mRNA	  expression	  of	  Notch1	  between	  donor	  and	   IPAH	   (Figure	  
4.10A).	  However,	  at	  protein	  level,	  we	  observed	  a	  substantial	  increase	  in	  Notch1ICD	  expression	  in	  
IPAH	  pulmonary	  arteries	  as	  compared	  to	  donors	  (Figure	  4.10B-­‐C).	  
	  
Figure	  4.9	  Expression	  of	  Notch	  receptors	  and	  ligands	  in	  Human	  donors	  and	  IPAH	  pulmonary	  arteries.	  (A)	  






	   	  
was	  analyzed	  by	  real-­‐time	  PCR	  using	  Ct	  method	  (n=3-­‐4)	  (B)	  Western	  blot	  analysis	  of	  Notch1ICD,	  followed	  by	  
(C)	  its	  densitometric	  analysis.	  GAPDH	  was	  taken	  as	  the	  loading	  control.	  *p<	  0.05	  Vs	  donors.	  
4.3	  Localization	  of	  Notch1	  in	  IPAH	  and	  donor	  lungs	  
In	  order	  to	  determine	  the	  localization	  of	  Notch1	  in	  pulmonary	  vessels,	   immunostaining	  of	  
Notch1	  was	  carried	  out	   in	  donor	  and	   IPAH	  human	   lungs.	  Only	  a	  weak	  expression	  of	  Notch1	  was	  
detected	   in	   pulmonary	   arteries	   of	   donor	   lungs	   (Figure	   4.10A-­‐F).	   In	   contrast,	   a	   strong	  
immunoreactivity	   of	   Notch1	   was	   observed	   in	   pulmonary	   arteries	   of	   IPAH	   lung	   tissues.	   The	  
expression	   was	   confined	   to	   the	   intimal	   layer,	   as	   revealed	   by	   serial	   section	   staining	   with	   von-­‐
willebrand	  factor	  (vWF),	  an	  endothelial	  marker	  and	  alpha	  smooth	  muscle	  actin	  (α-­‐actin),	  a	  smooth	  






	   	  
 
Figure	   4.10	   Immuno-­‐localization	   of	   Notch1	   in	   lungs	   from	   IPAH	   patients	   and	   donors.	   Representative	  
immunostaining	  microphotographs	  of	  the	  human	  lung	  sections	  from	  donors	  (A-­‐F)	  and	  IPAH	  patients	  (G-­‐R).	  
Staining	  was	   undertaken	   for	   Notch1,	   von	  Willebrand-­‐factor	   (brown;	   endothelial	   cells)	   and	   alpha	   smooth	  
muscle	  actin	  (purple;	  smooth	  muscle	  cells).	  Scale	  bar:	  20	  μm.	  






	   	  
In	  vitro	  studies	  were	  performed	  in	  hPAECs	  using	  Notch1	  siRNA	  to	  investigate	  the	  functional	  
role	  of	  Notch1	  upregulation	  observed	  in	  the	  initial	  screening	  studies.	  	  	  	  	  
4.5.1	  Transient	  Notch1	  knockdown	  by	  siRNA	  
Effective	   knock	   down	   of	   Notch1	   was	   achieved	   by	   using	   20nM	   siRNA	   in	   hPAECs.	   Cells	  
transfected	  with	  scrambled	  siRNA	  did	  not	  show	  any	  change	   in	  Notch1	  expression.	  Densitometric	  
analysis	   of	   the	  western	  blot	   for	  Notch1ICD	   showed	  85%	  knockdown	  efficiency	   (Figure	   4.11A-­‐B),	  
48hrs	   after	   siRNA	   transfection.	   Further,	   decrease	   in	   expression	   of	   Hes1,	   Notch	   target	   gene	   at	  
mRNA	   level	   by	   Notch1	   siRNA	   confirmed	   functional	   knock	   down	   (Figure	   4.11C).	   In	   addition,	  
expression	  of	  other	  Notch	  receptors	  (Notch2	  and	  Notch4)	  was	  analyzed	  to	  examine	  specificity	  of	  
knockdown.	  Western	  blot	  analysis	  revealed	  no	  effect	  of	  Notch1	  siRNA	  transfection	  on	  Notch2ICD	  
and	  Notch4ICD	  expression	  (Figure	  4.11D).	  	  
	  
Figure	   4.11	   Knockdown	   of	   Notch1	   in	   hPAECs.	   hPAECs	   were	   transiently	   transfected	   with	   20	   nM	   of	   si-­‐
scramble	   or	   si-­‐Notch1	   for	   48hrs.	   hPAECs	   treated	   with	   transfection	   reagent	   alone	   is	   the	   Mock.	   Protein	  
expression	   of	   Notch1ICD	   48hrs	   after	   si-­‐Notch1	   transfection,	   as	   shown	   by	   (A)	   western	   blot	   and	   (B)	  
densitometric	  analysis	  of	  the	  blot.	  (C)	  mRNA	  expression	  of	  Hes1	  as	  measured	  by	  real	  time	  PCR,	  48hrs	  after	  
si-­‐Notch1	  transfection.	  All	  values	  are	  expressed	  as	  ∆Ct.	  (D)	  Notch2ICD	  and	  Notch4ICD	  protein	  levels	  48hrs	  








	   	  
4.5.2	  Notch1	  knockdown	  attenuates	  hPAECs	  proliferation	  
With	   standardized	   siRNA	   knockdown	   conditions,	   proliferation	   of	   hPAECs	   was	   examined	  
48hrs	   after	   Notch1	   siRNA	   transfection	   using	   BrdU	   assay.	   Importantly,	   Notch1	   knock	   down	  
decreased	   (~40%)	   growth	   medium	   induced	   proliferation	   as	   compared	   to	   scrambled	   siRNA	  
transfected	  hPAECs	  (Figure	  4.12A).	  
	  
Figure	  4.12	  Notch1	  knockdown	  attenuates	  proliferation	  in	  hPAECs.	  (A)	  hPAECs	  proliferation	  as	  measured	  
by	  BrdU	  incorporation,	  48hrs	  after	  si-­‐Notch1	  transfection.	  ***p	  <0.001	  Vs	  si-­‐scramble,	  (n	  =	  5).	  (B)	  Effect	  of	  
si-­‐Notch1	  on	  cell	  cycle	  regulators	  was	  analyzed	  by	  western	  blotting	  with	  antibodies	  against	  p21	  and	  cyclin	  
B1,	  followed	  by	  (C)	  densitometric	  analysis	  of	  the	  blots.	  GAPDH	  was	  taken	  as	  the	  loading	  control.	  *p<	  0.05,	  
***p<	  0.001	  Vs	  Mock.	  n	  =	  3	  in	  each	  group.	  
4.5.3	  Inhibition	  of	  Notch1	  modulates	  cell	  cycle	  markers	  
Cyclins	  such	  as	  cyclinD1,	  cyclinB1	  and	  cyclin	  dependent	  kinase	   inhibitors	   (CDKIs)	   like	  p21,	  
p27	  are	  very	  important	  regulators	  of	  cell	  cycle	  and	  hence,	  proliferation.	  Therefore,	  we	  attempted	  
to	  study	  whether	  any	  of	  these	  cell	  cycle	  regulators	  are	  modulated	  by	  Notch1	  knockdown.	  Western	  
blots,	  followed	  by	  quantification	  indicated	  an	  upregulation	  of	  p21	  and	  downregulation	  of	  cyclinB1	  






	   	  
4.5.4	  Notch1	  knockdown	  promotes	  apoptosis	  in	  hPAECs	  
To	  determine	  whether	  Notch1	  plays	  a	   role	   in	  apoptosis	  of	  endothelial	   cells,	  TUNEL	  assay	  
was	   performed	   in	   hPAECs,	   48hrs	   after	   si-­‐Notch1	   transfection.	   si-­‐Notch1	   transfected	   cells	   were	  
significantly	   more	   sensitive	   to	   spontaneous	   apoptosis	   as	   knock	   down	   of	   Notch1	   led	   to	   ~20%	  
increase	   in	   number	   of	   apoptotic	   cells	   as	   compared	   to	   scrambled	   siRNA	   transfected	   cells	  
(Figure4.13A-­‐B).	   Additionally,	   western	   blots	   and	   densitometric	   quantification	   for	   Bcl-­‐2	   and	   Bax	  
proteins	  demonstrated	  a	  significant	  decrease	  in	  Bcl-­‐2	  protein	  levels	  in	  si-­‐Notch1	  transfected	  cells	  










	   	  
	  
Figure	  4.13	  Notch1	  knockdown	  induces	  apoptosis	  in	  hPAECs.	  (A)	  Representative	  images	  of	  scrambled	  and	  
si-­‐Notch1	   transfected	   cells	   that	   were	   assessed	   for	   apoptosis	   using	   in	   situ	   cell	   death	   detection	   method	  
(TUNEL	  assay).	  (B)	  Percentage	  of	  apoptotic	  (TUNEL	  positive)	  cells	  as	  counted	  using	  STEPanizer	  software	  (C)	  
Effect	   of	   Notch1	   knockdown	   was	   analyzed	   on	   apoptotic	   proteins	   by	   Western	   blotting	   with	   antibodies	  
against	  Bcl-­‐2	  and	  Bax	  followed	  by	  (D)	  densitometric	  analysis	  of	  the	  blots.	  GAPDH	  was	  taken	  as	  the	  loading	  
control.*p<	  0.05,	  **p<	  0.01	  Vs	  si-­‐scramble.	  n	  =	  3	  in	  each	  group.	  
4.6	   Effect	   of	   Notch1ICD	   over	   expression	   on	   cellular	   proliferation	   and	   apoptosis	   in	   human	  
pulmonary	  artery	  endothelial	  cells	  (hPAECs)	  
4.6.1	  Overexpression	  of	  Notch1ICD	  in	  hPAECs	  
Transfection	  with	  a	  plasmid	  containing	  human	  Notch1ICD	  cDNA	  under	  CMV	  promoter	  (1μg	  
plasmid/well)	  was	  carried	  out	   to	  overexpress	  NotchICD	   in	  hPAECs.	  Same	  plasmid	  backbone	  with	  
GFP	   under	   CMV	  promoter	  was	   used	   as	   a	   control	   plasmid.	  Western	   blot	   analysis	   using	   antibody	  
against	   C-­‐terminal	   of	   Notch1	   showed	   that	   cleaved	   Notch1	   band	   was	   strongly	   up	   regulated	   in	  
Notch1ICD	  transfected	  cells	  as	  compared	  to	  control	  vector	  transfected	  cells	  (Figure	  4.14A),	  48hrs	  
after	  transfection.	  Densitometric	  analysis	  confirmed	  an	  increase	  in	  N1ICD	  expression	  by	  two	  fold	  in	  
hPAECs	   (Figure	   4.14B).	   Transfection	   efficiency	   was	   monitored	   by	   observing	   the	   cells	   under	  
microscope	  for	  GFP	  expression	  in	  control	  GFP	  plasmid	  transfected	  cells	  (Figure	  4.14C).	  Functional	  
overexpression	   of	  Notch1	  was	   confirmed	  by	   significant	   increase	   in	  mRNA	   levels	   of	   downstream	  






	   	  
	  
Figure	   4.14	   Over-­‐expression	   of	   Notch1ICD	   in	   hPAECs.	   hPAECs	   were	   transiently	   transfected	   with	   1µg	  
(well/6-­‐well	  plate)	  of	  empty	  vector	  or	  N1ICD	  plasmid	  for	  48hrs.	  hPAECs	  treated	  with	  transfection	  reagent	  
alone	   is	   the	  Mock.	   (A)	  Notch1ICD	  expression,	  48hrs	  after	  plasmid	   transfection,	   as	   shown	  by	   the	  western	  
blot	  and	  (B)	  densitometric	  analysis	  of	  the	  same.	  ßactin	  was	  taken	  as	  the	  loading	  control.	  (C)	  Representative	  
images	   of	  mock	   and	  GFP	   transfected	   cells	   depicting	   the	   transfection	   efficiency.	   (D)	  mRNA	   expression	   of	  
Hes1	  as	  measured	  by	  real	  time	  PCR,	  48hrs	  after	  si-­‐Notch1	  transfection.	  All	  values	  are	  expressed	  as	  ∆Ct.	  *p	  
<0.05	  Vs	  Mock.	  n	  =	  3	  in	  each	  group.	  
4.6.2	  Notch1	  ICD	  overexpression	  increases	  proliferation	  of	  hPAECs	  
Proliferation	   of	   hPAECs	   was	   examined	   48hr	   after	   transfection	   of	   Notch1ICD	   and	   control	  
plasmids,	  using	  BrdU	  incorporation	  assay.	  Growth	  medium	  stimulated	  proliferation	  of	  hPAECs	  was	  
increased	  markedly	  by	  77%	  as	  compared	  to	  control	  plasmid	  transfected	  cells	  (Figure	  4.15A).	  
4.6.3	  Notch1	  ICD	  over-­‐expression	  modulates	  cell	  cycle	  markers	  
In	  order	  to	  check	  if	  Notch1	  constitutive	  activity	  modulated	  cell	  cycle	  regulators,	  similar	  to	  
its	  knockdown,	  we	  carried	  out	  western	  blots	  to	  check	  the	  expression	  of	  cell	  cycle	  markers,	  48hrs	  
after	   transfection.	   Densitometric	   analysis	   of	   the	   immunoblots	   demonstrated	   a	   significant	  
downregulation	   in	   p21	   expression	   while	   CyclinB1	   showed	   a	   slight	   increase	   in	   Notch1ICD	  






	   	  
	  
Figure	   4.15	   Notch1ICD	   overexpression	   increases	   hPAECs	   proliferation.	   (A)	   hPAECs	   proliferation	   as	  
measured	  by	  BrdU	  incorporation,	  48hrs	  after	  N1ICD	  plasmid	  transfection.	  ***p	  <0.001	  Vs	  empty	  vector,	  n	  =	  
5.	   (B)	   Effect	   of	   N1ICD	   overexpression	   was	   analyzed	   on	   cell	   cycle	   regulators	   by	   Western	   blotting	   with	  
antibodies	  to	  p21	  and	  cyclin	  B1	  followed	  by	  (C)	  densitometric	  analysis	  of	  the	  blots.	  GAPDH	  was	  taken	  as	  the	  
loading	  control.	  **p<	  0.05	  Vs	  Mock.	  n	  =	  3	  in	  each	  group.	  
4.6.4	  Notch1	  mediates	  anti-­‐apoptotic	  effect	  on	  hPAECs	  
Treatment	  of	  hPAECs	  with	  Notch1ICD	  expression	  plasmid	   for	  48hrs,	   led	   to	  an	   increase	   in	  
expression	   of	   anti-­‐apoptotic	   protein,	   Bcl-­‐2	   and	   a	   concomitant	   decrease	   in	   pro-­‐apoptotic,	   Bax	  
protein	   as	   observed	   by	   western	   blotting	   (Figure	   4.16A).	   This	   led	   to	   a	   significant	   decrease	   in	  
Bax/Bcl-­‐2	   ratio	   (Figure	   4.16B)	   in	   Notch1ICD	   transfected	   cells	   as	   compared	   to	   empty	   vector,	  







	   	  
	  
Figure	  4.16	  Notch1ICD	  overexpression	  promotes	   survival	  of	  hPAECs.	   (A)	   Effect	  of	  N1ICD	  overexpression	  
was	  analyzed	  on	  apoptotic	  proteins	  by	  Western	  blotting	  with	  antibodies	  against	  Bcl-­‐2	  and	  Bax	  followed	  by	  
(B)	  densitometric	  analysis	  of	  the	  blots.	  GAPDH	  was	  taken	  as	  the	  loading	  control.	  **p<	  0.05	  Vs	  empty	  vector.	  
n	  =	  3	  in	  each	  group.	  
4.7	   Effect	   of	   Notch1	   knock	   down	   and	   over-­‐expression	   on	   proliferation	   of	   human	   pulmonary	  
artery	  smooth	  muscle	  cells	  (hPASMCs)	  
In	  addition	  to	  endothelial	  cells,	  Notch1	  is	  reportedly	  expressed	  in	  vascular	  smooth	  muscle	  
cells.	  Hence,	  functional	  role	  of	  Notch1	  in	  proliferation	  of	  hPASMCs	  was	  also	  assessed.	  	  
4.7.1	  Notch1	  knock	  down	  has	  no	  effect	  on	  proliferation	  of	  hPASMCs	  
20nM	  of	  siRNA	  was	  sufficient	  to	  reduce	  the	  expression	  of	  Notch1	  at	  protein	  level	  by	  50%	  as	  
demonstrated	  in	  the	  western	  blot	  for	  Notch1ICD	  and	  its	  subsequent	  quantification	  (Figure	  4.17A-­‐
B).	  Western	   blot	   analysis	   for	  Notch3ICD	  demonstrated	   that	  Notch1	   siRNA	   is	   specific,	   as	  Notch1	  
siRNA	   transfection	   did	   not	   have	   any	   significant	   effect	   on	   expression	   of	   Notch3	   (Figure	   4.17C).	  
Proliferation	   of	   hPASMCs	   was	   examined	   48hr	   after	   si-­‐Notch1	   transfection	   using	   BrdU	  
incorporation	   assay.	   Interestingly,	   there	  was	  no	   change	  observed	   in	   growth	  medium	   stimulated	  






	   	  
	  
Figure	  4.17	  Knockdown	  of	  Notch1	   in	  hPASMCs.	  hPASMCs	  were	   transiently	   transfected	  with	  20nM	  of	   si-­‐
scramble	  or	  si-­‐Notch1	  for	  48hrs.	  hPASMCs	  treated	  with	  transfection	  reagent	  alone	  is	  the	  Mock.	  Notch1ICD	  
expression,	  	  48hrs	  after	  si-­‐Notch1	  transfection,	  as	  shown	  by	  (A)	  western	  blot	  and	  (B)	  densitometric	  analysis	  
of	   the	   same.	   (C)	  Notch3ICD	   protein	   levels	   48hrs	   after	   si-­‐Notch1	   transfection.	   ß	   actin	   was	   taken	   as	   the	  
loading	  control.	  ***p	  <0.001	  Vs	  Mock.	  n	  =	  3	  in	  each	  group.	  (D)	  hPASMCs	  proliferation	  as	  measured	  by	  BrdU	  
incorporation,	  48hrs	  after	  si-­‐Notch1	  transfection.	  	  
4.7.2	  Notch1	  over-­‐expression	  has	  no	  effect	  on	  proliferation	  of	  hPASMCs	  
Transfection	  with	  a	  plasmid	  containing	  Notch1ICD	  cDNA	  under	   control	  of	  CMV	  promoter	  
was	  carried	  out	  to	  obtain	  constitutive	  expression	  of	  Notch1ICD	  in	  hPASMCs.	  Transfection	  resulted	  
in	   a	   ~4	   fold	   increase	   in	   expression	   of	   Notch1ICD	   as	   demonstrated	   in	   western	   blot	   against	  
Notch1ICD	   (Figure	   4.18A-­‐B).	   Constitutive	   expression	   of	   Notch1ICD	   did	   not	   have	   any	   effect	   on	  







	   	  
	  
Figure	  4.18	  Overexpression	  of	  Notch1ICD	  in	  hPASMCs.	  hPASMCs	  were	  transiently	  transfected	  with	  1.5µg	  
(per	   well	   of	   6-­‐well	   plate)	   of	   empty	   vector	   or	   N1ICD	   plasmid	   for	   48hrs.	   PASMCs	   treated	   with	   only	  
transfection	  reagent	  is	  the	  Mock.	  (A)	  Notch1ICD	  expression,	  48hrs	  after	  plasmid	  transfection,	  as	  shown	  by	  
the	  western	  blot	  and	  (B)	  densitometric	  analysis	  of	  the	  same.	  ßactin	  was	  taken	  as	  loading	  control.	  **p	  <0.01	  
Vs	  Mock.	  n	  =	  3	   in	  each	  group.	   (C)	  hPASMCs	  proliferation	  as	  measured	  by	  BrdU	   incorporation,	  48hrs	  after	  
N1ICD	  plasmid	  transfection.	  	  
4.8	   Effect	   of	   pharmacological	   inhibition	  of	  Notch	   signaling	   using	   γ-­‐secretase	   inhibitor,	  DBZ	  on	  
hPAECs	  and	  hPASMCs	  
4.8.1	  Inhibition	  of	  Notch	  signaling	  by	  γ-­‐secretase	  inhibitor,	  DBZ	  
To	   study	   the	   functional	   role	   of	   Notch	   signaling	   in	   hPAECs	   and	   hPASMCs,	   γ-­‐secretase	  
inhibitor,	  DBZ	  was	  used	  to	   inhibit	  the	  endogenous	  notch	  activity.	  γ-­‐secretase	   inhibitor	  binds	  and	  
inhibits	  the	  enzyme	  complex,	  γ-­‐secretase,	  responsible	  for	  cleavage	  of	  Notch	  receptors.	  Treatment	  
with	  DBZ	  decreased	  γ-­‐secretase	  activity	  by	  50%	  after	  8hrs	  in	  hPAECs	  as	  observed	  by	  the	  reduced	  
protein	  levels	  of	  Notch1ICD	  (Figure	  4.19A-­‐B).	  Furthermore,	  DBZ	  dose	  dependently	  decreased	  the	  
expression	  of	  Hes1,	  downstream	  target	  gene	  of	  notch	  signaling	  pathway	   in	  both	  hPAECs	   (Figure	  






	   	  
	  
Figure	  4.19	  γ	  secretase	  inhibitor	  (DBZ)	  inhibits	  Notch	  signaling	  in	  hPASMCs	  and	  hPAECs.	  (A)	  Western	  blot	  
analysis	   of	   Notch1ICD	   after	   treatment	   of	   hPAECs	   with	   DBZ	   with	   GAPDH	   as	   the	   loading	   control.	   (B)	  
Quantification	  of	  the	  Western	  Blot.	  GAPDH	  was	  taken	  as	  the	  loading	  control.**p<	  0.01,	  ***p<	  0.001	  Vs	  0hr.	  
mRNA	  expression	  of	  Hes1	  in	  (C)	  hPAECs	  and	  (D)	  hPASMCs	  after	  24	  hrs	  treatment	  with	  DBZ	  as	  analyzed	  by	  
real	  time	  PCR.	  All	  values	  are	  expressed	  as	  ∆Ct.	  ***p<	  0.001	  Vs	  DMSO	  control.	  
4.8.2	  DBZ	  attenuates	  proliferation	  of	  hPAECs	  
We	  examined	  the	  effect	  of	  DBZ	  on	  proliferation	  of	  hPAECs	  by	  stimulating	  quiescent	  hPAECs	  
with	   5%	   FCS	   or	   VEGF	   (10ng/ml)	   in	   presence/absence	   of	   DBZ	   using	   BrdU	   incorporation	   assay.	  
Treatment	  with	  5%	  FCS	  resulted	   in	  a	  marked	   increase	   in	  proliferation	  of	  hPAECs	  (by	  88%)	  which	  
was	   reduced	   to	   less	   than	  half	   (by	   66%)	  by	  20μM	  DBZ	   (Figure	  4.20A).	   Interestingly,	   proliferation	  







	   	  
	  
Figure	   4.20	   γ	   secretase	   inhibitor	   (DBZ)	   attenuates	   proliferation	   in	   hPAECs.	  hPAECs	  were	   serum	   starved	  
and	  stimulated	  with	  (A)	  5%	  FCS	  or	  (B)	  10ng/ml	  VEGF	  in	  presence	  of	  various	  concentrations	  of	  DBZ	  or	  DMSO	  
(-­‐)	   and	  measured	   for	   the	   changes	   in	   proliferation	   by	   BrdU	   incorporation.	   All	   data	   are	   expressed	   as	   fold	  
increase	   of	   the	   non-­‐stimulated	   group	   and	   represent	  means	   ±	   SEM,	   n=5.	   *,	   p<0.05	  Vs	   non-­‐stimulated;	   †,	  
p<0.05	  Vs	  (A)	  FCS-­‐treated	  group	  or	  (B)	  VEGF-­‐	  treated	  group.	  
4.8.3	  DBZ	  inhibits	  proliferation	  of	  hPASMCs	  
Effect	  of	  DBZ	  on	  proliferation	  of	  hPASMCs	  was	  also	  investigated	  using	  BrdU	  incorporation	  
assay.	   Serum	   starved	   hPASMCs	   were	   stimulated	   with	   5%	   FCS	   or	   PDGF-­‐BB	   (10ng/ml)	   in	  
presence/absence	  of	  DBZ.	  Interestingly,	  DBZ	  significantly	  decreased	  DNA	  synthesis	  in	  both,	  5%	  FCS	  
(Figure	  4.21A)	  and	  PDGF-­‐BB	  (Figure	  4.21B)	  stimulated	  hPASMCs	  in	  a	  dose-­‐dependent	  manner	  with	  
maximum	  inhibition	  observed	  at	  20μM	  (by	  86%	  for	  5%	  FCS	  and	  76%	  for	  PDGF-­‐BB).	  
	  
Figure	   4.21	   γ	   secretase	   inhibitor	   (DBZ)	   attenuates	   proliferation	   in	   hPASMCs.	   hPASMCs	   were	   serum	  
starved	  and	  stimulated	  with	  (A)	  5%	  FCS	  or	  (B)10ng/ml	  PDGF-­‐BB	  in	  the	  presence	  of	  various	  concentrations	  
of	   DBZ	   or	   DMSO	   (-­‐)	   and	  measured	   for	   the	   changes	   in	   proliferation	   by	   BrdU	   incorporation.	   All	   data	   are	  
expressed	  as	  fold	  increase	  of	  the	  non-­‐stimulated	  group	  and	  represent	  means	  ±	  SEM,	  n=5.	  *,	  p<0.05	  Vs	  non-­‐






	   	  
5.	  DISCUSSION	  
Research	   carried	   out	   in	   past	   decade	   has	   very	   well	   established	   Notch	   signaling	   as	   an	  
important	  player	  in	  various	  aspects	  of	  vascular	  development,	  homeostasis	  [128,	  157,	  158]	  as	  well	  
as	  vascular	  injury	  [132,	  137,	  138].	  Indispensable	  involvement	  of	  Notch3	  in	  arterial	  smooth	  muscle	  
cell	  identity	  [124,	  125]	  and	  Notch1	  and	  Notch4	  in	  arterial	  endothelial	  phenotype	  and	  angiogenesis	  
[119],	   provides	   intriguing	   prospects	   of	   their	   involvement	   in	   the	   pathogenesis	   of	   pulmonary	  
hypertension.	  Recently,	  Li	  et	  al	  have	  reported	  increased	  activation	  of	  Notch3	  signaling	  in	  PASMCs	  
from	   PAH	   patients.	   They	   further	   demonstrated	   Notch3	   deletion	   protected	   mice	   against	  
development	  of	  hypoxia	   induced	  PH	   [147].	   Interestingly,	   this	   is	   the	   first	   and	  only	   study	   to	  date,	  
suggesting	   a	   link	   between	   Notch	   signaling	   and	   PAH	   development.	   Notch	   receptors,	   other	   than	  
Notch3,	  have	  also	  been	  implicated	  in	  vascular	  homeostasis	  and	  neointima	  formation	  after	  vascular	  
injury	   [138,	   139].	   Hence,	   it	   is	   important	   to	   study	   the	   expression	   pattern	   of	   the	   other	   Notch	  
receptors	  and	  ligands	  and	  to	  further	  determine	  their	  role	  in	  pathophysiology	  of	  PH.	  
5.1	  Expression	  of	  Notch	  receptors	  and	  ligands	  in	  IPAH	  patients	  
A	  complete	  expression	  analysis	  at	  mRNA	  and	  protein	  levels	  was	  carried	  out	  in	  lungs	  of	  IPAH	  
patients	   and	   donors.	   Profound	   changes	   were	   detected	   in	   Notch	   signaling	   molecules	   in	   lung	  
homogenates	   of	   IPAH	   patients	   as	   compared	   to	   donors.	   Notch	   receptors	   (Notch1,	   3	   and	   4)	   and	  
ligands	   (Jagged1,	   DLL1)	   were	   significantly	   upregulated	   in	   IPAH	   lungs	   at	   the	  mRNA	   level	   (Figure	  
4.9A).	   Although,	   western	   blot	   analysis	   did	   not	   indicate	   significant	   differences	   in	   Notch3ICD,	  
Notch4ICD,	   Jagged1	   and	   DLL1	   at	   protein	   levels	   (data	   not	   shown).	   This	   suggests	   a	   discrepancy	  
between	   transcription	   and	   translation	   regulation	   of	   these	   mentioned	   proteins	   and	   should	   be	  
investigated	  in	  future.	  Interestingly,	  a	  major	  increase	  was	  observed	  in	  Notch1ICD	  protein	  levels	  in	  
IPAH	  lungs	  indicating	  an	  increased	  activation	  of	  Notch1	  signaling	  pathway	  in	  lungs	  of	  IPAH	  patients	  
as	  compared	  to	  donors	  (Figure	  4.9B-­‐C).	  	  
	   To	   further	   validate,	   that	   the	   changes	   observed	   in	   Notch1	   were	   localized	   to	   pulmonary	  
vasculature,	  Notch1	   expression	  was	   analyzed	   in	   pulmonary	   arteries	   isolated	   from	   IPAH	  patients	  
and	   donors.	   Indeed,	   increased	   protein	   expression	   of	   Notch1ICD	   was	   detected	   in	   arteries	   from	  
IPAH	  patients.	  Though,	  there	  was	  no	  significant	  change	  observed	  in	  the	  mRNA	  expression	  (Figure	  
4.10).	   To	  our	  knowledge,	   this	   is	   the	   first	   study	  demonstrating	  an	   increased	  Notch1	  activation	   in	  






	   	  
5.2	  Expression	  of	  Notch	  receptors	  and	  ligands	  in	  experimental	  PH	  models	  
	   In	  present	  investigation,	  established	  animal	  models	  of	  PH	  were	  employed	  to	  further	  study	  
the	  role	  of	  Notch	  signaling	  in	  pathogenesis	  of	  PH.	  To	  begin	  with,	  expression	  studies	  at	  mRNA	  and	  
protein	   levels	   were	   performed	   in	   MCT	   induced	   PH	   rats.	   These	   studies	   demonstrated	   altered	  
expression	  of	  Notch	   receptors	  and	   ligands	   in	   lungs	  of	  MCT	   induced	  PH	   rats.	  At	   the	  mRNA	   level,	  
Notch3	   exhibited	   a	   strong	   upregulation	   while	   Notch1,	   Notch4	   and	   DLL4	   were	   significantly	  
decreased	   (Figure	   4.2).	  MCT	   induced	  PH	  model	   is	   characterized	   by	  medial	   hypertrophy	   and	   the	  
underlying	  mechanism	  of	  this	  model	   is	  thought	  to	  be	  MCT	  pyrole	  mediated	  endothelial	  damage,	  
triggering	   release	   of	   growth	   factors	   and	   cytokines	   [149].	   Notch4	   and	   DLL4	   are	   reported	   to	   be	  
exclusively	  expressed	  in	  endothelial	  cells	  [158]	  and	  furthermore,	  Notch1	  is	  abundantly	  expressed	  
in	   endothelium	   [159],	   hence,	   their	   observed	   decrease	   in	   expression	   might	   be	   associated	   with	  
endothelial	   damage.	   In	   accordance,	   a	   reduced	  protein	   expression	  of	  Notch1ICD,	  Notch4ICD	  and	  
DLL4	  was	  detected	  in	  MCT	  lungs.	  However,	  Notch3ICD	  western	  blot	  analysis	  revealed	  a	  decrease	  
in	  MCT	  lungs	  as	  compared	  to	  the	  healthy	  rat	  lungs,	  contrary	  to	  its	  mRNA	  expression	  (Figure	  4.3).	  
Though	  not	  extensively	  investigated,	  Notch3	  expression	  is	  also	  observed	  in	  macrophages	  [160]	  and	  
interestingly,	   MCT	   model	   of	   PH	   is	   characterized	   by	   adventitial	   inflammation,	   particularly	  
macrophage	  accumulation	  [20,	  150].	  Hence,	   increase	   in	  Notch3	  mRNA	  could	  represent	  the	  basal	  
expression	  of	  infiltrating	  inflammatory	  cells,	  along	  with	  smooth	  muscle	  cells	  and	  not	  the	  activated	  
Notch3	  signaling	  (as	  no	  increase	  was	  detected	  at	  the	  level	  of	  Notch3ICD	  in	  protein	  blots).	  It	  is	  well	  
established	   that	   notch	   receptor	   activation	   and	   cleavage	   is	   dependent	   on	   ligand	   availability	   and	  
binding.	  Therefore,	  a	  decrease	  observed	  in	  Notch3ICD	  protein	  levels	  could	  be	  a	  direct	  outcome	  of	  
the	  strong	  decrease	  observed	  in	  the	  protein	  levels	  of	  ligands	  (DLL4,	  DLL1	  and	  Jagged1)	  in	  MCT	  lung	  
homogenates.	  	  
The	   MCT	   model	   is	   recognized	   as	   the	   classical	   experimental	   PH	   model	   to	   study	  
pathophysiological	   mechanisms	   and	   therapeutic	   options	   for	   the	   disease.	   However,	   it	   only	  
represents	  the	  pathological	  features	  of	  group	  1	  (PAH)	  of	  the	  Dana	  Point	  classification	  of	  PH	  (Table	  
1).	   In	   order	   to	   analyze	   the	   contribution	   of	   notch	   signaling	   in	   PH	   due	   to	   different	   etiology,	   we	  
further	  investigated	  expression	  of	  notch	  receptors	  and	  ligands	  in	  Chronic	  Hypoxia	  induced	  PH	  mice	  
model.	  Chronic	  hypoxia	  model	  represents	  group	  3	  (PH	  owing	  to	  lung	  diseases	  and/or	  hypoxia)	  of	  
the	   Dana	   Point	   classification	   [151]	   and	   furthermore,	   addresses	   the	   aspect	   of	   interspecies	  






	   	  
Notch3	  and	  downregulation	  in	  DLL4	  expression	  at	  mRNA	  level	  in	  hypoxic	  mice	  lungs	  (Figure	  4.5A).	  
In	   agreement	  with	   these	   results,	   upregulation	   in	  Notch3ICD	  and	  DLL4	  was	   also	  observed	   at	   the	  
level	  of	  protein	  expression	  in	  hypoxic	  mice	  lungs	  (Figure	  4.5B).	  Chronic	  Hypoxia	  exposure	  of	  mice	  
is	  characterized	  by	  minimal	  vascular	  remodeling,	  depicted	  mainly	  by	  medial	  hypertrophy	  and	  no	  or	  
negligible	  endothelial	  damage	  or	  neointima	  formation	  [148,	  151].	  Hence,	  the	  significant	  decrease	  
observed	   in	   MCT	   model	   for	   some	   Notch	   receptors	   (Notch4	   and	   Notch1)	   are	   not	   seen	   here.	  
Interestingly,	  Notch	  pathway	   is	  known	  to	   intersect	  with	  hypoxic	  signaling.	  Using	  oxygen-­‐induced	  
retinopathy	  mice	  model,	  Liu	  et.	  al.	  have	  shown	  that	  Notch3	  is	  induced	  in	  retinal	  vasculature	  upon	  
hypoxic	  stimulation.	  On	  induction,	  it	  cooperates	  with	  HIF-­‐1α	  to	  regulate	  angiopoietin-­‐2	  expression	  
contributing	  to	  neovascularization	  [161].	  	  Additionally,	  Notch3	  has	  been	  recently	  demonstrated	  to	  
be	  involved	  in	  pathogenesis	  of	  chronic	  hypoxia	  induced	  PH	  in	  mice	  [147].	  Our	  results	  exhibiting	  an	  
upregulation	  of	  Notch3	  expression	  and	  cleavage	  in	  the	  lungs	  of	  hypoxia	  exposed	  mice	  are	  in	  line	  
with	  these	  findings.	  	  
	   MCT	  injection	  in	  rats	  and	  Hypoxia	  exposure	  of	  mice	  are	  the	  commonly	  employed	  models	  of	  
PH,	   mimicking	   medial	   hypertrophy	   observed	   in	   the	   disease	   condition	   [148,	   151].Additional	  
pathological	   changes	   observed	   in	   human	   pulmonary	   arterial	   hypertension,	   namely;	   intimal	  
proliferation	  and	  plexiform	   lesions	  are	  absent	   in	   these	  models.	  Hence,	   they	  may	  not	  be	  able	   to	  
recapitulate	  all	  the	  changes	  occurring	  in	  the	  human	  disease.	  A	  relatively	  new	  rat	  model,	  involving	  
hypoxia	   exposure	   after	   Su5416	   administration	   has	   been	   developed	   [155],	   capable	   of	   emulating	  
formation	   of	   neointimal	   lesions.	   Expression	   analysis	   of	   Notch	   family	   in	   lung	   homogenates	   from	  
Hypoxia+Su5416	  rats	  presented	  a	  similar	  picture	  as	  observed	  in	  IPAH	  patients.	  At	  the	  mRNA	  level,	  
many	   Notch	   receptors	   (Notch1,	   Notch2,	   and	   Notch3)	   and	   ligands	   (Jagged1,	   Jagged2)	   were	  
increased	  while	   ligand	  DLL4	  was	   downregulated	   in	   the	  Hox+Su5416	   rats	   (Figure	   4.7A).	  Western	  
blots	   followed	   by	   densitometric	   quantification	   revealed	   an	   upregulation	   of	   only	  Notch3ICD	   and	  
Notch1ICD	   proteins	   in	   lungs	   of	   Hox+Su5416	   rats	   as	   compared	   to	   healthy	   rats	   (Figure	   4.7B-­‐C).	  
Unlike	   MCT	   and	   chronic	   hypoxia	   exposure,	   Hox+Su5416	   rats	   are	   reported	   to	   mirror	   the	  
hyperproliferative	  endothelial	  cell	  etiology	  i.e.	  plexiform	  lesions,	  a	  hallmark	  of	  severe	  PAH.	  Hence,	  
the	  heightened	  expression	  of	  Notch1	  only	  observed	   in	  Hox+Su5416	   rat	   lungs	  among	   the	  animal	  
models,	   in	  agreement	  with	   the	  human	  data,	  hint	   towards	   its	   role	   in	  plexiform	   lesions.	  Plexiform	  
lesions,	   consisting	   of	   hyperproliferative	   altered	   endothelial	   cells	   are	   generally	   observed	   at	  






	   	  
increased	  shear	  stress	  [162,	  163].	  Similarly,	  VEGFR2	  blockade	  by	  Su5416	  with	  hypoxia	  exposure	  is	  
shown	   to	  mirror	   these	   shear	   stress	   conditions,	   leading	   to	   formation	  of	   plexiform	   lesions	   in	   rats	  
[164].	  Interestingly,	  an	  in	  vitro	  study	  has	  demonstrated	  increased	  activation	  of	  Notch1	  in	  ES	  cells-­‐	  
derived	  VEGFR2+	  cells,	  under	  shear	  stress	  [165],	  providing	  impetus	  to	  our	  hypothesis.	  
5.3	  Localization	  of	  Notch1	  in	  IPAH	  lungs	  	  
	   Unlike	   Notch3,	   exclusively	   expressed	   in	   SMCs,	   Notch1	   exhibits	   a	   more	   widespread	  
expression.	   Several	   reports	   have	   indicated	   Notch1	   expression	   in	   endothelial	   cells	   regulating	  
apoptosis	   and	  proliferation	   [130,	   166].	  Additionally,	  Notch1ICD	  was	   also	   found	   to	   regulate	   SMC	  
growth,	   apoptosis,	   and	   migration	   through	   CBF-­‐1/RBP-­‐Jk-­‐	   dependent	   pathways	   [139,	   167].	  
Immunohistochemical	   analysis	   of	  Notch1	   in	   human	   lung	   tissues	   from	  donors	   and	   IPAH	   patients	  
revealed	   localization	   of	   Notch1	   in	   intimal	   layer	   of	   pulmonary	   arteries.	   In	   line	   with	   screening	  
results,	   a	   stronger	   expression	   of	   Notch1	  was	   observed	   in	   intima	   of	   IPAH	   lungs	   as	   compared	   to	  
donor	  lungs.	  	  
	   Although	  well	   characterized	   in	   systemic	   vasculature	   [127,	   158]	   and	   vascular	   injury	   [137,	  
138],	  Notch1	   is	  poorly	  addressed	   in	  pulmonary	  vasculature.	  The	  significant	   increase	  observed	   in	  
Notch1	  expression	  and	  cleavage	  in	  lungs	  and	  pulmonary	  arteries	  of	  IPAH	  patients	  as	  well	  as	  lungs	  
of	  Hox+Su5416	  rats	   in	  our	   initial	  screening	  experiments	  suggest	  that	  Notch1	  might	  contribute	  to	  
pathogenesis	   of	   PH.	   Based	   on	   these	   results,	   we	   carried	   out	   in	   vitro	   studies	   to	   analyze	   the	  
functional	  role	  of	  Notch1	  signaling	  in	  human	  pulmonary	  arterial	  endothelial	  cells.	  	  
5.4	  Influence	  of	  Notch1	  on	  proliferation	  of	  hPAECs	  
	   Interestingly,	   endothelial	   cells	  within	   plexiform	   lesions	   of	   patients	  with	   PPH	   expand	   in	   a	  
monoclonal	   fashion,	   i.e.,	   they	  arise	   from	  a	   single	   cell	   [168,	  169].	  As	  monoclonal	   cell	   growth	  has	  
been	   consistently	   demonstrated	   in	   cancer	   and	   in	   smooth	   muscle	   cells	   within	   atherosclerotic	  
plaques,	   it	  was	  proposed	   that	  endothelial	   cell	  proliferation	   in	  PPH	  displays	  mechanistic	   features	  
common	  to	  neoplastic	  cell	  growth	  [170].	  Consistent	  with	  a	  neoplastic	  hypothesis	  of	  severe	  PAH,	  
endothelial	   cells	   obtained	   from	   the	   pulmonary	   arteries	   of	   patients	   with	   IPAH	   have	   been	  
characterized	   to	  be	  hyperproliferative	   and	  apoptosis	   resistant	   [171].	  Notch1	   aberrant	   activation	  
has	  been	   indicated	   in	  a	  variety	  of	   cancers.	  Activated	  Notch1	   signaling	   is	   shown	   to	  contribute	   to	  
~50%	   of	   human	   T-­‐cell	   acute	   lymphoblastic	   leukemia	   (T-­‐ALL)	   cases	   through	   gain	   of	   function	  






	   	  
cancerous	  cells	  [173].	  Later,	  Notch	  signaling	  was	  further	  shown	  to	  be	  associated	  with	  various	  solid	  
tumors,	   including	   breast	   cancer,	   colorectal	   cancer,	   non–small	   cell	   lung	   carcinoma	   (NSCLC),	   and	  
melanoma	   [174].	   Similarities	   between	   cancerous	   cells	   and	   altered	   endothelial	   cells	   of	   plexiform	  
lesions	  and	  the	  established	  role	  of	  Notch1	  as	  an	  oncogene,	   led	  us	  to	  examine	   its	  contribution	   in	  
endothelial	  proliferation	  and	  apoptosis.	  Hence,	  in	  our	  studies,	  we	  examined	  the	  effect	  of	  Notch1	  
knock	  down	  and	  over	  activity	  on	  proliferation	  of	  endothelial	  cells	  in	  vitro.	  
	   In	  our	  studies,	  Notch1	  downregulation,	  attained	  by	  specific	  siRNA	  mediated	  knock	  down,	  
resulted	   in	  a	  ~40%	  decrease	   in	  proliferation	  of	  hPAECs,	  measured	  by	  BrdU	   incorporation	   (Figure	  
4.12A).	  On	  the	  other	  hand,	  Notch1ICD	  over	  expression	  gave	  rise	  to	  a	  significant	  ~75%	  increase	  in	  
proliferation	  of	  hPAECs	  (Figure	  4.15A).	  Some	  earlier	  reports	  have	  implicated	  Notch1	  in	  regulation	  
of	   endothelial	   proliferation,	   however,	   with	   conflicting	   conclusions.	   In	   human	   aortic	   endothelial	  
cells,	  Notch1ICD	  over	  expression	  was	  shown	  to	   inhibit	  proliferation	  of	   the	  cells	  via	  repression	  of	  
MAPK	  and	  PI3K/Akt	  pathway	  [175].	  Another	  study	  also	  revealed	  induction	  of	  endothelial	  cell	  cycle	  
arrest	   by	   Notch1	   and	   Notch4	   activation	   with	   the	   aid	   of	   p21	   repression	   [130].	   Contradictory	   to	  
these	   reports,	   Takeshita	   et.	   al.	   demonstrated	   that	   Notch1	   is	   essential	   for	   VEGF	   induced	  
proliferation,	   migration	   and	   survival	   of	   endothelial	   cells	   [166].	   Using	   transgenic	   mice	   (N1+/-­‐
/ecN1+/-­‐/N4-­‐/-­‐),	   authors	   showed	   that	   Notch1,	   but	   not	  Notch4	   is	   critical	   for	   VEGF	   induced	   post	  
ischemic	   angiogenic	   response.	   In	   accordance	   with	   this	   report,	   another	   study	   linked	   reduced	  
Notch1	   cleavage	   with	   decreased	   proliferating	   cell	   nuclear	   antigen	   (PCNA)	   levels	   in	   endothelial	  
cells,	  when	  cocultured	  with	  Jagged1	  deficient	  vSMCs	  [176].	  
	   Our	   study	   supports	   the	   positive	   role	   of	   Notch1	   signaling	   in	   proliferation	   of	   pulmonary	  
artery	  endothelial	  cells.	  Cell	  proliferation	   is	   tightly	   regulated	  by	  expression	  and	  activation	  of	  cell	  
cycle	  regulators,	  cyclins,	  cyclin	  dependent	  kinases	  (Cdks)	  and	  Cdk	  inhibitors	  (CdkIs).	  Cdk	  inhibitors	  
like	  p21	  and	  p27	  have	  negative	  effects	  on	  cell	  cycle	  machinery	  by	  binding	  to	  cyclin-­‐Cdk	  complexes	  
and	   inhibiting	  them	  [177].	  To	  explore	  the	  mechanism	  involved	   in	  Notch1	  mediated	  regulation	  of	  
cell	   proliferation,	   the	   expression	   of	   cell	   cycle	   proteins	   was	   examined.	   The	   cell	   cycle	   markers,	  
namely	  p21	  and	  cyclinB1	  were	  found	  to	  be	  modulated	  by	  Notch1	  knockdown	  and	  overexpression	  
in	   hPAECs.	   We	   observed	   a	   marked	   increase	   in	   protein	   levels	   of	   cell	   cycle	   inhibitor,	   p21	   and	  
significant	   decrease	   in	   mitogenic	   protein,	   cyclinB1	   with	   Notch1	   knockdown	   (Figure	   4.12B-­‐C).	  






	   	  
immunoblotting	  (Figure	  4.15B-­‐C).	  Though,	  cyclinB1	  expression	  did	  not	  show	  any	  significant	  change	  
with	  Notch1	  over	  expression.	  p21,	  a	  well-­‐known	  CdkI,	  has	  been	  described	  as	  a	  direct	  target	  of	  RBP-­‐
Jκ	   dependent	   Notch1	   signaling	   [109,	   130],	   where	   authors	   demonstrated	   repression	   of	   p21	  
promoter	   activity	   under	   Notch1	   activation	   in	   HUVECs.	   Our	   results	   indicate	   towards	   a	   role	   of	  
Notch1	  in	  hPAECs	  cell	  cycle	  regulation	  via	  direct	  effect	  on	  p21	  expression.	  	  
5.5	  Effect	  of	  Notch1	  on	  survival	  of	  hPAECs	  
	   Resistance	   to	   apoptosis	   is	   another	   important	   characteristic	   of	   altered	   endothelial	   cells	  
found	   in	   the	   plexiform	   lesions	   of	   patients	   with	   PAH	   [171].	   DNA	   isolated	   from	   microdissected	  
endothelial	  cells	  within	  plexiform	  lesions	  of	  patients	  with	  PPH	  exhibit	  mutations	  within	  Bax	  gene,	  a	  
proapoptotic	   member	   of	   Bcl-­‐2	   family	   of	   proteins.	   Additionally,	   these	   endothelial	   cells	   have	  
reduced	   expression	   of	   Bax	   protein	   [170].	   Another	   study	   demonstrated	   decreased	   expression	   of	  
antiapoptotic	   protein,	   Bcl-­‐2	   in	   endothelial	   cells	   isolated	   from	   plexiform	   lesions	   [171].	   These	  
findings	   prompted	   us	   to	   analyze	   the	   effect	   of	   Notch1	   knock	   down	   and	   overexpression	   on	  
apoptosis	  of	  hPAECs.	  siRNA	  mediated	  knockdown	  of	  Notch1	  displayed	  a	  small	  but	  significant	  (20%)	  
increase	   in	   number	   of	   TUNEL–positive	   apoptotic	   vascular	   cells	   compared	   to	   scrambled	   siRNA	  
transfected	  cells	   (Figure	  4.13A-­‐B).	  At	   the	  same	  time,	  Bax/Bcl-­‐2	   ratio	  was	  utilized	   to	   substantiate	  
the	  findings	  from	  TUNEL	  assay.	  It	   is	  known	  that	  Bax	  and	  Bcl-­‐2	  regulate	  apoptosis	  downstream	  of	  
p53	  [178].	  Bcl-­‐2	  blocks	  cell	  death	  following	  various	  stimuli,	  demonstrating	  an	  anti-­‐apoptotic	  effect;	  
however,	   overexpression	   of	   Bax	   has	   a	   pro-­‐apoptotic	   effect	   and	   Bax	   also	   counters	   the	   anti-­‐
apoptotic	  activity	  of	  Bcl-­‐2	  [179,	  180].	  Many	  reports	  proposed	  and	  further,	  demonstrated	  that	  the	  
ratio	   of	   Bcl-­‐2	   to	   Bax	   might	   govern	   the	   sensitivity	   of	   cells	   to	   apoptotic	   stimuli	   [181,	   182].	  
Interestingly,	   we	   were	   able	   to	   observe	   a	   significant	   decrease	   in	   Bcl-­‐2	   protein	   levels	   and	  
concomitant	   increase	   in	   Bax	   protein	   expression	   on	   treatment	   of	   hPAECs	  with	   Notch1	   siRNA	   as	  
compared	   to	  scrambled,	   thus,	   lowering	  Bcl-­‐2/Bax	   ratio,	   indicative	  of	   increased	  apoptosis	   (Figure	  
4.13C-­‐D).	  In	  agreement,	  Notch1ICD	  constitutive	  expression	  led	  to	  an	  increased	  protein	  expression	  
of	  Bcl-­‐2,	  hence,	  an	  increased	  Bcl-­‐2/Bax	  ratio	  (Figure	  4.16A-­‐B).	  	  
	   Previous	  studies	  have	  defined	  an	  anti-­‐apoptotic	  role	  of	  Notch1	  signaling	  in	  both	  animal	  and	  
in	  vitro	  cell	  models	  [183],	  in	  the	  field	  of	  development	  and	  cancer.	  In	  endothelial	  cells,	  Notch4	  has	  
been	  shown	  to	  inhibit	  apoptosis,	  in	  response	  to	  inflammatory	  mediator,	  lipopolysaccharides	  (LPS)	  
via	   RBP-­‐Jκ-­‐dependent	   and	   -­‐independent	   pathways	   [129].	   However,	   not	   much	   is	   known	   about	  






	   	  
Notch1	  in	  promoting	  survival	  of	  hPAECs	  by	  regulating	  expression	  of	  Bcl-­‐2	  and	  to	  some	  extent,	  Bax.	  	  
5.6	  Effect	  of	  Notch1	  on	  proliferation	  of	  hPASMCs	  
	   It	  has	  been	  previously	  demonstrated	  that	  activated	  Notch1	   in	  SMCs	  mediated	  neointimal	  
formation	  after	  carotid	  artery	  ligation	  by	  regulating	  proliferation,	  apoptosis	  and	  migration	  of	  these	  
cells	   [139].	   This	   led	   us	   to	   investigate	   the	   involvement	   of	  Notch1	   in	   proliferation	   of	   hPASMCs	   in	  
vitro.	   However,	   siRNA	  mediated	   Notch1	   knock	   out	   did	   not	   show	   any	   effect	   on	   proliferation	   of	  
hPASMCs	  (Figure	  4.17D)	  and	  neither	  Notch1	  constitutive	  activation	  via	  Notch1ICD	  overexpression	  
effected	   proliferation	   as	  measured	   by	   BrdU	   incorporation	   (Figure	   4.18C).	   One	  major	   reason	   for	  
this	   observation	   could	   be	   that	   other	   Notch	   homologs	   are	   more	   important	   in	   regulating	   the	  
proliferative	  potential	  of	  PASMCs.	  Indeed,	  Notch3	  has	  been	  described	  to	  be	  essential	  for	  aberrant	  
proliferation	  of	  PASMCs	  in	  IPAH	  patients	  [147].	  
	   It	   can	   be	   inferred	   from	   these	   results	   that	   despite	   expression	   of	   Notch1	   in	   PASMCs,	   its	  
upregulation	  seen	  in	  IPAH	  patients	  and	  Hox+Su5416	  rats	  can	  be	  attributed	  to	  functional	  activity	  in	  
endothelial	  cells.	  These	  findings	  provide	  substantial	  evidence	  to	  our	  hypothesis	  of	  involvement	  of	  
Notch1	  in	  formation	  of	  plexiform	  lesions	  by	  contributing	  to	  endothelial	  proliferation	  and	  survival.	  	  
5.7	  Pharmacological	  inhibition	  of	  Notch	  signaling	  inhibits	  hPASMCs	  and	  hPAECs	  proliferation	  	  
	   Dysregulated	  Notch	   signaling	  has	   been	   indicated	   in	   numerous	  human	  diseases,	   including	  
broad	  range	  of	  cancers	  [141].	  This	  has	  led	  to	  rapid	  development	  of	  γ	  secretase	  inhibitors	  (GSIs)	  as	  
potent	   therapeutic	   option.	   Inhibition	   of	   Notch	   signaling	   achieved	   by	   GSIs	   has	   been	   extensively	  
used	  in	  various	  studies	  utilizing	  cell	  lines	  and	  animal	  models	  for	  different	  cancers	  [146,	  184,	  185]	  
establishing	   potential	   utility	   of	   GSI	   based	   treatments.	   Furthermore,	  GSIs	   are	   being	   evaluated	   in	  
clinical	  trials	  for	  breast	  cancer	  [143].	  Though	  it	  should	  be	  noted	  that	  GSI	  based	  therapy	  could	  also	  
be	  potentially	  relevant	  for	  developmental,	  vascular	  and	  cardiac	  conditions	  associated	  with	  Notch	  
pathway	  malfunction,	  including	  pulmonary	  hypertension.	  	  
In	  severe	  PAH,	  two	  of	  the	  major	  histological	  findings	  are	  medial	  wall	  thickening	  due	  to	  SMC	  
proliferation	   and	   plexiform	   lesions	   consisting	   of	   hyperproliferative	   endothelial	   cells	   [7,	   8,	   16].	  
Several	  reports	  have	  shown	  that	  targeting	  the	  medial	  wall	  thickening	  can	  be	  beneficial	  for	  PAH	  and	  
can	   even,	   reverse	   the	   remodeling	   observed	   in	   PAH	   patients	   and	   rodent	   models	   [33,	   48,	   82].	  






	   	  
[186,	  187];	  however,	   targeting	   strategies	   couldn't	  be	   formulated	  due	   to	   inability	  of	  any	  classical	  
animal	   model	   to	   depict	   this	   patho-­‐histological	   feature.	   Development	   of	   Hox+Su5416	   model,	  
characterized	  by	  medial	  remodeling	  along	  with	  plexiform	  lesions	  [155],	  has	  led	  the	  investigators	  to	  
develop	  strategies	  focusing	  on	  these	  lesions	  [155,	  156].	  	  
	   Based	   on	   our	   results,	  we	   demonstrated	   that	   increased	  Notch1	   expression	   and	   activity	   is	  
associated	  with	  endothelial	   proliferation	  occurring	   in	  plexiform	   lesions.	   In	  order	   to	  examine	   the	  
relevance	  of	  GSIs	  as	  a	  therapy	  in	  experimental	  PH,	  we	  used	  DBZ	  (γ	  secretase	  inhibitor,	  GSI)	  for	  our	  
in	  vitro	  studies.	  Hence,	  the	  effect	  of	  Notch	  signaling	  inhibitor,	  DBZ	  was	  studied	  on	  proliferation	  of	  
hPAECs.	  DBZ	  was	   able	   to	   significantly	   reduce	   growth	   factor	   induced	  proliferation	   of	   endothelial	  
cells	  (Figure	  4.20A).	  At	  the	  similar	  concentrations,	   it	   further	  effectively	  reduced	  VEGF	  (important	  
growth	   factor	   for	  ECs)	   induced	  proliferation	   (Figure	  4.20B).	   In	   fact,	   crosstalk	  between	  VEGF	  and	  
Notch	   signaling	  has	  already	  been	  established.	  VEGF	  was	   shown	   to	   increase	  expression	  of	  Notch	  
receptors	  and	  ligands	  in	  endothelial	  cells	  [131].	  Additionally,	  VEGF	  induced	  postnatal	  angiogenesis	  
involving	  endothelial	  proliferation	  and	  migration	  is	  mediated	  via	  γ	  secretase	  and	  Notch1	  activation	  
[166].	  Data	  from	  recent	  work	  dissecting	  Notch3	  signaling	  in	  PAH,	  revealed	  that	  the	  GSI,	  DAPT	  was	  
able	   to	   reduce	   the	   proliferation	   of	   PASMCs	   obtained	   from	  patients	  with	   IPAH	   [147].	  On	   similar	  
line,	  we	  investigated	  the	  effect	  of	  DBZ	  on	  proliferation	  of	  hPASMCs.	  Interestingly,	  serum	  induced	  
proliferation	  of	  hPASMCs	  was	  effectively	  reduced	  by	  DBZ	  (Figure	  4.21A).	  Moreover,	  DBZ	  reduced	  
PDGF	   induced	  proliferation	  of	  hPASMCs	   (Figure	  4.21B).	  PDGF	   is	  a	  potent	  mitogen	   for	  SMCs	   [45]	  
and	  known	  to	  be	  an	   important	  player	   in	  pathogenesis	  of	  PAH	   [46,	  47].	  Effect	  of	  Notch	  signaling	  
inhibitor	  on	  PDGF-­‐BB	   induced	  proliferation	  could	  be	  either	  due	   to	  direct	  effect	  of	  Notch	  on	  cell	  
proliferation	  markers	  or	  due	  to	  cross	  talk	  with	  PDGF	  signaling.	  Indeed,	  Notch3	  is	  shown	  to	  regulate	  
PDGF	  receptor	  β	  expression	  in	  vSMCs	  [135].	  	  
As	   observed	   from	  our	   results,	  DBZ	  was	   convincingly	   able	   to	   reduce	  proliferation	  of	   both	  
hPAECs	  and	  hPASMCs;	  hence,	  using	  GSI	  could	  provide	  a	  therapeutic	  option	  in	  experimental	  PH.	  
5.8	  Conclusion	  
In	  our	  study,	  we	  demonstrated	  an	  upregulation	  of	  Notch1	  expression	  and	  cleavage	  in	  lungs	  
and	  pulmonary	  arteries	  from	  IPAH	  patients.	  Similar	  upregulation	  was	  also	  observed	  in	  lungs	  from	  
Hypoxia+Su5416	   experimental	  model	   of	   PH.	   These	   screening	   results	  were	   further	   supported	   by	  






	   	  
from	  IPAH	  patients	  in	  comparison	  to	  donors.	  	  
In	  vitro	  loss	  of	  function	  studies	  using	  Notch1	  siRNA	  showed	  a	  reduction	  in	  proliferation	  of	  
hPAECs,	   accompanied	   by	   increased	   apoptosis	   of	   the	   cells.	   On	   the	   other	   hand,	   Notch1ICD	  
constitutive	  activation	  led	  to	  significant	  increase	  in	  proliferation	  and	  promoted	  survival	  of	  hPAECs.	  
Although	  this	  study	  did	  not	  identify	  the	  complete	  signaling	  pathway	  downstream	  of	  the	  Notch1ICD	  
translocation,	  leading	  to	  proliferation	  and	  survival	  of	  human	  pulmonary	  arterial	  endothelial	  cells,	  
however,	   we	   identified	   two	   major	   proteins,	   p21	   and	   Bcl-­‐2,	   modulated	   by	   Notch1	   (Figure	   5.1).	  
Additionally,	  Notch1	  knockdown	  or	  constitutive	  activation	  did	  not	  have	  any	  effect	  on	  proliferation	  
of	  hPASMCs,	  supporting	  endothelial	  specific	  effects	  of	  Notch1.	  Last	  but	  not	  the	  least,	  inhibition	  of	  
Notch	   signaling	   in	   vitro	   by	   GSI,	   DBZ,	   effectively	   attenuated	   proliferation	   in	   both,	   hPAECs	   and	  
hPASMCs,	  providing	  us	  with	  a	  platform	  for	  evaluating	  GSIs	  as	  a	  therapeutic	  option	  in	  experimental	  
PH	  in	  future.	  
	  
Figure5.1	  Schematic	  representation	  of	  proposed	  role	  of	  Notch1	  in	  endothelial	  proliferation	  and	  survival	  
in	  PH.	  	  
To	   the	   best	   of	   our	   knowledge,	   this	   is	   the	   first	   study	   demonstrating	   a	   role	   of	   Notch1	   in	  
vascular	   remodeling;	   essentially	   in	   endothelial	   proliferation	   and	   survival.	   Somatic	   mutations	   in	  
BMPR2	  rand	  BAX	  genes	  have	  been	  demonstrated	  in	  plexiform	  lesions	  in	  patients	  with	  IPAH	  [170],	  






	   	  
are	   observed	   only	   in	   40-­‐50%	   of	   familial	   PAH	   and	   not	   all	   plexiform	   lesions	   harbour	   somatic	  
mutations.	  Hence,	  other	  molecular	   factors	   could	  be	   involved	   in	  acquiring	  hyperproliferative	  and	  
antiapoptotic	  phenotype	  of	  endothelial	  cells	  in	  patients	  with	  severe	  PH.	  Based	  on	  our	  studies,	  it	  is	  
compelling	   to	   speculate	   that	   Notch1	   could	   qualify	   as	   one	   such	  molecular	  mediator	   and	   hence,	  
modulation	  of	  Notch1	  signaling	  in	  the	  endothelium	  may	  be	  beneficial	  for	  patients	  with	  pulmonary	  
hypertension.	  
5.9	  Future	  Outlook	  
	   Taken	   together,	   our	   data	   puts	   forward	   a	   role	   of	   endothelial	  Notch1	   signaling	   in	   vascular	  
remodeling,	   specifically	   aberrant	   endothelial	   proliferation	   associated	   with	   PAH.	   There	   are	   still	  
certain	   areas	   that	   need	   future	   investigation.	   Further	   studies	   regarding	   the	   underlying	   cause	   of	  
Notch1	  upregulation	  in	  pulmonary	  artery	  endothelial	  cells	  are	  needed.	  It	  would	  be	  interesting	  to	  
know	  whether	  the	  increase	  observed	  is	  a	  direct	  outcome	  of	  shear	  stress.	   It	  has	  not	  been	  proven	  
though	  speculated	  that	  shear	  stress	  may	  lead	  to	  conformational	  changes	  in	  Notch	  receptors	  that	  
increase	   their	   infinity	   towards	   proteases.	   Additionally,	   a	   possiblility	   of	   increased	   expression	   of	  
Notch	   ligands	   leading	  to	  elevated	  notch	  cleavage	  and	  signaling	  cannot	  be	  neglected.	   It	   is	   further	  
important	  to	  elucidate	  whether	  Notch1	  directly	  has	  an	  effect	  on	  the	  expression	  of	  p21	  and	  Bcl-­‐2	  or	  
the	   effect	   is	  mediated	   via	  Hes	   and	  Hey	   family	   of	   genes	   (known	   target	   genes	   of	  Notch	   signaling	  
pathway).	  	  
Most	   importantly,	   our	   findings	   need	   to	   be	   strengthened	   in	   vivo,	   in	   order	   to	   confirm	   a	  
possibility	  of	  therapeutic	  targeting	  of	  Notch	  signaling	  in	  patients	  with	  PAH.	  To	  test	  our	  concept	  in	  
vivo,	  two	  approaches	  could	  be	  employed.	  To	  precisely	  evaluate	  the	  role	  of	  Notch1	  in	  experimental	  
model	  of	  PH,	  Notch1	  can	  be	  knocked	  down	  in	  Hox+Su5416	  rats	  using	  adenoviral	  vectors	  carrying	  
Notch1	  shRNA.	  The	  effects	  of	  knockdown	  on	  pulmonary	  vascular	  remodeling	  can	  be	  evaluated	  by	  
measuring	   various	   hemodynamic	   parameters.	   Another	   approach	   could	   be	   treatment	   of	  
Hox+Su5416	   rats	   with	   GSI,	   to	   analyze	   the	   effect	   of	   Notch	   inhibition	   on	   pulmonary	   vascular	  
remodeling.	  Though	  GSIs	  inhibit	  the	  complete	  Notch	  signaling,	  they	  are	  the	  only	  available	  class	  of	  
therapeutic	   inhibitors	   of	   Notch	   receptors.	   Generally,	   inhibition	   of	   complete	   Notch	   signaling	   via	  
GSIs	  has	  been	  reported	  to	  result	  in	  off	  target	  gastrointestinal	  side	  effects.	  However,	  intratracheal	  
nebulisation	  as	  a	  mode	  of	  delivery	  might	  provide	  a	  chance	  to	  target	  notch	  signaling	  in	  PH	  within	  
acceptable	  levels	  of	  toxicity.	  In	  pulmonary	  hypertension,	  Notch3	  has	  been	  previously	  reported	  to	  






	   	  
mediating	  endothelial	  proliferation	  and	  apoptosis.	  Hence,	  the	  potential	  use	  of	  blocking	  the	  Notch	  
signaling	   by	   GSI	   treatment	   to	   target	   two	   important	   physio-­‐pathological	   features	   of	   vascular	  






















	   	  
6.	  SUMMARY	  
Pulmonary	   Hypertension	   is	   a	   disease	   condition	   characterized	   by	   elevated	   pulmonary	  
vascular	   resistance	  which	   is	   an	  outcome	  of	  excessive	  vascular	   remodeling	   in	  pulmonary	  arteries	  
involving	  deregulated	  proliferation	  of	  cells	  in	  all	  three	  layers	  of	  the	  vessels;	  intima,	  media	  as	  well	  
as	  adventitia.	  New	  therapeutic	  options	  targeting	  vascular	  remodeling	  process	  are	  being	  developed	  
and	   some	   are	   curently	   under	   clinical	   trials.	   Current	   evidence	   strongly	   supports	   involvement	   of	  
Notch	  signaling	  in	  vascular	  homeostasis	  and	  injury.	  Recently,	  the	  impact	  of	  Notch3	  and	  its	  target	  
gene,	  Hes5	  on	   increased	  proliferation	  of	  PASMCs	   in	  PAH	  patients	  has	  been	  described.	  However,	  
the	  role	  of	  other	  Notch	  receptors	  and	  ligands	  has	  not	  been	  studied.	  This	  led	  us	  to	  investigate	  the	  
expression	  and	  potential	  contribution	  of	  Notch	  signaling	  pathway	  in	  pathogenesis	  of	  PH.	  	  
	   Interestingly,	   we	   observed	   an	   increased	   expression	   of	   Notch1	   in	   lungs	   and	   pulmonary	  
arteries	  from	  patients	  with	  IPAH.	  In	  line	  with	  this	  finding,	  increased	  Notch1	  immunoreactivity	  was	  
detected	   in	   intima	   of	   pulmonary	   arteries	   in	   lung	   tissues	   from	   IPAH	   patients	   as	   compared	   to	  
donors.	   Furthermore,	   similar	   upregulation	   was	   observed	   in	   lungs	   from	   Hypoxia+Su5416	   rats	   as	  
compared	   to	   healthy	   rats.	   We	   demonstrate	   for	   the	   first	   time	   an	   upregulation	   of	   Notch1	   in	  
pulmonary	   hypertension	   patients.	   Additionally,	   absence	   of	   this	   increase	   in	   other	   two	   well	  
established	  experimental	  models	  depicting	  only	  medial	  hypertrophy	  phenotype,	  monocrotaline	  rat	  
model	   and	   chronic	   hypoxia	   mice	   model,	   led	   us	   to	   hypothesize	   that	   Notch1	   may	   contribute	  
substantially	  to	  pathogenesis	  of	  plexiform	  lesions.	  
	   In	  vasculature,	  Notch1	  expression	  is	  observed	  in	  both	  smooth	  muscle	  cells	  and	  endothelial	  
cells.	  We	  demonstrated	  a	  decrease	  in	  proliferation	  and	  increase	  in	  apoptosis	  of	  human	  pulmonary	  
artery	  endothelial	  cells	  (hPAECs)	  with	  siRNA	  mediated	  Notch1	  inhibition.	  In	  contrast,	  an	  increase	  in	  
proliferation	  and	  survival	  of	  hPAECs	  was	  observed	  on	  constitutive	  Notch1	  activation.	  These	  effects	  
were	  associated	  with	  modulation	  of	  expression	  of	  cell	  cycle	  inhibitor,	  p21	  and	  apoptosis	  inhibitor,	  
Bcl-­‐2.	   Interestingly,	   Notch1	   inhibition	   or	   activation	   did	   not	   have	   any	   effect	   on	   proliferation	   of	  
human	   pulmonary	   artery	   smooth	   muscle	   cells	   (hPASMCs),	   indicating,	   endothelial	   cell	   specific	  
effect	  of	  Notch1	  signaling	  in	  vasculature.	  	  	  
	   The	  anti-­‐proliferative	  and	  pro-­‐apoptotic	  effect	  of	  Notch1	  signaling	   inhibition,	  observed	   in	  






	   	  
hypertension.	   Presently,	   γ	   secretase	   inhibitors	   (GSIs)	   are	   the	   only	   clinically	   available	   inhibitors	  
targeting	   this	   pathway.	   GSIs	   inhibit	   the	   γ	   secretase	   enzyme,	   responsible	   for	   cleavage	   of	   Notch	  
receptors.	  In	  order	  to	  examine	  the	  relevance	  of	  GSIs	  as	  a	  therapy	  in	  experimental	  PH,	  we	  used	  DBZ	  
(a	  commercially	  available	  GSI)	   for	  our	   in	  vitro	  studies.	   Inhibition	  of	  Notch	  signaling	  by	  employing	  
DBZ	   effectively	   reduced	   expression	   of	   Hes-­‐1	   (target	   gene	   of	   Notch	   signaling	   pathway)	   and	  
attenuated	  proliferation	  of	  both,	  hPAECs	  and	  hPASMCs.	  	  
	   Taken	   together,	   this	   study	   puts	   forward	   a	   role	   of	   Notch1	   signaling	   in	   regulation	   of	  
proliferation	  and	  apoptosis	  of	  endothelial	  cells	  which	  might	  contribute	  to	  formation	  of	  plexiform	  
lesions	   observed	   in	   pulmonary	   hypertension.	   Nonetheless,	   our	   study	   needs	   to	   be	   further	  





















	   	  
7.	  ZUSAMMENFASSUNG	  
Pulmonale	   Hypertonie	   (PH)	   ist	   eine	   Erkrankung	   der	   Lungengefäße,	   die	   durch	   einen	  
erhöhten	   pulmonalen	   Gefäßwiderstand	   charakterisiert	   ist.	   Strukturelle	   Umbauprozesse	   in	   den	  
pulmonalen	  Gefäßen	  finden	  in	  allen	  drei	  Gefäßschichten	  –Intima,	  Media	  und	  Adventitia-­‐	  statt	   ist	  
und	   sind	   durch	   dysregulierte	   Proliferation/Apoptose	   von	   verschiedenen	   Gefäß-­‐Zellen	  
ausgezeichnet.	  Neue	  therapeutische	  Optionen,	  die	  den	  Prozess	  des	  Gefäßumbaus	  aufhalten	  oder	  
umzukehren,	   befinden	   sich	   momentan	   in	   der	   Entwicklung	   oder	   in	   klinischen	   Studien.	   Der	  
derzeitige	   Stand	   der	   wissenschaftlichen	   Erkenntnis	   legt	   eine	   Involvierung	   von	   Notch-­‐
Signalübertragungswegen	  in	  die	  vaskulare	  Homöostase	  nahe.	  So	  konnte	  unlängst	  der	  Einfluss	  von	  
Notch3	   und	   dessen	   Zielgen	   Hes5	   auf	   die	   erhöhte	   Proliferation	   von	   pulmonalarteriellen	   glatten	  
Muskelzellen	   (PASMCs)	   in	   Patienten	   mit	   pulmonalarterieller	   Hypertonie	   (PAH)	   nachgewiesen	  
werden.	   Der	   jeweilige	   Einfluss	   anderer	   Notch-­‐Rezeptoren	   sowie	   deren	   Liganden	   wurde	   jedoch	  
noch	   nicht	   beschrieben.	   In	   Folge	   dessen	   untersuchten	  wir	   die	   Expression	   und	   den	   potenziellen	  
Beitrag	  von	  Notch-­‐Signalwegen	  in	  der	  Pathogenese	  von	  PH.	  
Interessanterweise	  konnten	  wir	  eine	  erhöhte	  Expression	  von	  Notch1,	  sowohl	  in	  Lungen,	  als	  
auch	   in	   Pulmonalarterien	   von	   IPAH-­‐Patienten	   beobachten.	   In	   Übereinstimmung	   mit	   dieser	  
Erkenntnis	  wurde	   eine	   erhöhte	   Notch1-­‐Immunreaktivität	   in	   der	   Intima	   von	   Pulmonalarterien	   in	  
Lungengewebe	  von	  IPAH-­‐Patienten	  verglichen	  mit	  Donoren	  detektiert.	  Des	  Weiteren	  wurde	  eine	  
ähnlich	  erhöhte	  Expression	  in	  Lungen	  von	  Ratten	  mit	  PH	  (Hypoxia+Su5416	  Modell)	  verglichen	  mit	  
gesunden	  Ratten	  beobachtet.	  Damit	  demonstrieren	  wir	  zum	  ersten	  Mal	  eine	  Hochregulation	  von	  
Notch1	   in	   Patienten	   mit	   pulmonaler	   Hypertonie.	   Zusätzlich	   lässt	   die	   Abwesenheit	   dieser	  
Hochregulation	   in	   zwei	   weiteren	   gut	   etablierten	   experimentellen	   Modellen	   mit	   medialer	  
Hypertrophie,	  dem	  Monocrotalin-­‐injizierten	  Ratten-­‐Model	  und	  dem	  Maus-­‐Modell	  mit	  chronischer	  
Hypoxie,	  die	  Hypothese	  zu,	  dass	  Notch1	  substanziell	  zu	  der	  Pathogenese	  von	  plexiformen	  Läsionen	  
beiträgt.	  	  
Im	  Gefäßsystem	  selbst	  wird	  Notch1-­‐Expression	  sowohl	   in	  der	  glatten	  Muskulatur	  als	  auch	  
in	   den	   Endothelzellen	   beobachtet.	  Wir	   konnten	   eine	   erniedrigte	   Proliferation	   und	   eine	   erhöhte	  
Apoptoserate	   in	   humanen	   pulmonal-­‐arteriellen	   Endothelzellen	   (hPAECs)	   nach	   erfolgter	   siRNA-­‐
vermittelter	   Inhibition	   von	   Notch1	   demonstrieren.	   Im	   Gegensatz	   dazu	   konnte	   eine	   erhöhte	  
Proliferation	   und	  Überlebensrate	   von	   hPAECs	   nach	   konstitutiver	  Notch1-­‐Aktivierung	   beobachtet	  
werden.	   Diese	   Effekte	   waren	   mit	   modulierter	   Expression	   des	   Zellzyklus-­‐Inhibitors	   p21	   und	   des	  






	   	  
Aktivierung	   einen	   Effekt	   auf	   die	   Proliferation	   von	   humanen	   pulmonal-­‐arteriellen	   glatten	  
Muskelzellen	   (hPASMCs),	   was	   einen	   Endothel-­‐spezifischen	   Effekt	   von	   Notch1-­‐Signalwegen	   im	  
Gefäßsystem	  indiziert.	  	  
Die	   beobachteten	   anti-­‐proliferativen	   und	   pro-­‐apoptotischen	   Effekte	   nach	   Inhibition	   von	  
Notch1-­‐Signalwegen	  kennzeichnen	  die	  Notch1-­‐Inhibition	  als	  therapeutische	  Option	  für	  pulmonale	  
Hypertonie.	   Derzeitig	   sind	   γ-­‐Sekretase-­‐Inhibitoren	   (GSIs)	   die	   einzigen	   klinisch	   verfügbaren	  
Inhibitoren	  für	  diesen	  Signalweg.	  GSIs	  inhibieren	  das	  Enzym	  y-­‐Sekretase,	  das	  verantwortlich	  für	  die	  
Spaltung	   von	   Notch-­‐Rezeptoren	   ist.	   Um	   die	   Relevanz	   von	   GSIs	   als	   Therapie	   für	   experimentelle	  
pulmonale	   Hypertonie	   zu	   untersuchen,	   haben	   wir	   den	   kommerziell	   verfügbaren	   GSI	   „DBZ“	   in	  
unseren	  in	  vitro	  Studien	  appliziert.	  Inhibition	  des	  Notch-­‐Signalwegs	  durch	  die	  Anwendung	  von	  DBZ	  
reduzierte	  effektiv	  die	  Expression	  von	  Hes1,	  das	  Zielgen	  des	  Notch-­‐Signalwegs,	  und	  schwächte	  die	  
Proliferation	  von	  sowohl	  hPAECs	  als	  auch	  von	  hPASMCs	  ab.	  	  
Zusammengefasst	  zeigt	  diese	  Studie	  die	  Rolle	  von	  Notch1-­‐Signalwegen	  in	  Proliferation	  und	  
Apoptose	   von	   Endothelzellen,	   die	   zur	   Entstehung	   von	   plexiformen	   Läsionen,	   wie	   sie	   bei	   der	  
pulmonalen	   Hypertonie	   beobachtet	   werden,	   beitragen	   können.	   Gleichwohl	  muss	   unsere	   Studie	  
weiter	   durch	   in	   vivo	   Studien	   mit	   Applikation	   von	   GSI	   in	   experimentellen	   Modellen	   der	   PH	  	  















	   	  
8.	  APPENDIX	  
Table	  1	  App:	  List	  of	  primers	  used	  for	  real	  time	  PCRs	  
Gene	   Species	   Primers	   Annealing	  
(˙C)	  
Product	  Size	  
Notch1	   Rat	   F:GAGATGCTCCCAGCCAAGT	  
R:	  CCATGGTCCACAACATAGCA	  
60	   174	  
Notch2	   Rat	   F:	  GTGAAGATGCCCGCTCTG	  
R:	  CTGTGCCGTTGTGGTAGGTA	  
60	   151	  
Notch3	   Rat	   F:	  CCTTGCCGGAACGGTGCCAA	  
R:	  CCGTGTAGCCTGGCGCACAA	  
60	   184	  
Notch4	   Rat	   F:	  CTGGATTCGAGGGCAAGTTA	  
R:	  GGGTACAGGTTCCATGGTTG	  
60	   194	  
DLL1	   Rat	   F:	  GGAGAGAGGGGAGAAGATG	  
R:	  CCGGTTTGTCACAATATCCA	  
60	   108	  
DLL3	   Rat	   F:	  TGAAACCTGGAGAGAGCAGC	  
R:	  GAGAAGTGCAACTCCCATGC	  
60	   147	  
DLL4	   Rat	   F:	  GAATGTATCCCCCACAATGG	  
R:	  CCACTGTTGGAGCAAGTTGA	  
60	   158	  
Jagged1	   Rat,	  Mouse	   F:	  CAGGGTCTACGCCTGTCATC	  
R:	  AGCAAAGTGTAGGACCTCGG	  
60	   118	  
Jagged2	   Rat,	  Mouse	   F:	  GGATGTAATTTGCTCCACGG	  
R:	  CCCAGTTGGTCTCACAGTCA	  
60	   157	  
PBGD	   Rat	   F:	  ATGTCCGGTAACGGCGGC	  
R:	  CAAGGTTTTCAGCATCGCTAC	  
58	   135	  
Notch1	   Mouse	   F:	  GAGATGCTCCCAGCCAAGT	  
R:	  TCTTACACGGTGTGCTGAGG	  
60	   143	  
Notch2	   Mouse	   F:	  TTACCTACCACAACGGCACA	  
R:	  TCCTCTCCTGTGAATCCTGG	  
60	   175	  
Notch3	   Mouse	   F:	  GGGTCCGTCGTGAGCTGGGT	  	  	  
R:	  GCGGCTCTCCTCGCACATCC	  	  	  	  	  	  
60	   198	  
Notch4	   Mouse	   F:	  TGCCAGGATAATGTGAACC	  
R:	  AGGTACAGGTTCCGTGGTTG	  
60	   175	  
DLL1	   Mouse	   F:AGGTTGCTCTGTGTTCTGCC	  
R:	  CTCCCCTGGTTTGTCACAGT	  






	   	  
DLL3	   Mouse	   F:	  CCAGTAGCTGCCTGAACTCC	  
R:	  CACATCGAAGCCCGTAGAAT	  
60	   168	  
DLL4	   Mouse	   F:	  GTGCAATGAATGTATCCC	  
R:	  TGCAGGTATAACCCTTTGGC	  
60	   185	  
PBGD	   Mouse	   F:	  CTTCTGCAGACACCAGGGGA	  
R:	  GCCGTTTTCTTCCGCGGTT	  
58	   104	  
Notch1	   Human	   F:	  GTGAGACCTGCCTGAATGG	  
R:	  GTTGGGGTCCTGGCATC	  
60	   101	  
Notch2	   Human	   F:	  ATGACTGCCCTAACCACAGG	  
R:	  TTCATCCACATCCTCTGTGC	  
60	   119	  
Notch3	   Human	   F:	  GTGTGCAAATGGAGGTCGTT	  
R:	  CCACTGAACTCTGGCAGACA	  
60	   149	  
Notch4	   Human	   F:	  CACGTGAACCCATGTGAGTC	  
R:	  GCATCGAGTTCCTTTGAGC	  
60	   126	  
DLL1	   Human	   F:	  AGAGGGCTGCTCCGTTTT	  
R:	  CAGATCGGCTCTGTGCAGTA	  
60	   123	  
DLL3	   Human	   F:	  GCTCGAGGACGAATGTGAG	  
R:	  AGTCCAGCCCTCTAGGCATC	  
60	   106	  
DLL4	   Human	   F:	  GCACTCCCTGGCAATGTACT	  
R:	  CGACAGGTGCAGGTGTAGC	  
60	   145	  
Jagged1	   Human	   F:	  AACACCTTCAACCTCAAGGC	  
R:	  TCATTACTGGAATCCCACGC	  
60	   119	  
Jagged2	   Human	   F:	  AGGGTGTAATTTGCTCCACG	  
R:	  GGGTAGGGGACACACTCAT	  
60	   100	  
Hes1	   Human	   F:	  GCAGATGACGGCTGCGCTGA	  
R:	  GGCTGCCCGGGGTAGGTCAT	  
60	   195	  
PBGD	   Human	   F:	  CAGGAGTCAGACTGTAGG	  
R:	  ACTCTCATCTTTGGGCTGTTTTC	  
58	   179	  
	  
Table	  2	  App:	  List	  of	  primary	  antibodies	  	  





Notch1	   Rabbit	   1:200	   	   Santa	  Cruz	  






	   	  
actin	  
Notch2	   Rabbit	   1:200	   	   Santa	  Cruz	  
Notch3	   Rabbit	   1:200	   	   Santa	  Cruz	  
Notch4	   Rabbit	   1:200	   	   Santa	  Cruz	  
DLL1	   Rabbit	   1:200	   	   Santa	  Cruz	  
DLL3	   Rabbit	   1:200	   	   Santa	  Cruz	  
DLL4	   Rabbit	   1:200	   	   Santa	  Cruz	  
Jagged1	   Rabbit	   1:200	   	   Santa	  Cruz	  
Jagged2	   Rabbit	   1:200	   	   Santa	  Cruz	  
Von-­‐willibrand	  
factor	  
Mouse	   	   1:300	   Dako	  
ß-­‐actin	   Mouse	   1:5000	   	   Sigma	  Aldrich	  
GAPDH	   Mouse	   1:5000	   	   Novus	  
p21	   Mouse	   1:1000	   	   BD	  Transduction	  
Cyclin	  D1	   Rabbit	   1:200	   	   Santa	  Cruz	  
Cyclin	  B1	   Rabbit	   1:200	   	   Santa	  Cruz	  
p27	   Mouse	   1:200	   	   Santa	  Cruz	  
Bax	   Rabbit	   1:1000	   	   Cell	  Signaling	  
Bcl-­‐2	   Rabbit	   1:1000	   	   Cell	  Signaling	  
	  
Table3	  App:	  List	  of	  secondary	  antibodies	  
Antibody	   Dilution	  
WB	  
Company	  
HRP	  conjugated	  anti-­‐rabbit	  IgG	   1:40000	   Sigma	  Aldrich	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